日本臨牀　81/増刊5　最新臨床大腸癌学　2023

出版社： 日本臨牀社
発行日： 2023-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新臨床大腸癌学　2023
電子書籍版： 2023-05-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

24,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　最新臨床大腸癌学　2023

    I 総論
    　1. 大腸癌の疫学
    　2. 大腸癌リスク因子
    　3. 大腸がん検診
    　4. 大腸癌の組織発生, 発育・進展
    　5. 大腸癌の分子生物学的背景

    II 診断
    　1. 注腸 X 線造影検査
    　2. 通常内視鏡検査 ( スクリーニング )
    　3. 通常内視鏡検査 ( 精査 )
    　4. 拡大内視鏡検査 ( pit pattern 診断 )
    　5. 超拡大内視鏡
    　6. 画像強調拡大内視鏡検査 ( スクリーニング : LCI ほか )
    　7. 画像強調拡大内視鏡検査 ( JNET 分類 : NBI, BLI )
    　8. 大腸 T1b 癌 ESD における深部断端確保予測指標としての新しい術前 EUS 診断
    　9. 体外式腹部超音波検査
    　10. CT colonography ( 大腸 CT 検査 )
    　11. CT, MRI
    　12. PET / CT
    　13. カプセル内視鏡検査
    　14. 病理組織検査 ( 標本の取扱いと診断の基本 )
    　15. 脈管侵襲・簇出の病理診断
    　16. SM 浸潤度の病理診断
    　17. T1 大腸癌のリンパ節転移リスク因子
    　18. 大腸鋸歯状病変
    　19. 炎症性腸疾患関連腫瘍
    　20. 大腸癌と鑑別を要する疾患
    　21. 大腸ポリープの AI 診断
    　22. 大腸癌診療における遺伝子関連検査
    　23. 大腸がんのバイオマーカー

    III 内視鏡治療
    　1. 大腸腫瘍に対する内視鏡治療の適応
    　2. ポリペクトミー ( cold, hot ) の適応と実際
    　3. ESD の適応と実際
    　4. 全層切除と縫縮法
    　5. 大腸癌に関連した内視鏡的止血術
    　6. 狭窄拡張・ステント留置術
    　7. 早期大腸癌に対する内視鏡治療の根治度判定・追加手術の適応
    　8. 抗血栓薬服用者に対する対応
    　9. 内視鏡治療後のサーベイランス

    IV 外科手術
    　1. 腹腔鏡手術の進歩
    　2. ロボット手術の変遷と今後の展望
    　3. Laparoscopy and endoscopy cooperative surgery ( LECS )
    　4. 炎症性腸疾患関連腫瘍 ( UC, CD ) の手術適応と実際
    　5. T1 大腸癌に対する手術
    　6. 進行結腸癌に対する手術
    　7. 進行直腸癌に対する手術治療
    　8. 大腸癌肝・肺転移巣に対する手術
    　9. 高齢者・合併症併存患者に対する手術
    　10. 大腸癌術後のサーベイランス
    　11. ストーマを有する患者支援と周術期管理

    V 化学療法
    　1. 抗がん剤
    　2. 分子標的薬
    　3. 免疫チェックポイント阻害薬
    　4. 術前化学療法
    　5. 大腸癌の術後化学療法
    　6. 切除不能進行・再発大腸癌に対する化学療法
    　7. 高齢者・合併症併存患者に対する化学療法

    VI 放射線治療
    　1. 下部直腸癌に対する周術期 ( 術前・術後 ) 化学放射線療法
    　2. 転移巣に対する放射線治療
    　3. 粒子線 ( 重粒子線・陽子線 ) 治療

    VII その他の治療
    　1. 遺伝子治療
    　2. 免疫治療

    VIII 病態ほか
    　1. Adenoma - carcinoma sequence
    　2. De novo 発癌
    　3. 炎症性発がん
    　4. 放射線性腸炎と放射線関連大腸癌
    　5. 大腸癌と遺伝
    　6. 家族性大腸腺腫症, MUTYH 関連ポリポーシス
    　7. リンチ症候群
    　8. 大腸ポリポーシスと大腸癌
    　9. Serrated polyposis syndrome ( SPS ) の特徴と診断
    　10. Laterally spreading tumor ( LST )
    　11. 陥凹型早期大腸癌
    　12. 虫垂癌
    　13. ESD vs hybrid ESD vs precutting EMR
    　14. 内視鏡検査後発生大腸癌
    　15. 大腸癌の予防
    　16. 大腸癌の病理診断 : 病理診断の世界的情勢と日本
    　17. 大腸癌取扱い規約と TNM 分類の比較
    　18. 大腸癌治療ガイドラインと NCCN ガイドラインの比較

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1) 厚生労働省人口動態統計死因 (死因年次推移分類) 別にみた性・年次別死亡者及び死亡率 (人口10万対). [https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20210&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&stat_infid=000032235943&result_back=1&tclass4val=0] (2023年1月閲覧)
 
2) 国立がん研究センターがん情報サービス「がん統計」 (厚生労働省人口動態統計). [https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fganjoho.jp%2Freg_stat%2Fstatistics%2Fdata%2Fdl%2Fexcel%2Fcancer_mortality(1958-2021).xls&wdOrigin=BROWSELINK] (2023年1月閲覧)
 
3) 国立がん研究センターがん情報サービス「がん統計」 (全国がん登録). [https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fganjoho.jp%2Freg_stat%2Fstatistics%2Fdata%2Fdl%2Fexcel%2Fcancer_incidenceNCR(2016-2019).xls&wdOrigin=BROWSELINK] (2023年1月閲覧)
 
4) International Agency for Research on Cancer GLOBAL CANCER OBSERVATORY. [https://gco.iarc.fr/overtime/en/dataviz/trends?populations=12400_25000_27600_38000_39200_82600_84000&sexes=1&types=1&multiple_populations=1&cancers=106&years=1980_2018] (2023年1月閲覧)
 
5) Edwards BK, Ward E, Kohler BA, et al : Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116 : 544-573, 2010.
 
P.16 掲載の参考文献
1) Lichtenstein P, Holm NV, Verkasalo PK, et al : Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 : 78-85, 2000.
PubMed
2) World Cancer Reaserch Fund, American Institute for Cancer Research : Diet, Nutrition, Physical Activity and Colorectal Cancer 2017, revised 2018. [https://www.wcrf.org/wp-content/uploads/2021/02/Colorectal-cancer-report.pdf] (2023年1月閲覧)
 
3) 国立がん研究センター : 科学的根拠に基づくがんリスク評価とがん予防ガイドライン提言に関する研究. [http://epi.ncc.go.jp/can_prev/] (2023年1月閲覧)
 
4) がん研究振興財団 : 刊行物. [http://www.fpcr.or.jp/pamphlet.html] (2023年1月閲覧)
 
5) Goto A, Yamaji T, Sawada N, et al : Diabetes and cancer risk : A Mendelian randomization study. Int J Cancer 146 : 712-719, 2020.
 
6) Power AM, Talley NJ, Ford AC : Association between constipation and colorectal cancer : systematic review and meta-analysis of observational studies. Am J Gastroenterol 108 : 894-904, 2013.
PubMed
7) Watanabe T, Nakaya N, Kurashima K, et al : Constipation, laxative use and risk of colorectal cancer : The Miyagi Cohort Study. Eur J Cancer 40 : 2109-2115, 2004.
PubMed
8) Shiotani A, Ishikawa H, Mutoh M, et al : Impact of Diarrhea after Drinking on Colorectal Tumor Risk : A Case Control Study. Asian Pac J Cancer Prev 20 : 795-799, 2019.
 
9) Fukase K, Kato M, Kikuchi S, et al : Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial. Lancet 372 : 392-397, 2008.
PubMed
10) Castellarin M, Warren RL, Freeman JD, et al : Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22 : 299-306, 2012.
PubMed
11) Yachida S, Mizutani S, Shiroma H, et al : Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 25 : 968-976, 2019.
PubMed
12) Rubinstein MR, Wang X, Liu W, et al : Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14 : 195-206, 2013.
 
13) Gur C, Ibrahim Y, Isaacson B, et al : Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42 : 344-355, 2015.
PubMed
14) Nougayrede JP, Homburg S, Taieb F, et al : Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313 : 848-851, 2006.
PubMed
15) Xue M, Kim CS, Healy AR, et al : Structure elucidation of colibactin and its DNA cross-links. Science 365 : eaax 2685, 2019.
 
16) Zhou T, Hirayama Y, Tsunematsu Y, et al : Isolation of New Colibactin Metabolites from Wild-Type Escherichia coli and In Situ Trapping of a Mature Colibactin Derivative. J Am Chem Soc 143 : 5526-5533, 2021.
PubMed
17) Arthur JC, Perez-Chanona E, Muhlbauer M, et al : Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 : 120-123, 2012.
PubMed
18) Buc E, Dubois D, Sauvanet P, et al : High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8 : e56964, 2013.
PubMed
19) Namba S, Saito Y, Kogure Y, et al : Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers. Cancer Res 83 : 20-27, 2023.
PubMed
20) Ishikawa H, Mutoh M, Suzuki S, et al : The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients : a randomised trial. Gut 63 : 1755-1759, 2014.
PubMed
P.21 掲載の参考文献
1) 棟方昭博, 田畑育男, 樋口健四郎, ほか : 直腸鏡集団検診の試み. Gastroenterol Endosc 15 : 283, 1973.
 
2) 厚生省老人保健福祉部老人保健課 (監) : 老人保健法による大腸がん検診マニュアル, 日本医事新報社, 1992.
 
3) 健康増進法 (平成十四年法律第百三号). [https://elaws.e-gov.go.jp/document?lawid=414AC0000000103] (2022年12月閲覧)
 
4) がん予防重点健康教育及びがん検診実施のための指針 (健発第0331058号 平成20年3月31日厚生労働省健康局長通知別添). [https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000111662.pdf] (2022年12月閲覧)
 
5) 労働安全衛生法 (昭和四十七年法律第五十七号). [https://elaws.e-gov.go.jp/document?lawid=347AC0000000057] (2022年12月閲覧)
 
6) 労働安全衛生規則 (昭和四十七年労働省令第三十二号). [https://elaws.e-gov.go.jp/document?lawid=347M50002000032] (2022年12月閲覧)
 
7) 厚生労働省 : 職域におけるがん検診に関するマニュアル. [https://www.mhlw.go.jp/stf/shingi2/0000200734.html] (2022年12月閲覧)
 
8) 有効性に基づく大腸がん検診ガイドライン (平成16年度厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班), V 推奨レベル. p25-26, 三田村印刷所, 2005.
 
9) 日本消化器がん検診学会大腸がん検診精度管理委員会 (編) : 精検法. 大腸がん検診マニュアル, p37-38, 医学書院, 2013.
 
10) がん検診事業の評価に関する委員会 : 今後の我が国におけるがん検診事業評価の在り方について. [https://www.mhlw.go.jp/shingi/2008/03/dl/s0301-4c.pdf] (2022年12月閲覧)
 
11) 厚生労働省 : がん対策推進基本計画. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000183313.html] (2022年12月閲覧)
 
12) 厚生労働省 : 平成28年度地域保健・健康増進事業報告の概況. [https://www.mhlw.go.jp/toukei/saikin/hw/c-hoken/16/dl/gaikyo.pdf] (2022年12月閲覧)
 
13) 厚生労働省 : 平成28年国民生活基礎調査の概況. [https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa16/dl/16.pdf] (2022年12月閲覧)
 
14) がん情報サービス : がん検診について. [https://ganjoho.jp/med_pro/cancer_control/screening/screening.html] (2022年12月閲覧)
 
15) 鈴木康元 : 大腸がん検診-昨日・今日・明日-. 日本消化器がん検診学会雑誌 58 : 382-393, 2020.
 
16) 日本消化器がん検診学会大腸がん検診精度管理委員会 : 精密検査の手法として大腸CT検査の位置づけおよび必要条件と課題. 日本消化器がん検診学会雑誌 54 : 425-441, 2016.
 
P.28 掲載の参考文献
1) Morson BC, Dawson IMP : Gastrointestinal Pathology. Blackwell Science, Oxford, 1972.
 
2) Vogelstein B, Fearon ER, Hamilton SR, et al : Genetic alterations during colorectal-tumor development. N Engl J Med 319 : 525-532, 1988.
PubMed
3) Spratt JS Jr, Ackerman LV, Moyer CA : Relationship of polyps of the colon to colonic cancer. Ann Surg 148 : 682-698, 1958.
PubMed
4) 藤田幹夫, 藤井茂彦, 富永圭一, ほか : 大腸癌のすべて大腸癌の発生・進展分子生物学からみた大腸癌発生. 消化器外科 28 : 585-592, 2005.
 
5) 中村恭一 : 大腸癌の構造, 第2版, 医学書院. 2010.
 
6) WHO Classification of Tumours Editorial Board : WHO Classification of Tumours, 5th Edition, Volume 1. Digestive System Tumours, International Agency for Research on Cancer, Lyon, 2019.
 
7) Wang TC, Camilleri M, Lebwohl B, et al (ed) : Yamada's Textbook of Gastroenterology, Wiley-Blackwell, 2022.
 
8) Hashimoto T, Tanaka Y, Ogawa R, et al : Superficially serrated adenoma : a proposal for a novel subtype of colorectal serrated lesion. Mod Pathol 31 : 1588-1598, 2018.
PubMed
9) 狩谷淳, 水野幸一, 間山素行, ほか : IIc型早期大腸癌が認められた家族性大腸ポリポーシスの1例. 胃と腸 12 : 1359-1364, 1977.
 
10) 工藤進英, 小松泰介, 山野泰穂, ほか : Is型大腸sm癌を考えるIs型大腸sm癌の成り立ち内視鏡の立場からIs型亜分類の提案. 胃と腸 32 : 1639-1645, 1997.
 
11) 工藤進英, 石川恵子, 山野泰穂, ほか : 陥凹型および陥凹型由来大腸早期癌. Gastroenterological Endoscopy 42 : 3-7, 2000.
 
12) 原栄志, 工藤進英, 樫田博史, ほか : "IIc" の頻度精査患者を対象とした大腸陥凹型腫瘍の頻度. 早期大腸癌 8 : 15-20, 2004.
 
13) 工藤進英 : 早期大腸癌-平坦・陥凹型へのアプローチ, p42-45, 医学書院, 1993.
 
14) Uraoka T, Saito Y, Matsuda T, et al : Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 55 : 1592-1597, 2006.
PubMed
15) Miyamoto H, Ikematsu H, Fujii S, et al : Clinicopathological differences of laterally spreading tumors arising in the colon and rectum. Int J Colorectal Dis 29 : 1069-1075, 2014.
PubMed
16) Osera S, Fujii S, Ikematsu H, et al : Clinicopathological, endoscopic, and molecular characteristics of the "skirt" -a new entity of lesions at the margin of laterally spreading tumors. Endoscopy 48 : 448-455, 2016.
PubMed
17) Matsuda T, Fujii T, Sano Y, et al : Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy : the Japan Polyp Study Workgroup. Gut 70 : 1469-1478, 2020.
 
18) Shimoda T, Ikegami M, Fujisaki J, et al : Early colorectal carcinoma with special reference to its development de novo. Cancer 64 : 1138-1146, 1989.
PubMed
P.35 掲載の参考文献
1) Cancer Genome Atlas Network : Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 : 330-337, 2012.
PubMed
2) Campbell BB, Light N, Fabrizio D, et al : Comprehensive Analysis of Hypermutation in Human Cancer. Cell 171 : 1042-1056. e10, 2017.
 
3) Asaka S, Arai Y, Nishimura Y, et al : Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis 30 : 494-499, 2009.
 
4) Fujita M, Liu X, Iwasaki Y, et al : Population-based Screening for Hereditary Colorectal Cancer Variants in Japan. Clin Gastroenterol Hepatol 20 : 2132-2141.e9, 2022.
 
5) Loughrey MB, McGrath J, Coleman HG, et al : Identifying mismatch repair-deficient colon cancer : near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology 78 : 401-413, 2021.
 
6) Liu Y, Sethi NS, Hinoue T, et al : Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33 : 721-735.e8, 2018.
 
7) Zaidi SH, Harrison TA, Phipps AI, et al : Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun 11 : 3644, 2020.
PubMed
8) Kleeman SO, Leedham SJ : Not All Wnt Activation Is Equal : Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers (Basel) 12 : 2020.
PubMed
9) Cocco E, Benhamida J, Middha S, et al : Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Res 79 : 1047-1053, 2019.
PubMed
10) Sato K, Kawazu M, Yamamoto Y, et al : Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers. Clin Cancer Res 25 : 378-389, 2019.
PubMed
11) Siena S, Sartore-Bianchi A, Marsoni S, et al : Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol 29 : 1108-1119, 2018.
PubMed
12) Liao X, Morikawa T, Lochhead P, et al : Prognostic role of PIK3CA mutation in colorectal cancer : cohort study and literature review. Clin Cancer Res 18 : 2257-2268, 2012.
PubMed
13) Zhang J, Roberts TM, Shivdasani RA : Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141 : 50-61, 2011.
PubMed
14) Jung B, Staudacher JJ, Beauchamp D : Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology 152 : 36-52, 2017.
 
15) Liebl MC, Hofmann TG : The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel) 13 : 2021.
PubMed
16) Guinney J, Dienstmann R, Wang X, et al : The consensus molecular subtypes of colorectal cancer. Nat Med 21 : 1350-1356, 2015.
PubMed

II 診断

P.45 掲載の参考文献
1) Hirata M, Tanaka S, Oka S, et al : Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc 65 : 988-995, 2007.
PubMed
2) Saitoh Y, Waxman I, West AB, et al : Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 120 : 1657-1665, 2001.
 
3) Tanaka S, Oka S, Kaneko I, et al : Endoscopic submucosal dissection for colorectal neoplasia : possibility of standardization. Gastrointest Endosc 66 : 100-107, 2007.
PubMed
4) 斉藤裕輔, 富永素矢, 垂石正樹, ほか : 早期大腸癌の精密画像診断- 1) 注腸X線診断. 胃と腸 45 : 784-799, 2010.
 
5) Matsui T, Yao T, Yao K, et al : Natural history of superficial depressed colorectal cancer : retrospective radiographic and histologic analysis. Radiology 201 : 226-232, 1996.
PubMed
6) 渡二郎, 水上裕輔, 田邊裕貴, ほか : 転移性大腸癌の診断における注腸X線検査の再評価CT検査および内視鏡検査との診断能の比較. 臨床放射線 41 : 211-216, 1996.
 
7) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
8) 鶴田修 : 早期大腸癌-診断の進歩-. 日本消化器病学会雑誌 101 : 477-485, 2004.
Medical*Online
9) 広瀬朝子, 五島知郎, 浅尾高行, ほか : 注腸検査の苦痛軽減に関しての方法. 日本大腸検査学会雑誌 18 : 266-268, 2001.
 
10) 西川孝, 吉村平, 井本一郎, ほか : 注腸X線検査における蠕動運動抑制を目的としたPepermint混入法と芍薬甘草湯経口投与法の検討. 日本消化器集団検診学会雑誌 41 : 170-176, 2003.
 
11) Watari J, Saitoh Y, Obara T, et al : Early nonpolypoid colorectal cancer : radiographic diagnosis of depth of invasion. Radiology 205 : 67-74, 1997.
PubMed
12) 大腸ポリープ診療ガイドライン 2020 (日本消化器病学会編), BQ4-5 早期大腸癌に対する注腸造影検査の深達度診断能は? p59-60, 金原出版, 2020.
 
13) 牛尾恭輔, 後藤裕夫, 村松幸男, ほか : 消化管癌のX線診断における側面像の意義-二重造影像による深達度診断. 胃と腸 21 : 27-41, 1986.
 
14) 丸山雅一, 熊倉賢二 : 大腸早期癌のX線診断. 胃と腸 5 : 1343-1358, 1970.
 
15) 川崎啓祐, 鳥巣剛弘, 長畑誠修, ほか : 内視鏡完全一括切除可能な大腸T1癌の術前診断注腸造影の有用性と限界. 胃と腸 56 : 1035-1046, 2021.
 
P.50 掲載の参考文献
1) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
2) Rabeneck L, Paszat LF : Circumstances in which colonoscopy misses cancer. Frontline Gastroenterol 1 : 52-58, 2010.
PubMed
3) Adler J, Robertson DJ : Interval Colorectal Cancer After Colonoscopy : Exploring Explanations and Solutions. Am J Gastroenterol 110 : 1657-1665, 2015.
PubMed
4) Corley DA, Jensen CD, Marks AR, et al : Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 370 : 1298-1306, 2014.
PubMed
5) 斎藤豊, 岡志郎, 河村卓二, ほか : 大腸内視鏡スクリーニングとサーベイランスガイドライン. Gastroenterological Endoscopy 62 : 1519-1560, 2020.
 
6) Rex DK, Schoenfeld PS, Cohen J, et al : Quality indicators for colonoscopy. Am J Gastroenterol 110 : 72-90, 2015.
PubMed
7) Hilsden RJ, Bridges R, Dube C, et al : Defining Benchmarks for Adenoma Detection Rate and Adenomas Per Colonoscopy in Patients Undergoing Colonoscopy Due to a Positive Fecal Immunochemical Test. Am J Gastroenterol 111 : 1743-1749, 2016.
PubMed
8) Zhao S, Yang X, Wang S, et al : Impact of 9-Minute Withdrawal Time on the Adenoma Detection Rate : A Multicenter Randomized Controlled Trial. Clin Gastroenterol Hepatol 20 : e168-e181, 2022.
 
9) Lee TJ, Blanks RG, Rees CJ, et al : Longer mean colonoscopy withdrawal time is associated with increased adenoma detection : evidence from the Bowel Cancer Screening Programme in England. Endoscopy 45 : 20-26, 2013.
PubMed
10) Tholey DM, Shelton CE, Francis G, et al : Adenoma detection in excellent versus good bowel preparation for colonoscopy. J Clin Gastroenterol 49 : 313-319, 2015.
PubMed
11) Kudo T, Saito Y, Ikematsu H, et al : New-generation full-spectrum endoscopy versus standard forward-viewing colonoscopy : a multicenter, randomized, tandem colonoscopy trial (J-FUSE Study). Gastrointest Endosc 88 : 854-864, 2018.
 
12) Matsuda T, Fujii T, Sano Y, et al : Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy : the Japan Polyp Study Workgroup. Gut 70 : 1469-1478, 2020.
 
13) Uraoka T, Tanaka S, Oka S, et al : Feasibility of a novel colonoscope with extra-wide angle of view : a clinical study. Endoscopy 47 : 444-448, 2015.
PubMed
14) Barua I, Vinsard DG, Jodal HC, et al : Artificial intelligence for polyp detection during colonoscopy : a systematic review and meta-analysis. Endoscopy 53 : 277-284, 2021.
PubMed
15) Kamba S, Tamai N, Saitoh I, et al : Reducing adenoma miss rate of colonoscopy assisted by artificial intelligence : a multicenter randomized controlled trial. J Gastroenterol 56 : 746-757, 2021.
PubMed
P.61 掲載の参考文献
1) 消化管拡大内視鏡診断の実際-観察のコツと診断のポイント- (田尻久雄, 田中信治編), 金原出版, 2004.
 
2) 症例で身につける消化器内視鏡シリーズ大腸腫瘍診断改訂版豊富な写真で上がる診断力, Case Study で磨く実践力 (田中信治編), 羊土社, 2014.
 
3) 見逃しのない大腸内視鏡の挿入・観察法 (田中信治監, 永田信二, 岡志郎編), 日本メディカルセンター, 2012.
 
4) 治療に直結する大腸腫瘍診断のストラテジー. 消化器内視鏡 25 (8), 2013.
Medical*Online
5) 小野敏嗣 (編) : 教科書では教えてくれない! 私の消化器内視鏡Tips-とっておきの "コツ" を伝授します, 医学書院, 2018.
 
6) 大腸内視鏡診断の基本とコツ (田中信治監, 永田信二, 岡志郎編), 羊土社, 2019.
 
7) 大腸内視鏡拡大観察の基本と最新知見. 胃と腸 54 (1), 2019.
 
8) ついつい教えたくなる, とっておきのコツ. 消化器内視鏡 33 (2), 2021.
 
9) 大腸内視鏡スキルアップ-挿入から診断まで. 消化器内視鏡 33 (10), 2021.
Medical*Online
10) こんなときどうする. 消化器内視鏡 34 (3), 2022.
Medical*Online
P.67 掲載の参考文献
1) Iwatate M, Sano Y, Tanaka S, et al : Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. Dig Endosc 30 : 642-651, 2018.
PubMed
2) Kudo S, Hirota S, Nakajima T, et al : Colorectal tumours and pit pattern. J Clin Pathol 47 : 880-885, 1994.
PubMed
3) Saito S, Tajiri H, Ikegami M : Endoscopic features of submucosal deeply invasive colorectal cancer with NBI characteristics. Clin J Gastroenterol 8 : 353-359, 2015.
PubMed
4) 河野弘志, 鶴田修, 上野恵里奈, ほか : pit pattern観察による早期大腸癌の深達度診断. 胃と腸 50 : 676-685, 2015.
 
5) 工藤進英, 倉橋利徳, 樫田博史, ほか : 大腸腫瘍に対する拡大内視鏡観察と深達度診断-箱根シンポジウムにおけるV型亜分類の合意. 胃と腸 39 : 747-752, 2004.
 
6) Matsuda T, Fujii T, Saito Y, et al : Efficacy of the invasive/non-invasive pattern by magnifying chromoendoscopy to estimate the depth of invasion of early colorectal neoplasms. Am J Gastroenterol 103 : 2700-2706, 2008.
PubMed
P.72 掲載の参考文献
1) Kudo SE, Wakamura K, Ikehara N, et al : Diagnosis of colorectal lesions with a novel endocytoscopic classification-a pilot study. Endoscopy 43 : 869-875, 2011.
PubMed
2) Mori Y, Kudo S, Ikehara N, et al : Comprehensive diagnostic ability of endocytoscopy compared with biopsy for colorectal neoplasms : a prospective randomized noninferiority trial. Endoscopy 45 : 98-105, 2013.
PubMed
3) Kudo SE, Mori Y, Wakamura K, et al : Endocytoscopy can provide additional diagnostic ability to magnifying chromoendoscopy for colorectal neoplasms. J Gastroenterol Hepatol 29 : 83-90, 2014.
PubMed
4) Kudo T, Kudo SE, Wakamura K, et al : Diagnostic performance of endocytoscopy for evaluating the invasion depth of different morphological types of colorectal tumors. Dig Endosc 27 : 754-761, 2015.
PubMed
5) Kudo SE, Misawa M, Wada Y, et al : Endocytoscopic microvasculature evaluation is a reliable new diagnostic method for colorectal lesions. Gastrointest Endosc 82 : 912-923, 2015.
PubMed
6) Mori Y, Kudo SE, Wakamura K, et al : Novel computer-aided diagnostic system for colorectal lesions by using endocytoscopy. Gastrointest Endosc 81 : 621-629, 2015.
PubMed
7) Mori Y, Kudo SE, Chiu PW, et al : Impact of an automated system for endocytoscopic diagnosis of small colorectal lesions : an international web-based study. Endoscopy 48 : 1110-1118, 2016.
PubMed
8) Barua I, Wieszczy P, Kudo S-e, et al : Real-Time Artificial Intelligence-Based Optical Diagnosis of Neoplastic Polyps during Colonoscopy. NEJM Evidence 1 : EVIDoa2200003, 2022 (DOI : 10.1056/EVIDoa2200003).
 
9) Takeda K, Kudo SE, Mori Y, et al : Accuracy of diagnosing invasive colorectal cancer using computer-aided endocytoscopy. Endoscopy 49 : 798-802, 2017.
PubMed
P.79 掲載の参考文献
1) Nishihara R, Wu K, Lochhead P, et al : Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369 : 1095-1105, 2013.
PubMed
2) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
3) Keswani RN, Crockett SD, Calderwood AH : AGA Clinical Practice Update on Strategies to Improve Quality of Screening and Surveillance Colonoscopy : Expert Review. Gastroenterology 161 : 701-711, 2021.
PubMed
4) Zhao S, Wang S, Pan P, et al : Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy : A Systematic Review and Meta-analysis. Gastroenterology 156 : 1661-1674. e11, 2019.
 
5) Chang WY, Chiu HM : Can image-enhanced endoscopy improve adenoma detection rate? Dig Endosc 34 : 284-296, 2022.
PubMed
6) 斎藤豊, 岡志郎, 河村卓二, ほか : 大腸内視鏡スクリーングとサーベイランスガイドライン. Gastroenterol Endosc 62 : 1521-1560, 2020.
 
7) 吉田直久, 井上健, 稲田裕 : 大腸内視鏡検査における画像強調観察の現状と今後の展望. Gastroenterological Endoscopy 64 : 1421-1438, 2022.
 
8) Sano Y, Muto M, Tajiri H, et al : Optical/digital chromoendoscopy during colonoscopy using narrow-band imaging system. Dig Endosc 17 : S43-48, 2005.
 
9) Nagorni A, Bjelakovic G, Petrovic B : Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. Cochrane Database Syst Rev 1 : CD008361, 2012.
PubMed
10) Dinesen L, Chua TJ, Kaffes AJ : Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection. Gastrointest Endosc 75 : 604-611, 2012.
PubMed
11) Ogiso K, Yoshida N, Siah KT, et al : New-generation narrow band imaging improves visibility of polyps : a colonoscopy video evaluation study. J Gastroenterol 51 : 883-890, 2016.
PubMed
12) Uraoka T, Tanaka S, Oka S, et al : Feasibility of a novel colonoscope with extra-wide angle of view : a clinical study. Endoscopy 47 : 444-448, 2015.
PubMed
13) Horimatsu T, Sano Y, Tanaka S, et al : Next-generation narrow band imaging system for colonic polyp detection : a prospective multicenter randomized trial. Int J Colorectal Dis 30 : 947-954, 2015.
PubMed
14) Rex DK, Clodfelter R, Rahmani F, et al : Narrow-band imaging versus white light for the detection of proximal colon serrated lesions : a randomized, controlled trial. Gastrointest Endosc 83 : 166-171, 2016.
PubMed
15) Atkinson NSS, Ket S, Bassett P, et al : Narrow-Band Imaging for Detection of Neoplasia at Colonoscopy : A Meta-analysis of Data From Individual Patients in Randomized Controlled Trials. Gastroenterology 157 : 462-471, 2019.
PubMed
16) Yoshida N, Inoue K, Yasuda R, et al : An Additional 30-s Observation of the Right-Sided Colon with Narrow Band Imaging Decreases Missed Polyps : A Pilot Study. Dig Dis Sci 63 : 3457-3464, 2018.
PubMed
17) Teramoto A, Hamada S, Ogino B, et al : Updates in narrow-band imaging for colorectal polyps : Narrow-band imaging generations, detection, diagnosis, and artificial intelligence. Dig Endosc, 2022. DOI : 10.1111/den.14489
 
18) Sato T. TXI : Texture and Color Enhancement Imaging for Endoscopic Image Enhancement. J Healthc Eng 2021 : 5518948, 2021.
PubMed
19) Tamai N, Horiuchi H, Matsui H, et al : Visibility evaluation of colorectal lesion using texture and color enhancement imaging with video. DEN Open 2 : e90, 2022.
PubMed
20) Yoshida N, Inoue K, Dohi O, et al : Analysis of Texture and Color Enhancement Imaging for Improving the Visibility of Non-polypoid Colorectal Lesions. Dig Dis Sci 67 : 5657-5665, 2022.
PubMed
21) Yoshida N, Dohi O, Inoue K, et al : Blue Laser Imaging, Blue Light Imaging, and Linked Color Imaging for the Detection and Characterization of Colorectal Tumors. Gut Liver 13 : 140-148, 2019.
PubMed
22) Ono S, Kawada K, Dohi O, et al : Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract : A Randomized Trial. Ann Intern Med 174 : 18-24, 2021.
PubMed
23) Yoshida N, Hisabe T, Ikematsu H, et al : Comparison Between Linked Color Imaging and Blue Laser Imaging for Improving the Visibility of Flat Colorectal Polyps : A Multicenter Pilot Study. Dig Dis Sci 65 : 2054-2062, 2020.
PubMed
24) Yoshida N, Hayashi Y, Kashida H, et al : Images of laser and light-emitting diode colonoscopy for comparing large colorectal lesion visibility with linked color imaging and white light imaging : LECOL study. Dig Endosc 34 : 1413-1421, 2022.
PubMed
25) Yoshida N, Dohi O, Inoue K, et al : The efficacy of tumor characterization and tumor detectability of linked color imaging and blue laser imaging with an LED endoscope compared to a LASER endoscope. Int J Colorectal Dis 35 : 815-825, 2020.
PubMed
26) Ikematsu H, Sakamoto T, Togashi K, et al : Detectability of colorectal neoplastic lesions using a novel endoscopic system with blue laser imaging : a multicenter randomized controlled trial. Gastointest Endosc 86 : 386-394, 2017.
PubMed
27) Shimoda R, Sakata Y, Fujise T, et al : The adenoma miss rate of blue-laser imaging vs. white-light imaging during colonoscopy : a randomized tandem trial. Endoscopy 49 : 186-190, 2017.
PubMed
28) Min M, Deng P, Zhang W, et al : Comparison of linked color imaging and white-light colonoscopy for detection of colorectal polyps : a multicenter, randomized, crossover trial. Gastrointest Endosc 86 : 724-730, 2017.
PubMed
29) Fujimoto D, Muguruma N, Okamoto K, et al : Linked color imaging enhances endoscopic detection of sessile serrated adenoma/polyps. Endosc Int Open 6 : E322-E334, 2018.
PubMed
30) Dos Santos CEO, Malaman D, Yoshida N, et al : Blue laser imaging : a new image-enhanced endoscopy for the diagnosis of colorectal lesions. Eur J Gastroenterol Hepatol 30 : 1514-1520, 2018.
PubMed
31) Paggi S, Mogavero G, Amato A, et al : Linked color imaging reduces the miss rate of neoplastic lesions in the right colon : a randomized tandem colonoscopy study. Endoscopy 50 : 396-402, 2018.
 
32) Shinozaki S, Kobayashi Y, Hayashi Y, et al : Colon polyp detection using linked color imaging compared to white light imaging : Systematic review and meta-analysis. Dig Endosc 32 : 874-881, 2020.
PubMed
33) Miyaguchi K, Takabayashi K, Saito D, et al : Linked color imaging versus white light imaging colonoscopy for colorectal adenoma detection : A randomized controlled trial. J Gastroenterol Hepatol 36 : 2778-2784, 2021.
PubMed
34) Aniwan S, Vanduangden K, Kerr SJ, et al : Linked color imaging, mucosal exposure device, their combination, and standard colonoscopy for adenoma detection : a randomized trial. Gastrointest Endosc 94 : 969-977, 2021.
PubMed
35) Suzuki S, Aniwan S, Chiu HM, et al : Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions : An International Randomized Controlled Trial. Clin Gastroenterol Hepatol, S1542-3565 (22) 01010-2, 2022. (DOI : 10.1016/j.cgh.2022.10.021)
 
36) Yoshida N, Inada Y, Yasuda R, et al : Additional thirty seconds observation with linked color imaging improves detection of missed polyps in the right-sided colon. Gastroenterol Res Pract 2018 : 5059834, 2018.
PubMed
37) Leung WK, Guo CG, Ko MKL, et al : Linked color imaging versus narrow-band imaging for colorectal polyp detection : a prospective randomized tandem colonoscopy study. Gastrointest Endosc 91 : 104-112.e5, 2020.
 
38) Mori Y, Neumann H, Misawa M, et al : Artificial intelligence in colonoscopy-Now on the market. What's next? J Gastroenterol Hepatol 36 : 7-11, 2021.
PubMed
39) Yoshida N, Inoue K, Tomita Y, et al : An analysis about the function of a new artificial intelligence, CAD EYE with the lesion recognition and diagnosis for colorectal polyps in clinical practice. Int J Colorectal Dis 36 : 2237-2245, 2021.
PubMed
40) Neumann H, Kreft A, Sivanathan V, et al : Evaluation of novel LCI CAD EYE system for real time detection of colon polyps. PLoS One 16 : e0255955, 2021.
PubMed
41) Sakamoto T, Nakashima H, Nakamura K, et al : Performance of Computer-Aided Detection and Diagnosis of Colorectal Polyps Compares to That of Experienced Endoscopists. Dig Dis Sci 67 : 3976-3983, 2022.
PubMed
P.86 掲載の参考文献
1) Sano Y, Horimatsu T, Fu KI, et al : Magnifying observation of microvascular architecture of colorectal lesions using a narrow band imaging system. Dig Endosc 18 (Suppl 1) : S44-S51, 2006.
 
2) Hewett DG, Kaltenbach T, Sano Y, et al : Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology 143 : 599-607.e1, 2012.
 
3) Sano Y, Tanaka S, Kudo SE, et al : Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc 28 : 526-533, 2016.
PubMed
4) Yoshida N, Hisabe T, Inada Y, et al : The ability of a novel blue laser imaging system for the diagnosis of invasion depth of colorectal neoplasms. J Gastroenterol 49 : 73-80, 2014.
PubMed
5) 斎藤豊, 松田尚久, 中島健, ほか : The Japan NBI Expert Team (JNET) 大腸拡大Narrow Band Imaging (NBI) 分類の紹介. 日本消化器内視鏡学会雑誌 58 : 2314-2322, 2016.
 
6) Sano Y, Hirata D, Saito Y : Japan NBI Expert Team classification : Narrow-band imaging magnifying endoscopic classification of colorectal tumors. Dig Endosc 30 : 543-545, 2018.
PubMed
7) Hirata D, Kashida H, Iwatate M, et al : Effective use of the Japan Narrow Band Imaging Expert Team classification based on diagnostic performance and confidence level. World J Clin Cases 7 : 2658-2665, 2019.
PubMed
8) Utsumi T, Iwatate M, Sunakawa H, et al : Additional chromoendoscopy for colorectal lesions initially diagnosed with low confidence by magnifying narrow-band imaging : Can it improve diagnostic accuracy? Dig Endosc 30 (Suppl 1) : 45-50, 2018.
 
9) Iwatate M, Sano Y, Tanaka S, et al : Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. Dig Endosc 30 : 642-651, 2018.
PubMed
10) Sano W, Sano Y, Iwatate M, et al : Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features. Endosc Int Open 3 : E354-E358, 2015.
PubMed
11) Sano W, Fujimori T, Ichikawa K, et al : Clinical and endoscopic evaluations of sessile serrated adenoma/polyps with cytological dysplasia. J Gastroenterol Hepatol 33 : 1454-1460, 2018.
PubMed
12) Hirata D, Kashida H, Matsumoto T, et al : A Multicenter Prospective Validation Study on Selective Endoscopic Resection of Sessile Serrated Lesions Using Magnifying Colonoscopy in Clinical Practice. Digestion, 2023. (DOI : 10.1159/000527978)
 
13) Minegishi Y, Kudo SE, Miyata Y, et al : Comprehensive Diagnostic Performance of Real-Time Characterization of Colorectal Lesions Using an Artificial Intelligence-Assisted System : A Prospective Study. Gastroenterology 163 : 323-325.e3, 2022.
 
14) Hashimoto T, Tanaka Y, Ogawa R, et al : Superficially serrated adenoma : a proposal for a novel subtype of colorectal serrated lesion. Mod Pathol 31 : 1588-1598, 2018.
PubMed
15) Matsuda T, Fujii T, Saito Y, et al : Efficacy of the invasive/non-invasive pattern by magnifying chromoendoscopy to estimate the depth of invasion of early colorectal neoplasms. Am J Gastroenterol 103 : 2700-2706, 2008.
PubMed
P.93 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
2) Nakadoi K, Tanaka S, Kanao H, et al : Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol 27 : 1057-1062, 2012.
PubMed
3) Yamashita K, Oka S, Tanaka S, et al : Preceding endoscopic submucosal dissection for T1 colorectal carcinoma does not affect the prognosis of patients who underwent additional surgery : a large multicenter propensity score-matched analysis. J Gastroenterol 54 : 897-906, 2019.
 
4) Tamaru Y, Oka S, Tanaka S, et al : Long-term outcomes after treatment for T1 colorectal carcinoma : a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group. J Gastroenterol 52 : 1169-1179, 2017.
 
5) Asayama N, Oka S, Tanaka S, et al : Long-term outcomes after treatment for T1 colorectal carcinoma. Int J Colorectal Dis 31 : 571-578, 2016.
PubMed
6) 上杉憲幸, 松田尚久, 九嶋亮治, ほか : 大腸癌研究会プロジェクト研究「内視鏡切除後の深部断端陽性判定基準の標準化」. 胃と腸 49 : 1063-1070, 2014.
 
7) Nishimura T, Oka S, Kamigaichi Y, et al : Vertical tumor margin of endoscopic resection for T1 colorectal carcinoma affects the prognosis of patients undergoing additional surgery. Surg Endosc 36 : 5970-5978, 2022.
PubMed
8) Sano Y, Tanaka S, Kudo SE, et al : Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc 28 : 526-533, 2016.
PubMed
9) Sumimoto K, Tanaka S, Shigita K, et al : Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Gastrointest Endosc 85 : 816-821, 2017.
PubMed
10) Hosotani K, Imai K, Hotta K, et al : Diagnostic performance for T1 cancer in colorectal lesions ≧ 10 mm by optical characterization using magnifying narrow-band imaging combined with magnifying chromoendoscopy ; implications for optimized stratification by Japan Narrow-band Imaging Expert Team classification. Dig Endosc 33 : 425-432, 2021.
 
11) 稲場勇平, 斉藤裕輔, 小林裕, ほか : 大腸SM癌診療におけるEUS診断のコツ. 日本消化器内視鏡学会雑誌 61 : 1145-1157, 2019.
 
12) Ozawa S, Tanaka S, Hayashi N, et al : Risk factors for vertical incomplete resection in endoscopic submucosal dissection as total excisional biopsy for submucosal invasive colorectal carcinoma. Int J Colorectal Dis 28 : 1247-1256, 2013.
PubMed
13) Kamigaichi Y, Oka S, Tanino F, et al : Novel endoscopic ultrasonography classification for assured vertical resection margin (≧ 500 μm) in colorectal endoscopic submucosal dissection. J Gastroenterol Hepatol 37 : 2289-2296, 2022.
 
14) 松永厚生, 望月福治, 藤田直孝, ほか : 超音波内視鏡 (EUS) による大腸早期癌の深達度診断と問題点. 日本消化器内視鏡学会雑誌 38 : 279-287, 1996.
 
15) Mukae M, Kobayashi K, Sada M, et al : Diagnostic performance of EUS for evaluating the invasion depth of early colorectal cancers. Gastrointest Endosc 81 : 682-690, 2015.
PubMed
P.99 掲載の参考文献
1) 畠二郎, 長谷川雄一 (編) : 消化管エコー UPDATE (月刊Medical Technology 別冊), 医歯薬出版, 2013.
 
2) Atkinson NSS, Bryant RV, Dong Y, et al : How to perform gastrointestinal ultrasound : Anatomy and normal findings. World J Gastroenterol 23 : 6931-6941, 2017.
PubMed
3) Atkinson NS, Bryant RV, Dong Y, et al : WFUMB Position Paper. Learning Gastrointestinal Ultrasound : Theory and Practice. Ultrasound Med Biol 42 : 2732-2742, 2016.
PubMed
4) 相部剛 : 超音波内視鏡による消化管壁の層構造に関する基礎的, 臨床的研究 (1) 胃壁の層構造について. 日本消化器内視鏡学会雑誌 26 : 1447-1464, 1984.
 
5) 大原昇 : 高周波数超音波プローブ (20 MHz) による大腸壁基本層構造および大腸表面型腫瘍の検討. 日本消化器内視鏡学会雑誌 34 : 2527-2541, 1992.
 
6) Bluth EI, Merritt CR, Sullivan MA : Ultrasonic evaluation of the stomach, small bowel, and colon. Radiology 133 : 677-680, 1979.
PubMed
7) Fujii Y, Taniguchi N, Ono T, et al : Primary linitis plastica carcinoma of the colon accompanied by peritoneal abscess. J Clin Ultrasound 31 : 488-492, 2003.
PubMed
8) Rutgeerts LJ, Verbanck JJ, Crape AW, et al : Detection of colorectal cancer by routine ultrasound. J Belge Radiol 74 : 11-13, 1991.
 
9) Richardson NG, Heriot AG, Kumar D, et al : Abdominal ultrasonography in the diagnosis of colonic cancer. Br J Surg 85 : 530-533, 1998.
PubMed
10) Shirahama M, Koga T, Ishibashi H, et al : Sonographic features of colon carcinoma seen with highfrequency transabdominal ultrasound. J Clin Ultrasound 22 : 359-365, 1994.
 
11) Martinez-Ares D, Martin-Granizo Barrenechea I, Souto-Ruzo J, et al : The value of abdominal ultrasound in the diagnosis of colon cancer. Rev Esp Enferm Dig 97 : 877-886, 2005.
PubMed
P.105 掲載の参考文献
1) Nagata K, Endo S, Honda T, et al : Accuracy of CT Colonography for Detection of Polypoid and Nonpolypoid Neoplasia by Gastroenterologists and Radiologists : A Nationwide Multicenter Study in Japan. Am J Gastroenterol 112 : 163-171, 2017.
PubMed
2) Utano K, Nagata K, Honda T, et al : Diagnostic Performance and Patient Acceptance of Reduced-Laxative CT Colonography for the Detection of Polypoid and Non-Polypoid Neoplasms : A Multicenter Prospective Trial. Radiology 282 : 399-407, 2017.
PubMed
3) 大腸がん検診マニュアル [2021年度改訂版] (日本消化器がん検診学会大腸がん検診精度管理委員会編), 日本消化器がん検診学会雑誌 60 : 386-536, 2022.
 
4) 日本消化器がん検診学会大腸がん検診精度管理委員会 : 委員会報告精密検査の手法として大腸CT検査の位置づけおよび必要条件と課題. 日本消化器がん検診学会雑誌 54 : 425-441, 2016.
 
5) Spada C, Hassan C, Bellini D, et al : Imaging alternatives to colonoscopy : CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline-Update 2020. Endoscopy 52 : 1127-1141, 2020.
PubMed
6) Morris EJA, Goldacre R, Spata E, et al : Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England : a population-based study. Lancet Gastroenterol Hepatol 6 : 199-208, 2021.
 
7) Kuzuu K, Misawa N, Ashikari K, et al : Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan. JAMA Netw Open 4 : e2126334, 2021.
PubMed
8) Moreno CC, Yee J, Ahmed FS, et al : CT colonography's role in the COVID-19 pandemic : a safe (r), socially distanced total colon examination. Abdom Radiol (NY) 46 : 486-490, 2021.
PubMed
9) Nagata K, Takabayashi K, Yasuda T, et al : Adverse events during CT colonography for screening, diagnosis and preoperative staging of colorectal cancer : a Japanese national survey. Eur Radiol 27 : 4970-4978, 2017.
PubMed
10) 一般社団法人日本消化器がん検診学会 : 大腸CT検査技師認定制度. [https://www.jsgcs.or.jp/authorization/daichouct/index.html] (2023年1月閲覧)
 
11) Levin B, Lieberman DA, McFarland B, et al : American Cancer Society Colorectal Cancer Advisory Group ; US Multi-Society Task Force ; American College of Radiology Colon Cancer Committee : Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008 : a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58 : 130-160, 2008.
PubMed
12) US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al : Screening for Colorectal Cancer : US Preventive Services Task Force Recommendation Statement. JAMA 315 : 2564-2575, 2016.
PubMed
13) Hong YR, Xie Z, Turner K, et al : Utilization Pattern of Computed Tomographic Colonography in the United States : Analysis of the U.S. National Health Interview Survey. Cancer Prev Res (Phila) 14 : 113-122, 2021.
 
14) Johnson CD, Chen MH, Toledano AY, et al : Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359 : 1207-1217, 2008.
PubMed
15) Graser A, Stieber P, Nagel D, et al : Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58 : 241-248, 2009.
 
16) Heresbach D, Djabbari M, Riou F, et al : Accuracy of computed tomographic colonography in a nationwide multicentre trial, and its relation to radiologist expertise. Gut 60 : 658-665, 2011.
 
P.110 掲載の参考文献
1) 画像診断ガイドライン [2021年版] (日本医学放射線学会編), p32, 金原出版, 2021.
 
2) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), p6-49, 金原出版, 2018.
 
3) Mathur P, Smith JJ, Ramsey C, et al : Comparison of CT and MRI in the pre-operative staging of rectal adenocarcinoma and prediction of circumferential resection margin involvement by MRI. Colorectal Dis 5 : 396-401, 2003.
PubMed
4) Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, et al : MRI of Rectal Cancer : Tumor Staging, Imaging Techniques, and Management. Radiographics 39 : 367-387, 2019.
PubMed
5) Bipat S, Glas AS, Slors FJ, et al : Rectal cancer : local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiology 232 : 773-783, 2004.
 
6) Al-Sukhni E, Milot L, Fruitman M, et al : Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer : a systematic review and meta-analysis. Ann Surg Oncol 19 : 2212-2223, 2012.
 
7) Liu H, Yan F, Pan Z, et al : Evaluation of dual energy spectral CT in differentiating metastatic from non-metastatic lymph nodes in rectal cancer : Initial experience. Eur J Radiol 84 : 228-234, 2015.
 
8) Choi SH, Kim SY, Park SH, et al : Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis : Systematic review and meta-analysis. J Magn Reson Imaging 47 : 1237-1250, 2018.
PubMed
9) Barral M, Eveno C, Hoeffel C, et al : Diffusion-weighted magnetic resonance imaging in colorectal cancer. J Visc Surg 153 : 361-369, 2016.
PubMed
P.115 掲載の参考文献
1) FDG PET, PET/CT診療ガイドライン 2020, 日本核医学会, 令和2年 (2020年) 8 月. [http://jsnm.org/wp_jsnm/wp-content/uploads/2018/09/FDG_PET_petct_GL2020.pdf] (2023年1月閲覧)
 
2) Morita Y, Nogami M, Sakaguchi K, et al : Enhanced Release of Glucose Into the Intraluminal Space of the Intestine Associated With Metformin Treatment as Revealed by [18F] Fluorodeoxyglucose PET-MRI. Diabetes Care 43 : 1796-1802, 2020.
PubMed
3) 画像診断ガイドライン 2021年版 (日本医学放射線学会編), p320-322, 金原出版, 2021.
 
4) Dahmarde H, Parooie F, Salarzaei M : Is 18F-FDG PET/CT an Accurate Way to Detect Lymph Node Metastasis in Colorectal Cancer : A Systematic Review and Meta-Analysis. Contrast Media Mol Imaging 2020 : 5439378, 2020.
PubMed
5) Choi SH, Kim SY, Park SH, et al : Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis : Systematic review and meta-analysis. J Magn Reson Imaging 47 : 1237-1250, 2018.
PubMed
6) Maffione AM, Lopci E, Bluemel C, et al : Diagnostic accuracy and impact on management of (18) FFDG PET and PET/CT in colorectal liver metastasis : a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging 42 : 152-163, 2015.
 
7) Ozis SE, Soydal C, Akyol C, et al : The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer. World J Surg Oncol 12 : 26, 2014.
PubMed
8) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Colon Cancer, Version 2. 2022. [https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf] (2023年1月閲覧)
 
9) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
10) Lu YY, Chen JH, Chien CR, et al : Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA : a systematic review and meta-analysis. Int J Colorectal Dis 28 : 1039-1047, 2013.
 
11) Maffione AM, Chondrogiannis S, Capirci C, et al : Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer : a systematic review. Eur J Surg Oncol 40 : 1186-1194, 2014.
PubMed
12) Kawai K, Nozawa H, Hata K, et al : Optimal Interval for 18F-FDG-PET After Chemoradiotherapy for Rectal Cancer. Clin Colorectal Cancer 17 : e163-e170, 2018.
PubMed
13) Xia Q, Liu J, Wu C, et al : Prognostic significance of (18) FDG PET/CT in colorectal cancer patients with liver metastases : a meta-analysis. Cancer Imaging 15 : 19, 2015.
 
14) Hotta M, Minamimoto R, Gohda Y, et al : Prognostic value of 18F-FDG PET/CT with texture analysis in patients with rectal cancer treated by surgery. Ann Nucl Med 35 : 843-852, 2021.
PubMed
15) Gokden Y, Ozulker F, Ozulker T : Prevalence and Clinical Significance of Incidental Focal 18F-FDG Uptake in Colon on PET/CT Imaging. Mol Imaging Radionucl Ther 31 : 96-103, 2022.
PubMed
P.121 掲載の参考文献
1) 大宮直木 : 14-(2) 内視鏡検査が困難な場合の大腸がんスクリーニング大腸カプセル内視鏡. 下部消化管内視鏡スクリーニング検査マニュアル (日本消化器内視鏡学会監), p182-187, 医学図書出版, 2018.
 
2) 大宮直木 : カプセル内視鏡colon capsule endoscopy. 胃と腸 56 (増刊号消化管診断・治療手技のすべて 2021) : 738-739, 2021.
 
3) Ohmiya N, Hotta N, Mitsufuji S, et al : Multicenter feasibility study of bowel preparation with castor oil for colon capsule endoscopy. Dig Endosc 31 : 164-172, 2019.
PubMed
4) Saito Y, Saito S, Oka S, et al : Evaluation of the clinical efficacy of colon capsule endoscopy in the detection of lesions of the colon : prospective, multicenter, open study. Gastrointest Endosc 82 : 861-869, 2015.
PubMed
5) 大宮直木 : 大腸カプセル内視鏡検査の最前線. 胃と腸 57 : 1275-1279, 2022.
 
6) Adler SN, Hassan C, Metzger Y, et al : Second-generation colon capsule endoscopy is feasible in the out-of-clinic setting. Surg Endosc 28 : 570-575, 2014.
PubMed
P.125 掲載の参考文献
1) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
P.128 掲載の参考文献
1) Kojima M, Shimazaki H, Iwaya K, et al : Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer : a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum. J Clin Pathol 66 : 551-558, 2013.
 
2) Ikemastu H, Yoda Y, Matsuda T, et al : Long-term outcomes after resection for submucosal invasive colorectal cancers : Gastroenterology 144 : 551-559 ; quiz e14. 2013.
 
3) 味岡洋一, 大倉康男, 池上雅博, ほか : 早期大腸癌の内視鏡治療の適応拡大 (1) T1b癌 (1,000 μm 以深SM癌) リンパ節転移リスク層別化の検討. 大腸疾患 NOW2016 大腸癌の診断と治療 up data, p63-77, 日本メディカルセンター, 2016.
 
4) 河内洋, 江石義信, 小池盛雄, ほか : 大腸SM癌の病理診断とその問題点-簇出 tumor budding/sprouting. 胃と腸 44 : 1249-1254, 2009.
 
P.134 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2005年版 (大腸癌研究会編), 金原出版, 2005.
 
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
3) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
4) 味岡洋一 : 大腸T1癌内視鏡切除標本の正しい取り扱いと病理組織診断-SM浸潤度評価ポイントとピットフォール. 胃と腸 56 : 1069-1075, 2021.
 
5) 木村隆輔, 藤盛孝博 : DR (desmoplastic reaction). 胃と腸 47 : 825, 2012.
 
6) Matsuda T, Fukuzawa M, Uraoka T, et al : Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer : a retrospective multicenter study. Cancer Sci 102 : 1693-1697, 2011.
PubMed
7) 味岡洋一, 大倉康男, 池上雅博, ほか : 「SM浸潤距離」の評価, 標準化がなされているか-評価の現状と問題点-. 大腸癌FRONTIER 5 : 27-30, 2012.
 
P.139 掲載の参考文献
1) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
2) 味岡洋一 : 大腸pT1b癌リンパ節転移リスク層別化と病理診断精度管理の問題点. 大腸がん perspective 3 : 168-172, 2017.
Medical*Online
3) 斉藤裕輔, 岡志郎, 田中信治, ほか : 早期大腸癌内視鏡治療後の転移再発と予後の実態 (6) 内視鏡治療後経過観察し再発した大腸T1 (SM) 癌の転帰・予後. Intestine 23 : 239-244, 2019.
 
4) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
5) Kitajima K, Fujimori T, Fujii S, et al : Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma : a Japanese collaborative study. J Gastroenterol 39 : 534-543, 2004.
PubMed
6) Kojima M, Shimazaki H, Iwaya K, et al : Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer : a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum. J Clin Pathol 66 : 551-558, 2013.
 
7) Morodomi T, Isomoto H, Shirouzu K, et al : An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63 : 539-543, 1989.
PubMed
8) Ueno H, Mochizuki H, Hashiguchi Y, et al : Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127 : 385-394, 2004.
PubMed
9) Lugli A, Kirsch R, Ajioka Y, et al : Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 30 : 1299-1311, 2017.
PubMed
10) Kawachi H, Eishi Y, Ueno H, et al : A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer : a retrospective multicenter study. Mod Pathol 28 : 872-879, 2015.
PubMed
11) Argiles G, Tabernero J, Labianca R, et al : Localised colon cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31 : 1291-1305, 2020.
PubMed
12) Hassan C, Wysocki PT, Fuccio L, et al : Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer : European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy 51 : C1, 2019.
 
13) Vogel JD, Felder SI, Bhama AR, et al : The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum 65 : 148-177, 2022.
PubMed
14) Ueno H, Hase K, Hashiguchi Y, et al : Novel risk factors for lymph node metastasis in early invasive colorectal cancer : a multi-institution pathology review. J Gastroenterol 49 : 1314-1323, 2014.
PubMed
15) Dykstra MA, Gimon TI, Ronksley PE, et al : Classic and Novel Histopathologic Risk Factors for ymph Node Metastasis in T1 Colorectal Cancer : A Systematic Review and Meta-analysis. Dis Colon Rectum 64 : 1139-1150, 2021.
 
16) Ueno H, Hashiguchi Y, Kajiwara Y, et al : Proposed Objective Criteria for "Grade 3" in Early Invasive Colorectal Cancer. Am J Clin Pathol 134 : 312-322, 2010.
PubMed
17) 味岡洋一, 大倉康男, 池上雅博, ほか : 早期大腸癌の内視鏡治療適応拡大 (1) T1b癌 (1000 μm 以深SM癌) リンパ節転移リスク層別化の検討. 大腸疾患 NOW2016, p63-68, 日本メディカルセンター, 2016.
 
18) Yan S, Ding H, Zhao X, et al : Development and validation of a nomogram for further decision of radical surgery in pT1 colorectal cancer after local resection. Int J Colorectal Dis 36 : 1499-1506, 2021.
 
19) Wada Y, Shimada M, Murano T, et al : A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology 161 : 151-162.e1, 2021.
 
P.147 掲載の参考文献
1) Hawkins NJ, Bariol C, Ward RL : The serrated neoplasia pathway. Pathology 34 : 548-555, 2002.
PubMed
2) Torlakovic E, Skovlund E, Snover DC, et al : Morphologic Reappraisal of Serrated Colorectal Polyps. Am J Surg Pathol 27 : 65-81, 2003.
PubMed
3) Aust DE, Baretton GB ; Members of the Working Group GI-Pathology of the German Society of Pathology : Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps) -proposal for diagnostic criteria. Virchows Arch 457 : 291-297, 2010.
 
4) Nagtegaal ID, Odze RD, Klimstra D, et al : The 2019 WHO classification of tumours of the digestive system. Histopathology 76 : 182-188, 2020.
PubMed
5) Mizuguchi Y, Tanaka Y, Cho H, et al : Endoscopic features of isolated and traditional serrated adenoma-associated superficially serrated adenomas of the colorectum. Dig Endosc 34 : 153-162, 2022.
PubMed
6) Sano Y, Tanaka S, Kudo SE, et al : Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc 28 : 526-533, 2016.
PubMed
7) Kudo S, Tamura S, Nakajima T, et al : Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 44 : 8-14, 1996.
PubMed
8) Kutsukawa M, Kudo SE, Ikehara N, et al : Efficiency of endocytoscopy in differentiating types of serrated polyps. Gastrointest Endosc 79 : 648-656, 2014.
PubMed
9) Nagtegaal ID, Odze RD, Klimstra D, et al : The 2019 WHO classification of tumours of the digestive system. Histopathology 76 : 182-188, 2020.
PubMed
10) Hazewinkel Y, Lopez-Ceron M, East JE, et al : Endoscopic features of sessile serrated adenomas : validation by international experts using high-resolution white-light endoscopy and narrow-band imaging. Gastrointest Endosc 77 : 916-924, 2013.
PubMed
11) Yamada M, Sakamoto T, Otake Y, et al : Investigating endoscopic features of sessile serrated adenomas/polyps by using narrow-band imaging with optical magnification. Gastrointest Endosc 82 : 108-117, 2015.
PubMed
12) Uraoka T, Higashi R, Horii J, et al : Prospective evaluation of endoscopic criteria characteristic of sessile serrated adenomas/polyps. J Gastroenterol 50 : 555-563, 2015.
PubMed
13) Kimura T, Yamamoto E, Yamano HO, et al : A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol 107 : 460-469, 2012.
PubMed
14) Sano W, Fujimori T, Ichikawa K, et al : Clinical and endoscopic evaluations of sessile serrated adenoma/polyps with cytological dysplasia. J Gastroenterol Hepatol 33 : 1454-1460, 2018.
PubMed
15) Murakami T, Sakamoto N, Ritsuno H, et al : Distinct endoscopic characteristics of sessile serrated adenoma/polyp with and without dysplasia/carcinoma. Gastrointest Endosc 85 : 590-600, 2017.
PubMed
16) Murakami T, Kurosawa T, Fukushima H, et al : Sessile serrated lesions : Clinicopathological characteristics, endoscopic diagnosis, and management. Dig Endosc 34 : 1096-1109, 2022.
PubMed
17) Kasuga K, Saito Y, Takamaru H, et al : Optical real-time biopsy by endocytoscopy : a case of sessile serrated lesion with dysplasia. Endoscopy 54 : E249-E251, 2022.
PubMed
18) Mori Y, Kudo SE, Ogawa Y, et al : Diagnosis of sessile serrated adenomas/polyps using endocytoscopy (with videos). Dig Endosc 28 (Suppl 1) : 43-48, 2016.
 
19) 樫田博史 : 大腸鋸歯状病変とは. 近畿大学医学雑誌 37 : 3-9, 2012.
Medical*Online
20) 藤井隆広, 永田和弘, 斉藤豊, ほか : 大腸拡大内視鏡診断はどこまで病理診断に近づいたか-大腸上皮性腫瘍を対象として. 胃と腸 34 : 1653-1664, 1999.
 
21) Kashida H, Ikehara N, Hamatani S, et al : Endoscopic characteristics of colorectal serrated lesions. Hepatogastroenterology 58 : 1163-1167, 2011.
PubMed
22) 山野泰穂, 松下弘雄, 田中義人, ほか : 大腸鋸歯状病変の拡大内視鏡観察. 胃と腸 5 : 48-56, 1999.
 
23) 水口康彦, 橋本大輝, 豊嶋直也, ほか : Superficially serrated adenoma (SuSA) の特徴と意義. 消化器内視鏡 34 : 950-955, 2022.
Medical*Online
P.153 掲載の参考文献
1) Magro F, Gionchetti P, Eliakim R, et al : Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1 : Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 11 : 649-670, 2017.
PubMed
2) Eaden JA, Abrams KR, Mayberry JF : The risk of colorectal cancer in ulcerative colitis : a meta-analysis. Gut 48 : 526-535, 2001.
PubMed
3) Laukoetter MG, Mennigen R, Hannig CM, et al : Intestinal cancer risk in Crohn's disease : a metaanalysis. J Gastrointest Surg 15 : 576-583, 2011.
PubMed
4) Ullman TA, Itzkowitz SH : Intestinal inflammation and cancer. Gastroenterology 140 : 1807-1816, 2011.
PubMed
5) Sugimoto S, Shimoda M, Iwao Y, et al : Intramucosal poorly differentiated and signet-ring cell components in patients with ulcerative colitis-associated high-grade dysplasia. Dig Endosc 31 : 706-711, 2019.
PubMed
6) 岩男泰, 長沼誠, 下田将之, ほか : 拡大内視鏡による潰瘍性大腸炎関連腫瘍診断の現状と課題-初期病変を中心に. 胃と腸 55 : 142-149, 2020.
 
7) 炎症性腸疾患 (IBD) 診療ガイドライン 2020 (改訂第2版) (日本消化器病学会編), 南江堂, 2020.
 
8) Ikebata A, Shimoda M, Okabayashi K, et al : Demarcated redness associated with increased vascular density/size : a useful marker of flat-type dysplasia in patients with ulcerative colitis. Endosc Int Open 9 : E552-E561, 2021.
 
9) Sugimoto S, Naganuma M, Iwao Y, et al : Endoscopic morphologic features of ulcerative colitisassociated dysplasia classified according to the SCENIC consensus statement. Gastrointest Endosc 85 : 639-646.e2, 2017.
 
10) 味岡洋一 : 潰瘍性大腸炎におけるcolitis-associated cancer (炎症性発癌) 早期病変の病理診断-現状と問題点-. 日本消化器病学会雑誌 117 : 957-964, 2020.
Medical*Online
11) Laine L, Kaltenbach T, Barkun A, et al : SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 148 : 639-651.e28, 2015.
 
12) Mutaguchi M, Naganuma M, Sugimoto S, et al : Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. Dig Liver Dis 51 : 1257-1264, 2019.
PubMed
13) Higashi D, Katsuno H, Kimura H, et al : Current State of and Problems Related to Cancer of the Intestinal Tract Associated with Crohn's Disease in Japan. Anticancer Res 36 : 3761-3766, 2016.
PubMed
14) Noguchi T, Ishihara S, Uchino M, et al : Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. J Gastroenterol 58 : 14-24, 2023.
PubMed
15) 杉田昭 : 潰瘍性大腸炎, Crohn 病に合併した小腸, 大腸癌の特徴と予後-第12報--Crhon病の直腸肛門管癌 (痔瘻癌を含む) に対するsurveillance programの効果とMRIの意義-. 平成28年度厚生労働科学研究補助金難治性疾患等政策研究事業難治性炎症性腸管障害に関する調査研究分担研究報告書. 167-171, 2017.
 
P.160 掲載の参考文献
1) 清水誠治, 横溝千尋, 富岡秀夫, ほか : 狭窄を来す大腸疾患-診断のプロセスを含めた総合画像診断の立場から : 上皮性腫瘍, 非上皮性腫瘍, 炎症性疾患, それぞれに適した検査法の組み合わせ. 胃と腸 50 : 1255-1266, 2015.
 
2) 桑田剛, 小泉浩一, 江頭秀人, ほか : 潰瘍型を呈した無色素性直腸肛門部悪性黒色腫の1例. 胃と腸 47 : 403-412, 2012.
 
3) 清水誠治, 福田亘, 三原美香, ほか : 非上皮性腫瘍の臨床診断と治療の進め方. 早期大腸癌 12 : 19-24, 2008.
 
4) 福島正之, 森田高行, 岡村圭祐, ほか : FDG-PET検査で集積を認め悪性疾患との鑑別に苦慮した上行結腸脂肪腫の1例. 日本大腸肛門病学会雑誌 64 : 500-504, 2011.
 
5) 清水誠治, 福田亘, 三原美香, ほか : 非上皮性腫瘍と鑑別の必要な疾患 b. 転移性大腸癌. 早期大腸癌 12 : 66-70, 2008.
 
6) 松永心祐, 富岡秀夫, 清水誠治, ほか : 多発する表面型病変を形成した胃癌原発転移性大腸癌の1例. 胃と腸 38 : 1862-1868, 2003.
 
7) 清水誠治, 富岡秀夫, 多田正大 : 腸管子宮内膜症. 胃と腸 40 : 661-664, 2005.
 
8) 清水誠治, 石田英和, 富岡秀夫, ほか : 炎症性ポリープ-内視鏡診断の立場から. 胃と腸 48 : 1140-1148, 2013.
 
9) 清水誠治, 富岡秀夫, 横溝千尋, ほか : 内視鏡の読み方-直腸粘膜脱症候群. 臨牀消化器内科 31 : 591-595, 2016.
 
10) 麦谷達郎, 清水誠治, 江頭由太郎, ほか : 大腸憩室を背景に発生したと考えられるfiliform polyposisの1例. 胃と腸 47 : 1127-1134, 2012.
 
11) 清水誠治, 南竜城, 三宅清花, ほか : 腸結核 ; 炎症性腸疾患と鑑別すべき主な疾患とその鑑別診断. 日本臨牀 70 (増刊号 1 : 炎症性腸疾患) : 581-586, 2012.
 
12) 河野友彦, 岡信秀治, 初鹿佳輝, ほか : 1型進行大腸癌様の形態を呈したアメーバ性大腸炎の1例. Gastroenterological Endoscopy 63 : 1113-1118, 2021.
 
13) 伊藤繭, 清水誠治, 富岡秀夫, ほか : 特異な画像所見を呈したアメーバ性大腸炎の1例. 胃と腸 38 : 1463-1467, 2003.
 
P.166 掲載の参考文献
1) Bray F, Ferlay J, Soerjomataram I, et al : Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 : 394-424, 2018.
PubMed
2) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
3) Corley DA, Jensen CD, Marks AR, et al : Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 370 : 1298-1306, 2014.
PubMed
4) Hassan C, Piovani D, Spadaccini M, et al : Variability in adenoma detection rate in control groups of randomized colonoscopy trials : a systematic review and meta-analysis. Gastrointest Endosc 97 : 212-225.e7, 2023.
 
5) 鶴田修, 辻雄一郎, 河野弘志, ほか : 通常内視鏡下pit観察による大腸腫瘍・非腫瘍鑑別能の検討-5 mm以下の病変を対象として. 胃と腸 34 : 1613-1622, 1999.
 
6) von Renteln D, Kaltenbach T, Rastogi A, et al : Simplifying Resect and Discard Strategies for Real-Time Assessment of Diminutive Colorectal Polyps. Clin Gastroenterol Hepatol 16 : 706-714, 2018.
PubMed
7) Houwen BBSL, Hassan C, Coupe VMH, et al : Definition of competence standards for optical diagnosis of diminutive colorectal polyps : European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 54 : 88-99, 2022.
PubMed
8) Willems P, Djinbachian R, Ditisheim S, et al : Uptake and barriers for implementation of the resect and discard strategy : an international survey. Endosc Int Open 8 : E684-E692, 2020.
PubMed
9) Wang P, Berzin TM, Glissen Brown JR, et al : Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates : a prospective randomised controlled study. Gut 68 : 1813-1819, 2019.
 
10) Kamba S, Tamai N, Saitoh I, et al : Reducing adenoma miss rate of colonoscopy assisted by artificial intelligence : a multicenter randomized controlled trial. J Gastroenterol 56 : 746-757, 2021.
PubMed
11) Xu H, Tang RSY, Lam TYT, et al : Artificial Intelligence-Assisted Colonoscopy for Colorectal Cancer Screening : A Multicenter Randomized Controlled Trial. Clin Gastroenterol Hepatol 21 : 337-346.e3, 2023.
 
12) Huang D, Shen J, Hong J, et al : Effect of artificial intelligence-aided colonoscopy for adenoma and polyp detection : a meta-analysis of randomized clinical trials. Int J Colorectal Dis 37 : 495-506, 2022.
 
13) Lu Z, Zhang L, Yao L, et al : Assessment of the Role of Artificial Intelligence in the Association Between Time of Day and Colonoscopy Quality. JAMA Netw Open 6 : e2253840, 2023.
 
14) Byrne MF, Chapados N, Soudan F, et al : Real-time differentiation of adenomatous and hyperplastic diminutive colorectal polyps during analysis of unaltered videos of standard colonoscopy using a deep learning model. Gut 68 : 94-100, 2019.
PubMed
15) Jin EH, Lee D, Bae JH, et al : Improved Accuracy in Optical Diagnosis of Colorectal Polyps Using Convolutional Neural Networks with Visual Explanations. Gastroenterology 158 : 2169-2179.e8, 2020.
 
16) Hassan C, Balsamo G, Lorenzetti R, et al : Artificial Intelligence Allows Leaving-In-Situ Colorectal Polyps. Clin Gastroenterol Hepatol 20 : 2505-2513.e4, 2022.
 
P.173 掲載の参考文献
1) Leggett B, Whitehall V : Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138 : 2088-2100, 2010.
PubMed
2) Hinoi T : Cancer Genomic Profiling in Colorectal Cancer : Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. J Anus Rectum Colon 5 : 213-228, 2021.
PubMed
3) Guinney J, Dienstmann R, Wang X, et al : The consensus molecular subtypes of colorectal cancer. Nat Med 21 : 1350-1356, 2015.
PubMed
4) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
5) Yoshino T, Arnold D, Taniguchi H, et al : Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer : a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29 : 44-70, 2018.
PubMed
6) Kopetz S, Grothey A, Yaeger R, et al : Encorafenib, Binimetinib, and Cetuximab in BRAF V600-Emutated colorectal cancer. N Eng J Med 381 : 1632-1643, 2019.
 
7) 遺伝性大腸癌診療ガイドライン [2020年版] (大腸癌研究会編), 金原出版, 2020.
 
8) Nakamura Y, Okamoto W, Kato T, et al : Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer : a phase 2 trial. Nat Med 27 : 1899-1903, 2021.
PubMed
9) Sawada K, Nakamura Y, Yamanaka T, et al : Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 17 : 198-205, 2018.
PubMed
10) Le DT, Kim TW, Van Cutsem E, et al : Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer : KEYNOTE-164. J Clin Oncol 38 : 11-19, 2020.
PubMed
11) Akagi K, Oki E, Taniguchi H, et al : Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112 : 1105-1113, 2021.
 
12) Schwaederle M, Zhao M, Lee JJ, et al : Impact of Precision Medicine in Diverse Cancers : A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol 33 : 3817-3825, 2015.
PubMed
13) 大腸がん診療における遺伝子関連検査等のガイダンス [第4版] (日本臨床腫瘍学会編), 金原出版, 2019.
 
P.180 掲載の参考文献
1) Ashworth TR : A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 14 : 146-147, 1869.
 
2) Schuster E, Taftaf R, Reduzzi C, et al : Better together : circulating tumor cell clustering in metastatic cancer. Trends Cancer 7 : 1020-1032, 2021.
PubMed
3) Meng S, Tripathy D, Frenkel EP, et al : Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10 : 8152-8162, 2004.
PubMed
4) Yang C, Zhuang W, Hu Y, et al : Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer. World J Surg Oncol 16 : 13, 2018.
PubMed
5) Wu J, Li Z, Zou J, et al : A meta-analysis of the value of circulating tumor cells in monitoring postoperative recurrence and metastasis of colorectal cancer. PLoS One 17 : e0274282, 2022.
 
6) Cohen SJ, Punt CJ, Iannotti N, et al : Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20 : 1223-1229, 2009.
PubMed
7) Matsusaka S, Hanna DL, Ning Y, et al : Epidermal growth factor receptor mRNA expression : A potential molecular escape mechanism from regorafenib. Cancer Sci 111 : 441-450, 2020.
PubMed
8) Cai J, Huang L, Huang J, et al : Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer. J Cell Biochem 120 : 4935-4941, 2019.
PubMed
9) Satelli A, Mitra A, Brownlee Z, et al : Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21 : 899-906, 2015.
PubMed
10) De Angelis ML, Francescangeli F, Nicolazzo C, et al : An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile. J Exp Clin Cancer Res 41 : 86, 2022.
PubMed
11) Kahlert C, Melo SA, Protopopov A, et al : Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289 : 3869-3875, 2014.
PubMed
12) Jahr S, Hentze H, Englisch S, et al : DNA fragments in the blood plasma of cancer patients : quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 : 1659-1665, 2001.
PubMed
13) Schwarzenbach H, Hoon DS, Pantel K : Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11 : 426-437, 2011.
 
14) Yao W, Mei C, Nan X, et al : Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva : A qualitative study. Gene 590 : 142-148, 2016.
PubMed
15) Kustanovich A, Schwartz R, Peretz T, et al : Life and death of circulating cell-free DNA. Cancer Biol Ther 20 : 1057-1067, 2019.
PubMed
16) Lo YM, Chan KC, Sun H, et al : Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2 : 61ra91, 2010.
PubMed
17) Mouliere F, Chandrananda D, Piskorz AM, et al : Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 10 : eaat4921, 2018.
PubMed
18) Garcia-Olmo DC, Dominguez C, Garcia-Arranz M, et al : Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res 70 : 560-567, 2010.
PubMed
19) Takahashi RU, Prieto-Vila M, Hironaka A, et al : The role of extracellular vesicle microRNAs in cancer biology. Clin Chem Lab Med 55 : 648-656, 2017.
PubMed
20) Ogata-Kawata H, Izumiya M, Kurioka D, et al : Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 9 : e92921, 2014.
PubMed
21) Matsumura T, Sugimachi K, Iinuma H, et al : Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer 113 : 275-281, 2015.
PubMed
22) Li J, Song Y, Wang J, et al : Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer detection. Am J Transl Res 12 : 7395-7403, 2020.
 
23) Liu T, Zhang X, Gao S, et al : Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget 7 : 85551-85563, 2016.
PubMed
24) Yoshioka Y, Kosaka N, Konishi Y, et al : Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun 5 : 3591, 2014.
PubMed
25) Masuda T, Hayashi N, Kuroda Y, et al : MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) 9 : 124, 2017.
PubMed
26) Aherne ST, Madden SF, Hughes DJ, et al : Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer 15 : 329, 2015.
PubMed
27) Yan S, Jiang Y, Liang C, et al : Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer. J Cell Biochem 119 : 4113-4119, 2018.
 
28) Ye DX, Wang SS, Huang Y, et al : A 3-circular RNA signature as a noninvasive biomarker for diagnosis of colorectal cancer. Cancer Cell Int 19 : 276, 2019.
 
29) Xing L, Xia M, Jiao X, et al : Hsa_circ_0004831 serves as a blood-based prognostic biomarker for colorectal cancer and its potentially circRNA-miRNA-mRNA regulatory network construction. Cancer Cell Int 20 : 557, 2020.
PubMed
30) Fu Y, Huang L, Tang H, et al : hsa_circRNA_012515 Is Highly Expressed in NSCLC Patients and Affects Its Prognosis. Cancer Manag Res 12 : 1877-1886, 2020.
PubMed

III 内視鏡治療

P.190 掲載の参考文献
1) Ikematsu H, Murano T, Shinmura K : Depth diagnosis of early colorectal cancer : Magnifying chromoendoscopy or image enhanced endoscopy with magnification? Dig Endosc 34 : 265-273, 2022.
PubMed
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
3) Lash RH, Genta RM, Schuler CM : Sessile serrated adenomas : prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol 63 : 681-686, 2010.
PubMed
4) Liang JJ, Bissett I, Kalady M, et al : Importance of serrated polyps in colorectal carcinogenesis. ANZ J Surg 83 : 325-330, 2013.
PubMed
5) 大腸ポリープ診療ガイドライン 2020 (日本消化器病学会編), 南江堂, 2020.
 
6) Sano W, Sano Y, Iwatate M, et al : Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features. Endosc Int Open 3 : E354-E358, 2015.
PubMed
7) Uraoka T, Higashi R, Horii J, et al : Prospective evaluation of endoscopic criteria characteristic of sessile serrated adenomas/polyps. J Gastroenterol 50 : 555-563, 2015.
PubMed
8) Kimura T, Yamamoto E, Yamano HO, et al : A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol 107 : 460-469, 2012.
PubMed
9) Murakami T, Sakamoto N, Fukushima H, et al : Usefulness of the Japan narrow-band imaging expert team classification system for the diagnosis of sessile serrated lesion with dysplasia/carcinoma. Surg Endosc 35 : 4528-4538, 2021.
PubMed
10) Burgess NG, Pellise M, Nanda KS, et al : Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps. Gut 65 : 437-446, 2016.
PubMed
11) Saiki H, Nishida T, Yamamoto M, et al : Frequency of coexistent carcinoma in sessile serrated adenoma/polyps and traditional serrated adenomas removed by endoscopic resection. Endosc Int Open 4 : E451-E458, 2016.
PubMed
12) Winawer SJ, Zauber AG, Ho MN, et al : Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329 : 1977-1981, 1993.
PubMed
13) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
14) Sakamoto T, Matsuda T, Nakajima T, et al : Clinicopathological features of colorectal polyps : evaluation of the 'predict, resect and discard' strategies. Colorectal Dis 15 : e295-300, 2013.
PubMed
15) 田中信治, 樫田博史, 斎藤豊, ほか : 大腸ESD/EMRガイドライン (第2版). 日本消化器内視鏡学会雑誌 61 : 1321-1344, 2019.
 
16) 味岡洋一, 大倉康男, 池上雅博, ほか : 早期大腸癌の内視鏡治療適応拡大 (1) T1b癌 (1,000 μm 以深SM癌) リンパ節転移リスク層別化の検討. 大腸疾患 NOW 2016 大腸癌の診断と治療 up data, p63-68, 日本メディカルセンター, 2016.
 
17) Ikematsu H, Yoda Y, Matsuda T, et al : Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 144 : 551-559 ; quiz e14, 2013.
PubMed
18) Yoda Y, Ikematsu H, Matsuda T, et al : A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. Endoscopy 45 : 718-724, 2013.
PubMed
19) 膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019年 (第2版) (日本神経内分泌腫瘍研究会編), 金原出版, 2019.
 
20) Hotta K, Shimoda T, Nakanishi Y, et al : Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int 56 : 591-596, 2006.
PubMed
P.195 掲載の参考文献
1) Winawer SJ, Zauber AG, Ho MN, et al : Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329 : 1977-1981, 1993.
PubMed
2) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
3) Loberg M, Kalager M, Holme O, et al : Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 371 : 799-807, 2014.
PubMed
4) Shaukat A, Mongin SJ, Geisser MS, et al : Long-term mortality after screening for colorectal cancer. N Engl J Med 369 : 1106-1114, 2013.
PubMed
5) Nishihara R, Wu K, Lochhead P, et al : Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369 : 1095-1105, 2013.
PubMed
6) Takeuchi Y, Mabe K, Shimodate Y, et al : Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps : A Randomized Controlled Trial. Ann Intern Med 171 : 229-237, 2019.
PubMed
7) Woods A, Sanowski RA, Wadas DD, et al : Eradication of diminutive polyps : a prospective evaluation of bipolar coagulation versus conventional biopsy removal. Gastrointest Endosc 35 : 536-540, 1989.
PubMed
8) Efthymiou M, Taylor AC, Desmond PV, et al : Biopsy forceps is inadequate for the resection of diminutive polyps. Endoscopy 43 : 312-316, 2011.
PubMed
9) Draganov PV, Chang MN, Alkhasawneh A, et al : Randomized, controlled trial of standard, largecapacity versus jumbo biopsy forceps for polypectomy of small, sessile, colorectal polyps. Gastrointest Endosc 75 : 118-126, 2012.
PubMed
10) Kim JS, Lee BI, Choi H, et al : Cold snare polypectomy versus cold forceps polypectomy for diminutive and small colorectal polyps : a randomized controlled trial. Gastrointest Endosc 81 : 741-747, 2015.
PubMed
11) Jung YS, Park JH, Kim HJ, et al : Complete biopsy resection of diminutive polyps. Endoscopy 45 : 1024-1029, 2013.
PubMed
12) 浦岡俊夫, 滝沢耕平, 田中信治 : 大腸cold polypectomyガイドライン (大腸ESD/EMRガイドライン追補). 日本消化器内視鏡学会雑誌 63 : 1147-1158, 2021.
 
13) Ferlitsch M, Moss A, Hassan C, et al : Colorectal polypectomy and endoscopic mucosal resection (EMR) : European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 49 : 270-297, 2017.
PubMed
14) Kaltenbach T, Anderson JC, Burke CA, et al : Endoscopic Removal of Colorectal Lesions-Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 91 : 486-519, 2020.
PubMed
15) Tappero G, Gaia E, De Giuli P, et al : Cold snare excision of small colorectal polyps. Gastrointest Endosc 38 : 310-313, 1992.
PubMed
16) Lieberman D, Moravec M, Holub J, et al : Polyp size and advanced histology in patients undergoing colonoscopy screening : implications for CT colonography. Gastroenterology 135 : 1100-1105, 2008.
PubMed
17) Gupta N, Bansal A, Rao D, et al : Prevalence of advanced histological features in diminutive and small colon polyps. Gastrointest Endosc 75 : 1022-1030, 2012.
PubMed
18) Raad D, Tripathi P, Cooper G, et al : Role of the cold biopsy technique in diminutive and small colonic polyp removal : a systematic review and meta-analysis. Gastrointest Endosc 83 : 508-515, 2016.
 
19) Fujiya M, Sato H, Ueno N, et al : Efficacy and adverse events of cold vs hot polypectomy : A meta-analysis. World J Gastroenterol 22 : 5436-5444, 2016.
PubMed
20) 大腸ポリープ診療ガイドライン 2020 [改訂第2版] (日本消化器病学会編), 南江堂, 2020.
 
21) Kawamura T, Takeuchi Y, Asai S, et al : A comparison of the resection rate for cold and hot snare polypectomy for 4-9 mm colorectal polyps : a multicentre randomised controlled trial (CRESCENT study). Gut 67 : 1950-1957, 2018.
PubMed
22) Yamashina T, Fukuhara M, Maruo T, et al : Cold snare polypectomy reduced delayed postpolypectomy bleeding compared with conventional hot polypectomy : a propensity scorematching analysis. Endosc Int Open 5 : E587-E594, 2017.
PubMed
23) Shinozaki S, Kobayashi Y, Hayashi Y, et al : Efficacy and safety of cold versus hot snare polypectomy for resecting small colorectal polyps : Systematic review and meta-analysis. Dig Endosc 30 : 592-599, 2018.
PubMed
24) Suzuki S, Gotoda T, Kusano C, et al : Width and depth of resection for small colorectal polyps : hot versus cold snare polypectomy. Gastrointest Endosc 87 : 1095-1103, 2018.
PubMed
25) Ichise Y, Horiuchi A, Nakayama Y, et al : Prospective randomized comparison of cold snare polypectomy and conventional polypectomy for small colorectal polyps. Digestion 84 : 78-81, 2011.
PubMed
26) Zhang Q, Gao P, Han B, et al : Polypectomy for complete endoscopic resection of small colorectal polyps. Gastrointest Endosc 87 : 733-740, 2018.
PubMed
27) Matsuura N, Takeuchi Y, Yamashina T, et al : Incomplete resection rate of cold snare polypectomy : a prospective single-arm observational study. Endoscopy 49 : 251-257, 2017.
PubMed
28) Ito A, Suga T, Ota H, et al : Resection depth and layer of cold snare polypectomy versus endoscopic mucosal resection. J Gastroenterol 53 : 1171-1178, 2018.
PubMed
29) Hirose R, Yoshida N, Murakami T, et al : Histopathological analysis of cold snare polypectomy and its indication for colorectal polyps 10-14 mm in diameter. Dig Endosc 29 : 594-601, 2017.
PubMed
30) Muniraj T, Sahakian A, Ciarleglio MM, et al : Cold snare polypectomy for large sessile colonic polyps : a single-center experience. Gastroenterol Res Pract 2015 : 175959, 2015.
PubMed
31) Friedland S, Banerjee S, Kochar R, et al : Outcomes of repeat colonoscopy in patients with polyps referred for surgery without biopsy-proven cancer. Gastrointest Endosc 79 : 101-107, 2014.
PubMed
32) Longcroft-Wheaton G, Duku M, Mead R, et al : Risk stratification system for evaluation of complex polyps can predict outcomes of endoscopic mucosal resection. Dis Colon Rectum 56 : 960-966, 2013.
PubMed
33) Tutticci N, Burgess NG, Pellise M, et al : Characterization and significance of protrusions in the mucosal defect after cold snare polypectomy. Gastrointest Endosc 82 : 523-528, 2015.
PubMed
34) Horiuchi A, Hosoi K, Kajiyama M, et al : Prospective, randomized comparison of 2 methods of cold snare polypectomy for small colorectal polyps. Gastrointest Endosc 82 : 686-692, 2015.
PubMed
35) Takeuchi Y, Yamashina T, Matsuura N, et al : Feasibility of cold snare polypectomy in Japan : A pilot study. World J Gastrointest Endosc 7 : 1250-1256, 2015.
PubMed
36) Deenadayalu VP, Rex DK : Colon polyp retrieval after cold snaring. Gastrointest Endosc 62 : 253-256, 2005.
PubMed
37) Matsumoto M, Yoshii S, Shigesawa T, et al : Safety of Cold Polypectomy for Colorectal Polyps in Patients on Antithrombotic Medication. Digestion 97 : 76-81, 2018.
PubMed
38) Makino T, Horiuchi A, Kajiyama M, et al : Delayed Bleeding Following Cold Snare Polypectomy for Small Colorectal Polyps in Patients Taking Antithrombotic Agents. J Clin Gastroenterol 52 : 502-507, 2018.
PubMed
39) Arimoto J, Chiba H, Ashikari K, et al : Safety of Cold Snare Polypectomy in Patients Receiving Treatment with Antithrombotic Agents. Dig Dis Sci 64 : 3247-3255, 2019.
PubMed
P.203 掲載の参考文献
1) 田中信治, 樫田博史, 斎藤豊, ほか : 大腸ESD/EMRガイドライン (第2版). 日本消化器内視鏡学会雑誌 61 : 1321-1344, 2019.
 
2) Toyonaga T, Nishino E, Man-I M, et al : Principles of quality controlled endoscopic submucosal dissection with appropriate dissection level and high quality resected specimen. Clin Endosc 45 : 362-374, 2012.
PubMed
3) Ishida T, Toyonaga T, Ohara Y, et al : Efficacy of forced coagulation with low high-frequency power setting during endoscopic submucosal dissection. World J Gastroenterol 23 : 5422-5430, 2017.
PubMed
4) Nakajima T, Saito Y, Tanaka S, et al : Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. Surg Endosc 27 : 3262-3270, 2013.
PubMed
5) Takamaru H, Saito Y, Yamada M, et al : Clinical impact of endoscopic clip closure of perforations during endoscopic submucosal dissection for colorectal tumors. Gastrointest Endosc 84 : 494-502.e1, 2016.
 
6) Saito Y, Uraoka T, Yamaguchi Y, et al : A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 72 : 1217-1225, 2010.
PubMed
7) Ito S, Hotta K, Imai K, et al : Risk factors of post-endoscopic submucosal dissection electrocoagulation syndrome for colorectal neoplasm. J Gastroenterol Hepatol 33 : 2001-2006, 2018.
PubMed
8) Li R, Cai S, Sun D, et al : Risk factors for delayed bleeding after endoscopic submucosal dissection of colorectal tumors. Surg Endosc 35 : 6583-6590, 2021.
PubMed
9) Yamasaki Y, Takeuchi Y, Uedo N, et al : Traction-assisted colonic endoscopic submucosal dissection using clip and line : a feasibility study. Endosc Int Open 4 : E51-E55, 2016.
 
10) Ohara Y, Toyonaga T, Tanaka S, et al : Risk of stricture after endoscopic submucosal dissection for large rectal neoplasms. Endoscopy 48 : 62-70, 2016.
PubMed
11) Jacob H, Toyonaga T, Ohara Y, et al : Endoscopic submucosal dissection of cecal lesions in proximity to the appendiceal orifice. Endoscopy 48 : 829-836, 2016.
 
12) Yoshizaki T, Toyonaga T, Tanaka S, et al : Feasibility and safety of endoscopic submucosal dissection for lesions involving the ileocecal valve. Endoscopy 48 : 639-645, 2016.
PubMed
13) Toyonaga T, Tanaka S, Man-I M, et al : Clinical significance of the muscle-retracting sign during colorectal endoscopic submucosal dissection. Endosc Int Open 3 : E246-E251, 2015.
PubMed
14) Hayashi Y, Sunada K, Takahashi H, et al : Pocket-creation method of endoscopic submucosal dissection to achieve en bloc resection of giant colorectal subpedunculated neoplastic lesions. Endoscopy 46 (Suppl 1) : E421-E422, 2014.
 
15) Toyonaga T, Ohara Y, Baba S, et al : Peranal endoscopic myectomy (PAEM) for rectal lesions with severe fibrosis and exhibiting the muscle-retracting sign. Endoscopy 50 : 813-817, 2018.
PubMed
P.211 掲載の参考文献
1) Kobayashi N, Takeuchi Y, Ohata K, et al : Outcomes of endoscopic submucosal dissection for colorectal neoplasms : Prospective, multicenter, cohort trial. Dig Endosc 34 : 1042-1051, 2022.
PubMed
2) Ohata K, Kobayashi N, Sakai E, et al : Long-term Outcomes After Endoscopic Submucosal Dissection for Large Colorectal Epithelial Neoplasms : A Prospective, Multicenter, Cohort Trial From Japan. Gastroenterology 163 : 1423-1434.e2, 2022.
 
3) Kadota T, Ikematsu H, Sasaki T, et al : Protocol for a single-arm confirmatory trial of adjuvant chemoradiation for patients with high-risk rectal submucosal invasive cancer after local resection : Japan Clinical Oncology Group Study JCOG1612 (RESCUE study). BMJ Open 10 : e034947, 2020.
 
4) Toyonaga T, Ohara Y, Baba S, et al : Peranal endoscopic myectomy (PAEM) for rectal lesions with severe fibrosis and exhibiting the muscle-retracting sign. Endoscopy 50 : 813-817, 2018.
PubMed
5) Schmidt A, Beyna T, Schumacher B, et al : Colonoscopic full-thickness resection using an over-thescope device : a prospective multicentre study in various indications. Gut 67 : 1280-1289, 2018.
 
6) Ozeki Y, Hirasawa K, Ikeda R, et al : Safety and efficacy of water pressure endoscopic submucosal dissection for colorectal tumors with submucosal fibrosis (with video). Gastrointest Endosc 94 : 607-617.e2, 2021.
 
7) Hayashi Y, Miura Y, Yamamoto H : Pocket-creation method for the safe, reliable, and efficient endoscopic submucosal dissection of colorectal lateral spreading tumors. Dig Endosc 27 : 534-535, 2015.
PubMed
8) Guillaumot MA, Barret M, Jacques J, et al : Endoscopic full-thickness resection of early colorectal neoplasms using an endoscopic submucosal dissection knife : a retrospective multicenter study. Endosc Int Open 8 : E611-E616, 2020.
PubMed
9) Meier B, Stritzke B, Kuellmer A, et al : Efficacy and Safety of Endoscopic Full-Thickness Resection in the Colorectum : Results From the German Colonic FTRD Registry. Am J Gastroenterol 115 : 1998-2006, 2020.
PubMed
10) Pohl H, Grimm IS, Moyer MT, et al : Clip Closure Prevents Bleeding After Endoscopic Resection of Large Colon Polyps in a Randomized Trial. Gastroenterology 157 : 977-984.e3, 2019.
 
11) Crockett SD, Khashab M, Rex DK, et al : Clip Closure Does Not Reduce Risk of Bleeding After Resection of Large Serrated Polyps : Results From a Randomized Trial. Clin Gastroenterol Hepatol 20 : 1757-1765.e4, 2022.
 
12) Goto O, Sasaki M, Akimoto T, et al : Endoscopic hand-suturing for defect closure after gastric endoscopic submucosal dissection : a pilot study in animals and in humans. Endoscopy 49 : 792-797, 2017.
PubMed
13) Horenkamp-Sonntag D, Liebentraut J, Engel S, et al : Use of over-the-scope clips in the colon in clinical practice : results from a German administrative database. Endoscopy 52 : 1103-1110, 2020.
 
14) Goto O, Sasaki M, Ishii H, et al : A new endoscopic closure method for gastric mucosal defects : feasibility of endoscopic hand suturing in an ex vivo porcine model (with video). Endosc Int Open 2 : E111-E116, 2014.
 
15) Abe S, Saito Y, Tanaka Y, et al : A novel endoscopic hand-suturing technique for defect closure after colorectal endoscopic submucosal dissection : a pilot study. Endoscopy 52 : 780-785, 2020.
PubMed
P.217 掲載の参考文献
1) Tajiri H, Kitano S : Complications associated with endoscopic mucosal resection : definition of bleeding that can be viewed as accidental. Digestive Endoscopy 16 : S134-S136, 2004.
 
2) Oka S, Tanaka S, Kanao H, et al : Current status in the occurrence of postoperative bleeding, perforation and residual/local recurrence during colonoscopic treatment in Japan. Dig Endosc 22 : 376-380, 2010.
PubMed
3) Nakajima T, Saito Y, Tanaka S, et al : Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. Surg Endosc 27 : 3262-3270, 2013.
PubMed
4) Kobayashi N, Takeuchi Y, Ohata K, et al : Outcomes of endoscopic submucosal dissection for colorectal neoplasms : Prospective, multicenter, cohort trial. Dig Endosc 34 : 1042-1051, 2022.
PubMed
5) Ochi M, Kawagoe R, Kamoshida T, et al : High total Joule heat increases the risk of post-endoscopic submucosal dissection electrocoagulation syndrome after colorectal endoscopic submucosal dissection. World J Gastroenterol 27 : 6442-6452, 2021.
PubMed
6) Tashima T, Nakano Y, Jinushi R, et al : Gel immersion endoscopic submucosal dissection for an anorectal tumor with hemorrhoids close to the dentate line. Endoscopy 54 : E298-E299, 2022.
 
7) Khurelbaatar T, Miura Y, Yano T, et al : Electrolyte-free gel immersion endoscopic submucosal dissection of gastric lesions. Endoscopy 54 : E512-E513, 2022.
PubMed
8) Subramaniam S, Kandiah K, Chedgy F, et al : A novel self-assembling peptide for hemostasis during endoscopic submucosal dissection : a randomized controlled trial. Endoscopy 53 : 27-35, 2021.
PubMed
9) Parikh ND, Zanocco K, Keswani RN, et al : A cost-efficacy decision analysis of prophylactic clip placement after endoscopic removal of large polyps. Clin Gastroenterol Hepatol 11 : 1319-1324, 2013.
PubMed
10) Ogasawara N, Yoshimine T, Noda H, et al : Clinical risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal tumors in Japanese patients. Eur J Gastroenterol Hepatol 28 : 1407-1414, 2016.
PubMed
11) Seo M, Song EM, Cho JW, et al : A risk-scoring model for the prediction of delayed bleeding after colorectal endoscopic submucosal dissection. Gastrointest Endosc 89 : 990-998.e2, 2019.
 
12) Miyakawa A, Kuwai T, Sakuma Y, et al : The efficacy of prophylactic clip closure of mucosal defects after colorectal endoscopic submucosal dissection on delayed bleeding. Scand J Gastroenterol 56 : 1236-1242, 2021.
PubMed
13) Yano T, Shinozaki S, Yamamoto H : Crossed-clip strangulation for the management of small intestinal polyps in patients with Peutz-Jeghers syndrome. Dig Endosc 30 : 677, 2018.
PubMed
14) Yano T, Nemoto D, Ono K, et al : Gel immersion endoscopy : a novel method to secure the visual field during endoscopy in bleeding patients (with videos). Gastrointest Endosc 83 : 809-811, 2016.
PubMed
15) Yano K, Yano T, Nagayama M, et al : Hemostasis of an actively bleeding lesion at the ileocecal valve by low-pressure endoscopy using the gel immersion technique. VideoGIE 6 : 184-186, 2021.
PubMed
P.222 掲載の参考文献
1) van Hooft JE, Veld JV, Arnold D, et al : Self-expandable metal stents for obstructing colonic and extracolonic cancer : European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Update 2020. Endoscopy 52 : 389-407, 2020.
PubMed
2) Matsuzawa T, Ishida H, Yoshida S, et al : A Japanese prospective multicenter study of self-expandable metal stent placement for malignant colorectal obstruction : short-term safety and efficacy within 7 days of stent procedure in 513 cases. Gastrointest Endosc 82 : 697-707.e1, 2015.
 
3) Kuwai T, Yamaguchi T, Imagawa H, et al : Factors related to difficult self-expandable metallic stent placement for malignant colonic obstruction : A post-hoc analysis of a multicenter study across Japan. Dig Endosc 31 : 51-58, 2019.
PubMed
4) Kuwai T, Mizumoto T, Tamaru Y, et al : Challenges in colonic stenting : Giving up is not an option. Dig Endosc 34 : 1491-1493, 2022.
 
5) Tao K, Kuwai T, Ishaq S, et al : Newly developed proximal release-type colonic stent placement for malignant lower rectal obstruction. VideoGIE 5 : 250-251, 2020.
PubMed
6) Matsuda A, Miyashita M, Matsumoto S, et al : Optimal Interval From Placement of a Self-expandable Metallic Stent to Surgery in Patients With Malignant Large Bowel Obstruction : A Preliminary Study. Surg Laparosc Endosc Percutan Tech 28 : 239-244, 2018.
PubMed
7) Khot UP, Lang AW, Murali K, et al : Systematic review of the efficacy and safety of colorectal stents. Br J Surg 89 : 1096-1102, 2002.
PubMed
8) Sasaki T, Yoshida S, Isayama H, et al : Short-Term Outcomes of Colorectal Stenting Using a Low Axial Force Self-Expandable Metal Stent for Malignant Colorectal Obstruction : A Japanese Multicenter Prospective Study. J Clin Med 10 : 4936, 2021.
PubMed
9) Tomita M, Saito S, Makimoto S, et al : Self-expandable metallic stenting as a bridge to surgery for malignant colorectal obstruction : pooled analysis of 426 patients from two prospective multicenter series. Surg Endosc 33 : 499-509, 2019.
PubMed
10) Kuwai T, Tamaru Y, Kusunoki R, et al : Long-term outcomes of standardized colonic stenting using WallFlex as a bridge to surgery : Multicenter prospective cohort study. Dig Endosc 34 : 840-849, 2022.
PubMed
11) Kuwai T, Yoshida S, Matsuzawa T, et al : Sa1145 A Prospective, Multicenter Study of Palliative Colonic Stenting for Malignant Colorectal Obstruction in Japan : Long-Term Efficacy and Safety in 200 Patients. Gastrointest Endosc 83 (5 Suppl) : AB230, 2016.
 
12) Kuwai T, Kyo R, Yoshida S, et al : Sa1719 A Prospective, Multicenter Study of Palliative Colonic Stenting for Malignant Colorectal Obstruction in Japan : Long-Term Efficacy and Safety in 87 Patients. Gastrointest Endosc 85 (5 Suppl) : AB254, 2017.
 
13) van Halsema EE, van Hooft JE, Small AJ, et al : Perforation in colorectal stenting : a meta-analysis and a search for risk factors. Gastrointest Endosc 79 : 970-983.e5, 2014.
 
14) Yoon JY, Jung YS, Hong SP, et al : Outcomes of secondary stent-in-stent self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc 74 : 625-633, 2011.
PubMed
P.227 掲載の参考文献
1) Tanaka S, Terasaki M, Kanao H, et al : Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors. Dig Endosc 24 (Suppl 1) : 73-79, 2012.
 
2) Oka S, Tanaka S, Saito Y, et al : Local recurrence after endoscopic resection for large colorectal neoplasia : a multicenter prospective study in Japan. Am J Gastroenterol 110 : 697-707, 2015.
PubMed
3) Tanaka S, Kashida H, Saito Y, et al : Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc 32 : 219-239, 2020.
PubMed
4) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), p12-14, p56-57, 金原出版, 2022.
 
5) Belderbos TD, van Erning FN, de Hingh IH, et al : Long-term Recurrence-free Survival After Standard Endoscopic Resection Versus Surgical Resection of Submucosal Invasive Colorectal Cancer : A Population-based Study. Clin Gastroenterol Hepatol 15 : 403-411.e1, 2017.
 
6) Overwater A, Kessels K, Elias SG, et al : Endoscopic resection of high-risk T1 colorectal carcinoma prior to surgical resection has no adverse effect on long-term outcomes. Gut 67 : 284-290, 2018.
PubMed
7) Takamaru H, Saito Y, Sekiguchi M, et al : Endoscopic Resection Before Surgery Does Not Affect the Recurrence Rate in Patients With High-Risk T1 Colorectal Cancer. Clin Transl Gastroenterol 12 : e00336, 2021.
PubMed
8) Tamaru Y, Oka S, Tanaka S, et al : Long-term outcomes after treatment for T1 colorectal carcinoma : a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group. J Gastroenterol 52 : 1169-1179, 2017.
 
9) Kunihiro M, Tanaka S, Haruma K, et al : Electrocautery snare resection stimulates cellular proliferation of residual colorectal tumor : an increasing gene expression related to tumor growth. Dis Colon Rectum 43 : 1107-1115, 2000.
PubMed
10) 味岡洋一, 大倉康男, 池上雅博, ほか : 早期大腸癌の内視鏡治療の適応拡大 (1) T1b癌 (1,000 μ以深SM癌) リンパ節転移リスク層別化の検討. 大腸疾患 NOW2016, p63-77, 日本メディカルセンター, 2016.
 
11) Kajiwara Y, Oka S, Tanaka S, et al : Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection : A nationwide, multicenter study. Gastrointest Endosc, 2023. (DOI : 10.1016/j.gie.2023.01.022)
 
12) Kobayashi H, Mochizuki H, Morita T, et al : Characteristics of recurrence after curative resection for T1 colorectal cancer : Japanese multicenter study. J Gastroenterol 46 : 203-211, 2011.
PubMed
13) Okamoto Y, Mitomi H, Ichikawa K, et al : Effect of skip lymphovascular invasion on hepatic metastasis in colorectal carcinomas. Int J Clin Oncol 20 : 761-766, 2015.
PubMed
14) 上杉憲幸, 松田尚久, 九嶋亮治, ほか : 切除断端の病理学的評価からみた早期大腸癌内視鏡治療後の中・長期経過-大腸癌研究会プロジェクト研究より. 胃と腸 50 : 437-447, 2015.
 
15) Nishimura T, Oka S, Kamigaichi Y, et al : Vertical tumor margin of endoscopic resection for T1 colorectal carcinoma affects the prognosis of patients undergoing additional surgery. Surg Endosc 36 : 5970-5978, 2022.
PubMed
P.233 掲載の参考文献
1) Ono S, Fujishiro M, Hirano K, et al : Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol 44 : 1185-1189, 2009.
PubMed
2) 加藤元嗣, 古田隆久, 伊藤透, ほか : 抗血栓薬服用者に対する消化器内視鏡に関連した偶発症の全国調査結果. Gastroenterological Endoscopy 59 : 1532-1536, 2017.
 
3) 藤本一眞, 藤城光弘, 加藤元嗣, ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterological Endoscopy 54 : 2075-2102, 2012.
 
4) 加藤元嗣, 上堂文也, 掃本誠治, ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン直接経口抗凝固薬 (DOAC) を含めた抗凝固薬に関する追補 2017. Gastroenterological Endoscopy 59 : 1547-1558, 2017.
 
5) 田中信治, 樫田博史, 斎藤豊, ほか : 大腸ESD/EMRガイドライン. Gastroenterological Endoscopy 61 : 1321-1344, 2019.
 
6) Kobayashi N, Takeuchi Y, Ohata K, et al : Outcomes of endoscopic submucosal dissection for colorectal neoplasms : Prospective, multi center, cohort trial. Dig Endosc 34 : 1042-1051, 2022.
 
7) 北山大祐, 望月暁, 松尾恵五, ほか : 大腸ポリープに対するCold snare polypectomyの有用性と安全性についての検討. Gastroenterological Endoscopy 58 : 2191-2198, 2016.
 
8) 浦岡俊夫, 滝沢耕平, 田中信治, ほか : 大腸cold polypectomyガイドライン (大腸ESD/EMRガイドライン追補). Gastroenterological Endoscopy 63 : 1147-1158, 2021.
 
9) Sibon I, Orgogozo JM : Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62 : 1187-1189, 2004.
PubMed
10) Palareti G, Legnani C, Guazzaloca G, et al : Activation of blood coagulation after abrupt of stepwise withdrawal of oral anticoagulants-a prospective study. Thromb Haemost 72 : 222-226, 1994.
PubMed
11) Choudari CP, Rajgopal C, Palmer KR : Acute gastrointestinal haemorrhage in anticoagulated patients : diagnoses and response to endoscopic treatment. Gut 35 : 464-466, 1994.
PubMed
12) Gerson LB, Gage BF, Owens DK, et al : Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol 95 : 1717-1724, 2000.
PubMed
13) Boustiere C, Veitch A, Vanbiervliet G, et al : Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 43 : 445-461, 2011.
PubMed
14) Ninomiya Y, Oka S, Tanaka S, et al : Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin. J Gastroenterol 50 : 1041-1046, 2015.
PubMed
15) Singh M, Mehta N, Murthy UK, et al : Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest Endosc 71 : 998-1005, 2010.
PubMed
16) Ishigami H, Arai M, Matsumura T, et al : Heparin-bridging therapy is associated with a high risk of post-polypectomy bleeding regardless of polyp size. Dig Endosc 29 : 65-72, 2017.
PubMed
P.237 掲載の参考文献
1) 斎藤豊, 岡志郎, 河村卓二, ほか : 大腸内視鏡スクリーニングとサーベイランスガイドライン. Gastroenterological Endoscopy 62 : 1519-1560, 2020.
 
2) 大腸癌治療ガイドライン 医師用 2019年版 (大腸癌研究会編), 金原出版, 2019.
 
3) Matsuda T, Fujii T, Sano Y, et al : Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy : the Japan Polyp Study Workgroup. Gut 70 : 1469-1478, 2020.
 
4) Hotta K, Matsuda T, Tanaka K : Large-scale questionnaire on the usage of cold snare polypectomy for colorectal polyps in Japanese clinical practice. Dig Endosc 32 : 993, 2020.
PubMed
5) Shimada S, Hotta K, Takada K, et al : Complete endoscopic removal rate of detected colorectal polyps in a real world out-patient practical setting. Scand J Gastroenterol 58 : 422-428, 2023.
 
6) Sekiguchi M, Otake Y, Kakugawa Y, et al : Incidence of Advanced Colorectal Neoplasia in Individuals With Untreated Diminutive Colorectal Adenomas Diagnosed by Magnifying Image-Enhanced Endoscopy. Am J Gastroenterol 114 : 964-973, 2019.
PubMed
7) Gupta S, Lieberman D, Anderson JC, et al : Recommendations for Follow-Up After Colonoscopy and Polypectomy : A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 158 : 1131-1153.e5, 2020.
 
8) Hassan C, Antonelli G, Dumonceau JM, et al : Post-polypectomy colonoscopy surveillance : European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Update 2020. Endoscopy 52 : 687-700, 2020.
PubMed
9) Hotta K, Matsuda T, Tanaka K : Post-polypectomy colonoscopy surveillance in the real clinical practice : Nationwide survey of 792 board certified institutions of the Japan Gastroenterological Endoscopy Society. Dig Endosc 32 : 824, 2020.
PubMed
10) Wieszczy P, Kaminski MF, Franczyk R, et al : Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies. Gastroenterology 158 : 875-883.e5, 2020.
 
11) Ohata K, Kobayashi N, Sakai E, et al : Long-term Outcomes After Endoscopic Submucosal Dissection for Large Colorectal Epithelial Neoplasms : A Prospective, Multicenter, Cohort Trial From Japan. Gastroenterology 163 : 1423-1434.e2, 2022.
 
12) Oka S, Tanaka S, Saito Y, et al : Local recurrence after endoscopic resection for large colorectal neoplasia : a multicenter prospective study in Japan. Am J Gastroenterol 110 : 697-707, 2015.
PubMed
13) Nakajima T, Sakamoto T, Hori S, et al : Optimal surveillance interval after piecemeal endoscopic mucosal resection for large colorectal neoplasia : a multicenter randomized controlled trial. Surg Endosc 36 : 515-525, 2022.
PubMed
14) Hassan C, Quintero E, Dumonceau JM, et al : Post-polypectomy colonoscopy surveillance : European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 45 : 842-851, 2013.
PubMed

IV 外科手術

P.245 掲載の参考文献
1) 渡邊昌彦, 大上正裕, 寺本龍生, ほか : 早期大腸癌に対する低侵襲手術の適応. 日本消化器外科学会雑誌 26 : 2548-2551, 1993.
 
2) 奥田準二 : 腹腔鏡下結腸進行癌手術のKnack & Pitfall. 手術 67 : 1201-1210, 2013.
 
3) 奥田準二, 田中慶太朗, 山本誠士, ほか : 局所解剖の俯瞰の上に拡大視効果を活かした腹腔鏡下大腸吻合のコツ. 手術 71 : 515-526, 2017.
 
4) 奥田準二, 田中慶太朗, 山本誠士, ほか : 右側結腸癌に対する腹腔鏡下体内吻合術-完全腹腔鏡下結腸右半切除術-. 日本外科学会雑誌 121 : 301-305, 2020.
 
5) Hamamoto H, Suzuki Y, Takano Y, et al : Medium-term oncological outcomes of totally laparoscopic colectomy with intracorporeal anastomosis for right-sided and left-sided colon cancer : propensity score matching analysis. BMC Surg 22 : 345, 2022.
PubMed
6) Masubuchi S, Okuda J, Yamamoto M, et al : Natural orifice specimen extraction in laparoscopic colorectal cancer surgery : A case series study. Int J Surg Case Rep 78 : 204-209, 2021.
PubMed
7) 奥田準二, 田中慶太朗, 近藤圭策, ほか : 腹腔鏡下ISRの手術手技. 外科 77 : 275-282, 2015.
 
8) 奥田準二, 山本誠士, 鱒渕真介, ほか : 肥満患者に対する腹腔鏡下ISRの工夫と新展開-Reborn手術. 手術 72 : 1839-1848, 2018.
 
9) Hamamoto H, Okuda J, Yamamoto M, et al : Preventing anastomotic leakage after laparoscopic intersphincteric resection without a diverting stoma : "pull-through/reborn". Asian J Endosc Surg 14 : 314-317, 2021.
PubMed
10) 奥田準二, 高山昇一, 杉本聡, ほか : 括約筋間直腸切除術手術手技の進化. 外科 85 : 68-76, 2023.
 
P.251 掲載の参考文献
1) Weber PA, Merola S, Wasielewski A, et al : Telerobotic-Assisted Laparoscopic Right and Sigmoid Colectomies for Benign Disease. Dis Colon Rectum 45 : 1689-1694, 2002.
PubMed
2) Pigazzi A, Ellenhorn JD, Ballantyne GH, et al : Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. Surg Endosc 20 : 1521-1525, 2006.
PubMed
3) Marubashi S, Takahashi A, Kakeji Y, et al : Surgical outcomes in gastroenterological surgery in Japan : Report of the National Clinical Database 2011-2019. Ann Gastroenterol Surg 5 : 639-658, 2001.
 
4) Shiroshita H, Inomata M, Akira S, et al : Current Status of Endoscopic Surgery in Japan : The 15th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg 15 : 415-426, 2022.
 
5) Matsuyama T, Endo H, Yamamoto H, et al : Outcomes of robot-assisted versus conventional laparoscopic low anterior resection in patients with rectal cancer : propensity-matched analysis of the National Clinical Database in Japan. BJS Open 5 : zrab083, 2001.
 
6) Fleming CA, Cullinane C, Lynch N, et al : Urogenital function following robotic and laparoscopic rectal cancer surgery : meta-analysis. Br J Surg 108 : 128-137, 2021.
PubMed
7) Kim HJ, Choi GS, Park JS, et al : The impact of robotic surgery on quality of life, urinary and sexual function following total mesorectal excision for rectal cancer : a propensity score-matched analysis with laparoscopic surgery. Colorectal Dis 20 : O103-O113, 2018.
PubMed
8) Feng Q, Yuan W, Li T, et al : Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL) : short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 7 : 991-1004, 2022.
PubMed
9) UMIN-CTR臨床試験登録情報の閲覧 : 進行直腸癌に対するロボット支援下直腸切除術の腫瘍学的妥当性に関する多施設共同, 前向きregistry研究. [https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000045179]
 
10) Ngu JC, Ng YY : Robotics confers an advantage in right hemicolectomy with intracorporeal anastomosis when matched against conventional laparoscopy. J Robot Surg 12 : 647-653, 2018.
PubMed
11) Park JS, Kang H, Park SY, et al : Long-term oncologic after robotic versus laparoscopic right colectomy : a prospective randomized study. Surg Endosc 33 : 2975-2981, 2019.
PubMed
12) Cuk P, Kjar MD, Mogensen CB, et al : Short-term outcomes in robot-assisted compared to laparoscopic colon cancer resections : a systematic review and meta-analysis. Surg Endosc 36 : 32-46, 2022.
 
13) Tschann P, Szeverinski P, Weigl MP, et al : Short- and Long-Term Outcome of Laparoscopic-versus Robotic-Assisted Right Colectomy : A Systematic Review and Meta-Analysis. J Clin Med 11 : 2022.
 
14) JRCT臨床研究等提出・公開システム : 切除可能結腸癌に対するロボット支援下結腸切除術の安全性に関する検討-多施設共同, 前向き, ヒストリカルコントロール, feasibility研究-. [https://jrct.niph.go.jp/latest-detail/jRCT1032190036]
 
P.255 掲載の参考文献
1) Hiki N, Yamamoto Y, Fukunaga T, et al : Laparoscopic and endoscopic cooperative surgery for gastrointestinal stromal tumor dissection. Surg Endosc 22 : 1729-1735, 2008.
PubMed
2) Goto O, Mitsui T, Fujishiro M, et al : New method of endoscopic full-thickness resection : a pilot study of non-exposed endoscopic wall-inversion surgery in an ex vivo porcine model. Gastric Cancer 14 : 183-187, 2011.
 
3) Inoue H, Ikeda H, Hosoya T, et al : Endoscopic mucosal resection, endoscopic submucosal dissection, and beyond : full-layer resection for gastric cancer with nonexposure technique (CLEAN-NET). Surg Oncol Clin N Am 21 : 129-140, 2012.
PubMed
4) Fujishima H, Etoh T, Hiratsuka T, et al : Serosal and muscular layers incision technique in laparoscopic surgery for gastric gastrointestinal stromal tumors. Asian J Endosc Surg 10 : 92-95, 2017.
PubMed
5) Beck DE, Karulf RE : Laparoscopic-assisted full-thickness endoscopic polypectomy. Dis Colon Rectum 36 : 693-695, 1993.
PubMed
6) Nakajima K, Sharma SK, Lee SW, et al : Avoiding colorectal resection for polyps : is CELS the best method? Surg Endosc 30 : 807-818, 2016.
PubMed
7) Fukunaga Y, Tamegai Y, Chino A, et al : New technique of en bloc resection of colorectal tumor using laparoscopy and endoscopy cooperatively (laparoscopy and endoscopy cooperative surgery-colorectal). Dis Colon Rectum 57 : 267-271, 2014.
PubMed
8) Tamegai Y, Fukunaga Y, Suzuki S, et al : Laparoscopic and endoscopic cooperative surgery (LECS) to overcome the limitations of endoscopic resection for colorectal tumors. Endosc Int Open 6 : E1477-E1485, 2018.
PubMed
9) Suzuki S, Fukunaga Y, Tamegai Y, et al : The short-term outcomes of laparoscopic-endoscopic cooperative surgery for colorectal tumors (LECS-CR) in cases involving endoscopically unresectable colorectal tumors. Surg Today 49 : 1051-1057, 2019.
PubMed
10) Suzuki K, Saito S, Fukunaga Y : Current Status and Prospects of Endoscopic Resection Technique for Colorectal Tumors. J Anus Rectum Colon 5 : 121-128, 2021.
PubMed
11) 日吉幸晴, 福長洋介, 鈴木桂悟, ほか : 大腸腫瘍に対するLECS. 手術 75 : 1679-1683, 2021.
 
P.261 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」 (久松班). 潰瘍性大腸炎・クローン病診断基準・治療指針, 2022.
 
2) Ullman TA, Itzkowitz SH : Intestinal inflammation and cancer. Gastroenterology 140 : 1807-1816, 2011.
PubMed
3) Robles AI, Traverso G, Zhang M, et al : Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology 150 : 931-943, 2016.
PubMed
4) Eaden JA, Abrams KR, Mayberry JF : The risk of colorectal cancer in ulcerative colitis : a meta-analysis. Gut 48 : 526-535, 2001.
PubMed
5) Kishikawa J, Hata K, Kazama S, et al : Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc 30 : 236-244, 2018.
PubMed
6) Ekbom A, Helmick C, Zack M, et al : Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 : 1228-1233, 1990.
PubMed
7) Watanabe T, Konishi T, Kishimoto J, et al : Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer : a nationwide Japanese study. Inflamm Bowel Dis 17 : 802-808, 2011.
 
8) Hata K, Anzai H, Ikeuchi H, et al : Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol 114 : 483-489, 2019.
PubMed
9) Nugent FW, Haggit RC, Colcher H, et al : Malignant potential of chronic ulcerative colitis. Preliminary report. Gastroenterology 76 : 1-5, 1979.
PubMed
10) Watanabe T, Ajioka Y, Mitsuyama K, et al : Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 151 : 1122-1130, 2016.
PubMed
11) Riddell RH, Goldman H, Ransohoff DF, et al : Dysplasia in inflammatory bowel disease : standardized classification with provisional clinical applications. Hum Pathol 14 : 931-968, 1983.
PubMed
12) Bernstein CN, Shanahan F, Weinstein WM : Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343 : 71-74, 1994.
 
13) Itzkowitz SH, Harpaz N : Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 : 1634-1648, 2004.
PubMed
14) Canavan C, Abrams KR, Mayberry J : Meta-analysis : colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23 : 1097-1104, 2006.
PubMed
15) Noguchi T, Ishihara S, Uchino M, et al : Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. J Gastroenterol 58 : 14-24, 2023.
PubMed
P.268 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), p12, 金原出版, 2022.
 
2) Yamaoka Y, Imai K, Shiomi A, et al : Endoscopic resection of T1 colorectal cancer prior to surgery does not affect surgical adverse events and recurrence. Surg Endosc 34 : 5006-5016, 2020.
 
3) Kim HJ, Choi GS, Park JS, et al : The impact of robotic surgery on quality of life, urinary and sexual function following total mesorectal excision for rectal cancer : a propensity score-matched analysis with laparoscopic surgery. Colorectal Dis 20 : O103-O113, 2018.
PubMed
4) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), p14, 金原出版, 2018.
 
5) Murono K, Kawai K, Ishihara S, et al : Evaluation of the vascular anatomy of the right-sided colon using three-dimensional computed tomography angiography : a single-center study of 536 patients and a review of the literature. Int J Colorectal Dis 31 : 1633-1638, 2016.
 
6) Murono K, Nozawa H, Kawai K, et al : Vascular anatomy of the splenic flexure : a review of the literature. Surg Today 52 : 727-735, 2022.
PubMed
7) Watanabe J, Ota M, Suwa Y, et al : Evaluation of lymph flow patterns in splenic flexural colon cancers using laparoscopic real-time indocyanine green fluorescence imaging. Int J Colorectal Dis 32 : 201-207, 2017.
PubMed
8) Ito K, Takemura N, Inagaki F, et al : Arterial blood supply to the pancreas from accessary middle colic artery. Pancreatology 19 : 781-785, 2019.
 
P.272 掲載の参考文献
1) 大腸癌治療ガイドライン [医師用 2022年版] (大腸癌研究会編), 金原出版, 2022.
 
2) Kotake K, Mizuguchi T, Moritani K, et al : Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 29 : 847-852, 2014.
PubMed
3) Kotake K, Kobayashi H, Asano M, et al : Influence of extent of lymph node dissection on survival for patients with pT2 colon cancer. Int J Colorectal Dis 30 : 813-820, 2015.
PubMed
4) Sugihara K, Kobayashi H, Kato T, et al : Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49 : 1663-1672, 2006.
PubMed
5) West NP, Hohenberger W, Weber K, et al : Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 28 : 272-278, 2010.
 
6) Hohenberger W, Weber K, Matzel K, et al : Standardized surgery for colonic cancer : complete mesocolic excision and central ligation-technical notes and outcome. Colorectal Dis 11 : 354-365, 2009.
PubMed
7) Spasojevic M, Stimec BV, Dyrbekk AP, et al : Lymph node distribution in the d3 area of the right mesocolon : implications for an anatomically correct cancer resection. A postmortem study. Dis Colon Rectum 56 : 1381-1387, 2013.
PubMed
8) Yada H, Sawai K, Taniguchi H, et al : Analysis of vascular anatomy and lymph node metastases warrants radical segmental bowel resection for colon cancer. World J Surg 21 : 109-115, 1997.
PubMed
9) Kuzu MA, Ismail E, Celik S, et al : Variations in the Vascular Anatomy of the Right Colon and Implications for Right-Sided Colon Surgery. Dis Colon Rectum 60 : 290-298, 2017.
PubMed
10) Watanabe J, Ota M, Suwa Y, et al : Real-Time Indocyanine Green Fluorescence Imaging-Guided Complete Mesocolic Excision in Laparoscopic Flexural Colon Cancer Surgery. Dis Colon Rectum 59 : 701-705, 2016.
PubMed
11) Watanabe J, Ota M, Suwa Y, et al : Evaluation of lymph flow patterns in splenic flexural colon cancers using laparoscopic real-time indocyanine green fluorescence imaging. Int J Colorectal Dis 32 : 201-207, 2017.
PubMed
12) Huang X, Lv B, Zhang S, et al : Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction : a meta-analysis. J Gastrointest Surg 18 : 584-591, 2014.
PubMed
13) Cirocchi R, Farinella E, Trastulli S, et al : Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer : a systematic review and meta-analysis. Surg Oncol 22 : 14-21, 2013.
PubMed
14) Cennamo V, Luigiano C, Coccolini F, et al : Meta-analysis of randomized trials comparing endoscopic stenting and surgical decompression for colorectal cancer obstruction. Int J Colorectal Dis 28 : 855-863, 2013.
PubMed
15) Zhang Y, Shi J, Shi B, et al : Self-expanding metallic stent as a bridge to surgery versus emergency surgery for obstructive colorectal cancer : a meta-analysis. Surg Endosc 26 : 110-119, 2012.
 
16) Matsuzawa T, Ishida H, Yoshida S, et al : A Japanese prospective multicenter study of self-expandable metal stent placement for malignant colorectal obstruction : short-term safety and efficacy within 7 days of stent procedure in 513 cases. Gastrointest Endosc 82 : 697-707. e1, 2015.
 
17) Sasaki T, Yoshida S, Isayama H, et al : Short-Term Outcomes of Colorectal Stenting Using a Low Axial Force Self- Expandable Metal Stent for Malignant Colorectal Obstruction : A Japanese Multicenter Prospective Study. J Clin Med 10 : 4936, 2021.
PubMed
18) Khot UP, Lang AW, Murali K, et al : Systematic review of the efficacy and safety of colorectal stents. Br J Surg 89 : 1096-1102, 2002.
PubMed
19) Saito S, Yoshida S, Isayama H, et al : A prospective multicenter study on self-expandable metallic stents as a bridge to surgery for malignant colorectal obstruction in Japan : efficacy and safety in 312 patients. Surg Endosc 30 : 3976-3986, 2016.
PubMed
20) 大腸ステント安全手技研究会ホームページ. [http://colon-stent.com]
 
21) van Hooft JE, Veld JV, Arnold D, et al : Self-expandable metal stents for obstructing colonic and extracolonic cancer : European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Update 2020. Endoscopy 52 : 389-407, 2020.
PubMed
P.280 掲載の参考文献
1) Nagtegaal ID, Quirke P : What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26 : 303-312, 2008.
PubMed
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
3) Titu LV, Tweedle E, Rooney PS : High tie of the inferior mesenteric artery in curative surgery for left colonic and rectal cancers : a systematic review. Dig Surg 25 : 148-157, 2008.
PubMed
4) Seike K, Koda K, Saito N, et al : Laser Doppler assessment of the influence of division at the root of the inferior mesenteric artery on anastomotic blood flow in rectosigmoid cancer surgery. Int J Colorectal Dis 22 : 689-697, 2007.
PubMed
5) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
6) Collard M, Lefevre JH : Ultimate Functional Preservation With Intersphincteric Resection for Rectal Cancer. Front Oncol 10 : 297, 2020.
PubMed
7) Komori K, Kimura K, Kinoshita T, et al : Necessary circumferential resection margins to prevent rectal cancer relapse after abdomino-peranal (intersphincteric) resection. Langenbecks Arch Surg 401 : 189-194, 2016.
PubMed
8) Ueno H, Mochizuki H, Hashiguchi Y, et al : Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg 245 : 80-87, 2007.
PubMed
9) 金光幸秀, 塚本俊輔, 森谷弘乃介, ほか : 直腸癌に対する側方リンパ節郭清の歴史. 臨床外科 76 : 525-534, 2021.
 
10) Fujita S, Mizusawa J, Kanemitsu Y, et al : Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212) : A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg 266 : 201-207, 2017.
 
11) Sugihara K, Kobayashi H, Kato T, et al : Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49 : 1663-1672, 2006.
PubMed
12) Ogura A, Konishi T, Cunningham C, et al : Neoadjuvant (Chemo) radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes : Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol 37 : 33-43, 2019.
PubMed
13) Peacock O, Manisundaram N, Dibrito SR, et al : Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer After Total Neoadjuvant Therapy (TNT). Ann Surg 276 : 654-664, 2022.
PubMed
14) PelvEx Collaborative : Surgical and Survival Outcomes Following Pelvic Exenteration for Locally Advanced Primary Rectal Cancer : Results From an International Collaboration. Ann Surg 269 : 315-321, 2019.
PubMed
15) PelvEx Collaborative : Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg 105 : 650-657, 2018.
PubMed
P.285 掲載の参考文献
1) 大腸癌治療ガイドライン [2022年版] (大腸癌研究会編), 金原出版, 2022.
 
2) Tsilimigras DI, Sahara K, Hyer JM, et al : Trends and outcomes of simultaneous versus staged resection of synchronous colorectal cancer and colorectal liver metastases. Surgery 170 : 160-166, 2021.
PubMed
3) Karam E, Bucur P, Gil C, et al : Simultaneous or staged resection for synchronous liver metastasis and primary rectal cancer : a propensity score matching analysis. BMC Gastroenterol 22 : 201, 2022.
PubMed
4) Wu Y, Mao A, Wang H, et al : Association of Simultaneous vs Delayed Resection of Liver Metastasis With Complications and Survival Among Adults With Colorectal Cancer. JAMA Netw Open 5 : e2231956, 2022.
 
5) Beppu T, Sakamoto Y, Hasegawa K, et al : A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection : multicenter data collection as a project study for hepatic surgery of the Japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci 19 : 72-84, 2012.
 
6) Fretland AA, Dagenborg VJ, Bjornelv GMW, et al : Laparoscopic Versus Open Resection for Colorectal Liver Metastases : The OSLO-COMET Randomized Controlled Trial. Ann Surg 267 : 199-207, 2018.
PubMed
7) Aghayan DL, Kazaryan AM, Dagenborg VJ, et al : Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial. Ann Intern Med 174 : 175-182, 2021.
PubMed
8) Robles-Campos R, Lopez-Lopez V, Brusadin R, et al : Open versus minimally invasive liver surgery for colorectal liver metastases (LapOpHuva) : a prospective randomized controlled trial. Surg Endosc 33 : 3926-3936, 2019.
PubMed
9) Margonis GA, Sergentanis TN, Ntanasis-Stathopoulos I, et al : Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases : A Systematic Review and Meta-analysis. Ann Surg 267 : 1047-1055, 2018.
PubMed
10) Sadot E, Groot Koerkamp B, Leal JN, et al : Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer : surgical technique or biologic surrogate? Ann Surg 262 : 476-485, 2015.
PubMed
11) Watanabe K, Nagai K, Kobayashi A, et al : Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 96 : 1058-1065, 2009.
PubMed
12) Hirosawa T, Itabashi M, Ohnuki T, et al : Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer : a multi-institutional cumulative follow-up study. Surg Today 43 : 494-499, 2013.
PubMed
13) Sakamaki Y, Ishida D, Tanaka R : Prognosis of patients with recurrence after pulmonary metastasectomy for colorectal cancer. Gen Thorac Cardiovasc Surg 68 : 1172-1178, 2020.
PubMed
14) Fenton HM, Finan PJ, Milton R, et al : National variation in pulmonary metastasectomy for colorectal cancer. Colorectal Dis 23 : 1306-1316, 2021.
PubMed
15) Yun JS, Kim E, Na KJ, et al : Thoracoscopic pulmonary metastasectomy in metastatic colorectal cancer : Surgical outcomes and prognostic factors. Thorac Cancer 12 : 2537-2543, 2021.
 
P.292 掲載の参考文献
1) 国立がん研究センター : がん情報サービス「最新がん統計」 [https://ganjoho.jp/reg_stat/statistics/stat/summary.html]
 
2) 総務省 : 人口推計 2021年 (令和3年) 10月1日現在, 令和4年4月15日. [https://www.stat.go.jp/data/jinsui/2021np/pdf/2021np.pdf] (2023年3月閲覧)
 
3) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
4) Kotake K, Asano M, Ozawa H, et al : Tumour characteristics, treatment patterns and survival of patients aged 80 years or older with colorectal cancer. Colorectal Dis 17 : 205-215, 2015.
PubMed
5) 高齢者に関する定義検討ワーキンググループ報告書, 日本老年医学会・日本老年学会, 2017. [https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20170410_01_01.pdf]
 
6) Aparicio T, Pamoukdjian F, Quero L, et al : Colorectal cancer care in elderly patients : Unsolved issues. Dig Liver Dis 48 : 1112-1118, 2016.
PubMed
7) 淺利昌大, 青山徹, 公盛啓介, ほか : 高齢者大腸癌手術におけるD3リンパ節郭清の意義. 癌と化学療法 47 : 259-261, 2020.
Medical*Online
8) Seishima R, Miyata H, Okabayashi K, et al : Safety and feasibility of laparoscopic surgery for elderly rectal cancer patients in Japan : a nationwide study. BJS Open 5 : zrab007, 2021.
PubMed
9) Longo WE, Virgo KS, Johnson FE, et al : Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum 43 : 83-91, 2000.
PubMed
10) 藤田信子 : 腹腔鏡手術の循環への影響. 日本臨床麻酔学会誌 42 : 270-274, 2022.
Medical*Online
11) Chen LK, Woo J, Assantachai P, et al : Asian Working Group for Sarcopenia : 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc 21 : 300-307.e2, 2020.
 
12) Lieffers JR, Bathe OF, Fassbender K, et al : Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 107 : 931-936, 2012.
PubMed
13) 小野寺時夫, 五関謹秀, 神前五郎 : Stage IV・V (Vは大腸癌) 消化器癌の非治癒切除・姑息手術に対するTPNの適応と限界. 日本外科学会雑誌 85 : 1001-1005, 1984.
 
14) Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, et al : CONUT : a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20 : 38-45, 2005.
 
15) Takagi K, Buettner S, Ijzermans JNM : Prognostic significance of the controlling nutritional status (CONUT) score in patients with colorectal cancer : A systematic review and meta-analysis. Int J Surg 78 : 91-96, 2020.
PubMed
P.297 掲載の参考文献
1) がん情報サービス : 最新がん統計. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html] (2023年1月閲覧)
 
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
3) 石黒めぐみ, 望月英隆, 杉原健一, ほか : 大腸癌に合併する多発癌・重複がんに関するフォローアップについて. 日本大腸肛門病会誌 59 : 863-868, 2006.
 
4) Benson AB, Venook AP, Al-Hawary MM, et al : Colon Cancer, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19 : 329-359, 2021.
 
5) Argiles G, Tabernero J, Labianca R, et al : Localised colon cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31 : 1291-1305, 2020.
PubMed
6) Glynne-Jones R, et al : Rectal cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (Suppl 4) : iv22-iv40, 2017.
 
7) 阿彦友佳, 愛甲丞, 志田大 : 大腸手術後サーベイランス-日本と欧米のガイドラインの視点から. INTESTINE 25 : 93-97, 2021.
 
8) 佐々木和人, 石原聡一郎 : 「大腸癌治療ガイドライン 医師用 2019年版, 2022年版」改訂のポイント. Medical Practice 39 : 646-654, 2022.
Medical*Online
9) 橋口陽二郎, 小澤毅士, 松田圭二, ほか : 大腸癌治療ガイドライン 2019, 知っておくべき主な改訂ポイント. 臨床外科 74 : 940-947, 2019.
 
10) 小泉彩香, 小林宏寿 : 大腸癌の治療成績と術後サーベイランス. 医学と薬学 79 : 349-354, 2022.
Medical*Online
P.302 掲載の参考文献
1) Saito N, Ono M, Sugito M, et al : Early results of intersphincteric resection for patients with very low rectal cancer : an active approach to avoid a permanent colostomy. Dis Colon Rectum 47 : 459-466, 2004.
PubMed
2) Yamada K, Ogata S, Saiki Y, et al : Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 52 : 1065-1071, 2009.
PubMed
3) Akagi Y, Shirouzu K, Ogata Y, et al : Oncologic outcomes of intersphincteric resection without preoperative chemoradiotherapy for very low rectal cancer. Surg Oncol 22 : 144-149, 2013.
PubMed
4) Koda K, Shuto K, Matsuo K, et al : Layer-oriented total pelvic exenteration for locally advanced primary colorectal cancer. Int J Colorectal Dis 31 : 59-66, 2016.
PubMed
5) 小杉千弘, 幸田圭史, 清水宏明, ほか : 骨盤内臓全摘に必要な解剖. 臨床外科 73 : 111-118, 2018.
 
6) Hartmann H : 30th Congress Francais de Chirurgie-Process. Verheaux, Memoires, et Discussions 30 : 411, 1921.
 
7) Miles WE Eng FRCS, Lond LRCP : A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon. Lancet 172 : 1812-1813, 1908.
 
8) 小杉千弘, 幸田圭史, 清水宏明, ほか : ストーマ造設術の適応疾患と基本手技. 手術 75 : 797-804, 2021.
 
9) Shiomi A, Ito M, Maeda K, et al : Effects of a diverting stoma on symptomatic anastomotic leakage after low anterior resection for rectal cancer : a propensity score matching analysis of 1,014 consecutive patients. J Am Coll Surg 220 : 186-194, 2015.
PubMed
10) 小杉千弘, 幸田圭史, 清水宏明, ほか : この一冊で網羅! ストーマ造設・管理のすべて一時的人工肛門の造設. 消化器外科 43 : 273-280, 2020.
 
11) Edwards DP, Leppington-Clarke A, Sexton R, et al : Stoma-related complications are more frequent after transverse colostomy than loop ileostomy : a prospective randomized clinical trial. Br J Surg 88 : 360-363, 2001.
PubMed
12) 小杉千弘, 幸田圭史, 平野敦史, ほか : ストーマケアに役立つ知識の整理と活用 1 ストーマ構造の理解 (消化管). WOC Nursing 4 (12) : 7-13, 2016.
 
13) 消化管ストーマ造設の手引き (日本ストーマ・排泄リハビリテーション学会, 日本大腸肛門病学会編), 文光堂, 2014.
 

V 化学療法

P.310 掲載の参考文献
1) Heidelberger C, Chaudhuri NK, Danneberg P, et al : Fluorinated pyrimidines, a new class of tumourinhibitory compounds. Nature 179, 663-666, 1957.
PubMed
2) Ford HER, Mitchell F, Cunningham D, et al : Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8 : 103-109, 2002.
PubMed
3) Ogura K, Ohnuma T, Minamide Y, et al : Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res 11 : 5104-5111, 2005.
PubMed
4) 室圭, 大村健二 (編) : フッ化ピリミジン製剤 (5-FU, DIF, 5-FU (UFT) + LV, カペシタビン). 消化器癌化学療法 第5版, p12-21, 南山堂, 2021.
 
5) Cassidy J, Clarke S, Diaz-Rubio E, et al : Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26 : 2006-2012, 2008.
PubMed
6) Xu RH, Muro K, Morita S, et al : Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT) : a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19 : 660-671, 2018.
PubMed
7) Cunningham D, Lang I, Marcuello E, et al : Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX) : an open-label, randomised phase 3 trial. Lancet Oncol 14 : 1077-1085, 2013.
PubMed
8) Scheithauer W, McKendrick J, Begbie S, et al : Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer : safety results of a randomized, phase III trial. Ann Oncol 14 : 1735-1743, 2003.
 
9) Baba H, Yamada Y, Takahari D, et al : S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer : updated overall survival analyses of the open-label, non-inferiority, randomised phase III : SOFT study. ESMO open 2 : e000135, 2017.
PubMed
10) Yamada Y, Denda T, Gamoh M, et al : S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE) : a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29 : 624-631, 2018.
PubMed
11) Muro K, Boku N, Shimada Y, et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11 : 853-860, 2010.
 
12) Hamaguchi T, Shimada Y, Mizusawa J, et al : Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910) : an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3 : 47-56, 2018.
PubMed
13) Grothey A, Sobrero AF, Shields AF, et al : Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378 : 1177-1188, 2018.
PubMed
14) Mayer RJ, Van Cutsem E, Falcone A, et al : Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372 : 1909-1919, 2015.
PubMed
15) Pfeiffer P, Yilmaz M, Moller S, et al : TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer : an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21 : 412-420, 2020.
PubMed
P.320 掲載の参考文献
1) 大腸癌治療ガイドライン [医師用 2022年版] (大腸癌研究会編), 金原出版, 2022.
 
2) Saltz LB, Clarke S, Diaz-Rubio E, et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study. J Clin Oncol 26 : 2013-2019, 2008.
PubMed
3) Bennouna J, Sastre J, Arnold D, et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol 14 : 29-37, 2013.
PubMed
4) Van Cutsem E, Kohne CH, Hitre E, et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 : 1408-1417, 2009.
PubMed
5) Douillard JY, Siena S, Cassidy J, et al : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study. J Clin Oncol 28 : 4697-4705, 2010.
PubMed
6) Heinemann V, von Weikersthal LF, Decker T, et al : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a andomised, open-label, phase 3 trial. Lancet Oncol 15 : 1065-1075, 2014.
 
7) Venook AP, Niedzwiecki D, Lenz HJ, et al : Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer : A Randomized Clinical Trial. JAMA 317 : 2392-2401, 2017.
 
8) Arnold D, Lueza B, Douillard JY, et al : Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28 : 1713-1729, 2017.
PubMed
9) Watanabe J, Muro K, Shitara K, et al : Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer : A Randomized Clinical Trial. JAMA 329 : 1271-1282, 2023.
PubMed
10) Tabernero J, Hozak RR, Yoshino T, et al : Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, doubleblind, phase III study. Ann Oncol 29 : 602-609, 2018.
 
11) Van Cutsem E, Tabernero J, Lakomy R, et al : Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30 : 3499-3506, 2012.
 
12) Kopetz S, Grothey A, Yaeger R, et al : Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 381 : 1632-1643, 2019.
PubMed
13) Tabernero J, Grothey A, Van Cutsem E, et al : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer : Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 39 : 273-284, 2021.
PubMed
14) Bekaii-Saab TS, Ou FS, Ahn DH, et al : Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS) : a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20 : 1070-1082, 2019.
PubMed
15) Nakamura Y, Okamoto W, Kato T, et al : Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer : a phase 2 trial. Nat Med 27 : 1899-1903, 2021.
PubMed
P.326 掲載の参考文献
1) Brahmer JR, Drake CG, Wollner I, et al : Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors : safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 : 3167-3175, 2010.
PubMed
2) Lipson EJ, Sharfman WH, Drake CG, et al : Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19 : 462-468, 2013.
 
3) Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-2454, 2012.
PubMed
4) Le DT, Uram JN, Wang H, et al : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-2520, 2015.
PubMed
5) Le DT, Kim TW, Van Cutsem E, et al : Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer : KEYNOTE-164. J Clin Oncol 38 : 11-19, 2020.
PubMed
6) Overman MJ, McDermott R, Leach JL, et al : Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142) : an open-label, multicentre, phase 2 study. Lancet Oncol 18 : 1182-1191, 2017.
PubMed
7) Overman MJ, Lonardi S, Wong KYM, et al : Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36 : 773-779, 2018.
PubMed
8) Andre T, Lonardi S, Wong KYM, et al : Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer : 4-year follow-up from CheckMate 142. Ann Oncol 33 : 1052-1060, 2022.
PubMed
9) Andre T, Shiu KK, Kim TW, et al : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 383 : 2207-2218, 2020.
PubMed
10) Diaz LA Jr, Shiu KK, Kim TW, et al : Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177) : final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23 : 659-670, 2022.
 
11) Cercek A, Lumish M, Sinopoli J, et al : PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 386 : 2363-2376, 2022.
PubMed
12) Chalabi M, Fanchi LF, Dijkstra KK, et al : Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26 : 566-576, 2020.
PubMed
13) Chalabi M, Verschoor YL, van den Berg J, et al : Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer : The NICHE-2 study. Ann Oncol 33 (Suppl 7) : S1389, 2022.
 
14) Eng C, Kim TW, Bendell J, et al : Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370) : a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 20 : 849-861, 2019.
PubMed
15) Hoff S, Grunewald S, Rose L, et al : Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer. Zopf D. Ann Oncol 28 (Suppl 5) : v423, 2017.
 
16) Doleschel D, Hoff S, Koletnik S, et al : Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res 40 : 288, 2021.
PubMed
17) Fukuoka S, Hara H, Takahashi N, et al : Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer : An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol 38 : 2053-2061, 2020.
 
18) Gomez-Roca C, Yanez E, Im SA, et al : LEAP-005 : A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort. J Clin Oncol 39 (3 Suppl) : 94, 2021.
 
P.331 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
2) Colon Cancer Verson 3. 2022, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) [www.nccn.org/professionals/physician_gls/pdf/colon.pdf]
 
3) Conroy T, Bosset JF, Etienne PL, et al : Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22 : 702-715, 2021.
PubMed
4) Andre T, Boni C, Mounedji-Boudiaf L, et al : Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 : 2343-2351, 2004.
PubMed
5) Haller DG, Tabernero J, Maroun J, et al : Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29 : 1465-1471, 2011.
PubMed
6) Andre T, Meyerhardt J, Iveson T, et al : Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration) : final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21 : 1620-1629, 2020.
PubMed
7) Yoshino T, Oki E, Misumi T, et al : Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer : The Randomized Phase III ACHIEVE Trial. J Clin Oncol 40 : 3419-3429, 2022.
 
8) Ishibe A, Watanabe J, Suwa Y, et al : A prospective, single-arm, multicenter trial of diverting stoma followed by neoadjuvant chemotherapy using mFOLFOX6 for obstructive colon cancer : YCOG1305 (PROBE study). Ann Surg 276 : 140-145, 2022.
 
9) de Gooyer JM, Verstegen MG, 't Lam-Boer J, et al : Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer : A Nationwide Propensity-Score Matched Cohort Analysis. Dig Surg 37 : 292-301, 2020.
PubMed
10) Dehal A, Graff-Baker AN, Vuong B, et al : Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. J Gastrointest Surg 22 : 242-249, 2018.
PubMed
11) Jakobsen A, Andersen F, Fischer A, et al : Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 54 : 1747-1753, 2015.
PubMed
12) Karoui M, Rullier A, Piessen G, et al : Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers : A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22). Ann Surg 271 : 637-645, 2020.
PubMed
13) Karoui M, Gallois C, Piessen G, et al : Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 23 : 1357-1369, 2021.
PubMed
14) Foxtrot Collaborative Group : Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer : the pilot phase of a randomised controlled trial. Lancet Oncol 13 : 1152-1160, 2012.
PubMed
15) Morton D, Seymour M, Magill L, et al : Preoperative Chemotherapy for Operable Colon Cancer : Mature Results of an International Randomized Controlled Trial. J Clin Oncol : 41 : 1541-1552, 2023. DOI : 10.1200/JCO.22.00046.
 
16) Williams CJM, Fish R, Akerman L, et al : Incorporating neoadjuvant chemotherapy into locally advanced colon cancer treatment pathways : real-life experience of implementing FOxTROT. Colorectal Dis, 2022. (DOI : 10.1111/codi.16450)
 
17) Tie J, Cohen JD, Wang Y, et al : Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer : a prospective biomarker study. Gut 68 : 663-671, 2019.
PubMed
18) Zhou J, Wang C, Lin G, et al : Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer : A Prospective Multicenter Study. Clin Cancer Res 27 : 301-310, 2021.
 
P.338 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
2) Wolmark N, Rockette H, Mamounas E, et al : Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon : results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 : 3553-3559, 1999.
 
3) Lembersky BC, Wieand HS, Petrelli NJ, et al : Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon : results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24 : 2059-2064, 2006.
PubMed
4) Twelves C, Wong A, Nowacki MP, et al : Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 : 2696-2704, 2005.
PubMed
5) Yoshida M, Ishiguro M, Ikejiri K, et al : S-1 as adjuvant chemotherapy for stage III colon cancer : a randomized phase III study (ACTS-CC trial). Ann Oncol 25 : 1743-1749, 2014.
PubMed
6) Hamaguchi T, Shimada Y, Mizusawa J, et al : Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910) : an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3 : 47-56, 2018.
PubMed
7) Andre T, Boni C, Navarro M, et al : Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 : 3109-3116, 2009.
 
8) Yothers G, O'Connell MJ, Allegra CJ, et al : Oxaliplatin as adjuvant therapy for colon cancer : updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 : 3768-3774, 2011.
PubMed
9) Haller DG, Tabernero J, Maroun J, et al : Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29 : 1465-1471, 2011.
PubMed
10) Grothey A, Sobrero AF, Shields AF, et al : Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378 : 1177-1188, 2018.
PubMed
11) Yoshino T, Oki E, Misumi T, et al : Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer : The Randomized Phase III ACHIEVE Trial. J Clin Oncol 40 : 3419-3429, 2022.
 
12) Andre T, Meyerhardt J, Iveson T, et al : Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration) : final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21 : 1620-1629, 2020.
PubMed
13) Yoshino T, Argiles G, Oki E, et al : Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol 32 : 1496-1510, 2021.
PubMed
14) Cohen R, Taieb J, Fiskum J, et al : Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin : An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 39 : 642-651, 2021.
PubMed
15) Kanemitsu Y, Shimizu Y, Mizusawa J, et al : Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603) : A Phase II or III Randomized Controlled Trial. J Clin Oncol 39 : 3789-3799, 2021.
PubMed
16) Kotani D, Oki E, Nakamura Y, et al : Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29 : 127-134, 2023.
PubMed
P.344 掲載の参考文献
1) Simmonds PC : Palliative chemotherapy for advanced colorectal cancer : systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321 : 531-535, 2000.
 
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
3) Yamazaki K, Nagase M, Tamagawa H, et al : Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27 : 1539-1546, 2016.
PubMed
4) Chionh F, Lau D, Yeung Y, et al : Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 7 : CD008398, 2017.
PubMed
5) Cremolini C, Antoniotti C, Stein A, et al : Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol, 2020 (DOI : 10.1200/JCO.20.01225).
 
6) Yamada Y, Denda T, Gamoh M, et al : S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE) : a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29 : 624-631, 2018.
PubMed
7) Arnold D, Lueza B, Douillard JY, et al : Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28 : 1713-1729, 2017.
PubMed
8) Yoshino T, Watanabe J, Shitara K, et al : Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) : Results from the phase 3 PARADIGM trial. J Clin Oncol 40 (Suppl) : LBA1, 2022.
 
9) Muro K, Watanabe J, Shitara K, et al : LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer : PARADIGM trial results. Ann Oncol 33 (Suppl 4) : S377, 2022.
 
10) Innocenti F, Ou FS, Qu X, et al : Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol 37 : 1217-1227, 2019.
PubMed
11) Stintzing S, Heinrich K, Tougeron D, et al : Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC : The phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol 39 (Suppl) : Abstract No. 3502, 2021.
 
12) Bennouna J, Sastre J, Arnold D, et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol 14 : 29-37, 2013.
PubMed
13) Tabernero J, Yoshino T, Cohn AL, et al : Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE) : a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16 : 499-508, 2015.
 
14) Van Cutsem E, Tabernero J, Lakomy R, et al : Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30 : 3499-3506, 2012.
 
15) Hecht JR, Cohn A, Dakhil S, et al : SPIRITT : A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer 14 : 72-80, 2015.
PubMed
16) Bennouna J, Hiret S, Bertaut A, et al : Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer : The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol 5 : 83-90, 2019.
PubMed
17) Shitara K, Yonesaka K, Denda T, et al : Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci 107 : 1843-1850, 2016.
 
18) Parisi A, Cortellini A, Cannita K, et al : Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer : The Multicenter "SLAVE" Study. Cancers (Basel) 12 : 1259, 2020.
PubMed
19) Kopetz S, Grothey A, Yaeger R, et al : Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 381 : 1632-1643, 2019.
PubMed
20) Grothey A, Van Cutsem E, Sobrero A, et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 303-312, 2013.
PubMed
21) Mayer RJ, Van Cutsem E, Falcone A, et al : Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372 : 1909-1919, 2015.
PubMed
22) Moriwaki T, Fukuoka S, Taniguchi H, et al : Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS) : A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 23 : 7-15, 2018.
PubMed
23) Yoshino T, Mizunuma N, Yamazaki K, et al : TAS-102 monotherapy for pretreated metastatic colorectal cancer : a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13 : 993-1001, 2012.
PubMed
24) Pfeiffer P, Yilmaz M, Moller S, et al : TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer : an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21 : 412-420, 2020.
PubMed
25) Andre T, Shiu KK, Kim TW, et al : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 383 : 2207-2218, 2020.
PubMed
26) Overman MJ, McDermott R, Leach JL, et al : Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142) : an open-label, multicentre, phase 2 study. Lancet Oncol 18 : 1182-1191, 2017.
PubMed
27) Overman MJ, Lonardi S, Wong KYM, et al : Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36 : 773-779, 2018.
PubMed
28) Nakamura Y, Okamoto W, Kato T, et al : Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer : a phase 2 trial. Nat Med 27 : 1899-1903, 2021.
PubMed
29) Meric-Bernstam F, Hainsworth J, Bose R, et al : MyPathway HER2 basket study : Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol 39 (Suppl) : Abstract 3004, 2021.
 
30) Weiss J, Yaeger RD, Johnson ML, et al : KRYSTAL-1 : Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol 32 (Suppl 5) : S1294, Abstract No. LBA6, 2021.
 
31) Cremolini C, Rossini D, Dell'Aquila E, et al : Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan : A Phase 2 Single-Arm Clinical Trial. JAMA Oncol 5 : 343-350, 2019.
PubMed
32) Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al : Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer : The CHRONOS trial. J Clin Oncol 39 (Suppl) : Abstract 3506, 2021.
 
P.351 掲載の参考文献
1) 高齢者のがん薬物療法ガイドライン (日本臨床腫瘍学会/日本癌治療学会編), p12-13, 南江堂, 2019.
 
2) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), p34-35, 金原出版, 2022.
 
3) Li D, Sun C, Kim H, et al : Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer : a randomized clinical trial. JAMA Oncol 7 : e214158, 2021.
 
4) Sanoff HK, Carpenter WR, Sturmer T, et al : Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30 : 2624-2634, 2012.
PubMed
5) McCleary NJ, Meyerhardt JA, Green E, et al : Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer : findings from the ACCENT database. J Clin Oncol 31 : 2600-2606, 2013.
PubMed
6) Haller DG, O'Connell MJ, Cartwright TH, et al : Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer : a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 26 : 715-724, 2015.
PubMed
7) Grothey A, Sobrero AF, Shields AF, et al : Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378 : 1177-1188, 2018.
PubMed
8) Yoshino T, Oki E, Misumi T, et al : Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer : The Randomized Phase III ACHIEVE Trial. J Clin Oncol 40 : 3419-3429, 2022.
 
9) Goldberg RM, Tabah-Fisch I, Bleiberg H, et al : Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 : 4085-4091, 2006.
PubMed
10) Hamaguchi T, Takashima A, Mizusawa J, et al : A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer : JCOG1018 study (RESPECT). J Clin Oncol 40 (4 Suppl) : 10, 2022.
PubMed
11) Cunningham D, Lang I, Marcuello E, et al : Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX) : an open-label, randomised phase 3 trial. Lancet Oncol 14 : 1077-1085, 2013.
PubMed
12) Yoshida M, Muro K, Tsuji A, et al : Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer 51 : 935-941, 2015.
PubMed
13) Sastre J, Massuti B, Pulido G, et al : First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors : A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 51 : 1371-1380, 2015.
 
14) がん薬物療法時の腎障害診療ガイドライン 2022 (日本腎臓学会, 日本癌治療学会, 日本臨床腫瘍学会, 日本腎臓病薬物療法学会編), p70-72, ライフサイエンス出版, 2022.
 
15) Andre T, Shiu KK, Kim TW, et al : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 383 : 2207-2218, 2020.
PubMed

VI 放射線治療

P.359 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
2) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for rectal cancer. Version 4. 2022.
 
3) Colorectal Cancer Collaborative Group : Adjuvant radiotherapy for rectal cancer : a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358 : 1291-1304, 2001.
 
4) Camma C, Giunta M, Fiorica F, et al : Preoperative radiotherapy for resectable rectal cancer : A meta-analysis. JAMA 284 : 1008-1015, 2000.
PubMed
5) Francois Y, Nemoz CJ, Baulieux J, et al : Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer : the Lyon R90-01 randomized trial. J Clin Oncol 17 : 2396, 1999.
 
6) Hofheinz RD, Wenz F, Post S, et al : Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer : a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13 : 579-588, 2012.
PubMed
7) Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M, et al : Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 : 980-987, 1997.
PubMed
8) Peeters KC, Marijnen CA, Nagtegaal ID, et al : The TME trial after a median follow-up of 6 years : increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246 : 693-701, 2007.
PubMed
9) Socha J, Kairevice L, K?epka L, et al : Should Short-Course Neoadjuvant Radiation Therapy Be Applied for Low-Lying Rectal Cancer? A Systematic Review and Meta-Analysis of the Randomized Trials. Int J Radiat Oncol Biol Phys 108 : 1257-1264, 2020.
 
10) Wo JY, Anker CJ, Ashman JB, et al : Radiation Therapy for Rectal Cancer : Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol 11 : 13-25, 2021.
PubMed
11) Sauer R, Becker H, Hohenberger W, et al : Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 : 1731-1740, 2004.
PubMed
12) Matsusaka S, Ishihara S, Kondo K, et al : A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial). Radiother Oncol 116 : 209-213, 2015.
 
13) Bahadoer RR, Dijkstra EA, van Etten B, et al : Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO) : a randomised, open-label, phase 3 trial. Lancet Oncol 22 : 29-42, 2021.
PubMed
14) Conroy T, Bosset JF, Etienne PL, et al : Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22 : 702-715, 2021.
PubMed
15) Garcia-Aguilar J, Patil S, Gollub MJ, et al : Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol 40 : 2546-2556, 2022.
PubMed
P.365 掲載の参考文献
1) Katagiri H, Okada R, Takagi T, et al : New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3 : 1359-1367, 2014.
PubMed
2) Roos DE, Turner SL, O'Brien PC, et al : Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 75 : 54-63, 2005.
 
3) Steenland E, Leer JW, van Houwelingen H, et al : The effect of a single fraction compared to multiple fractions on painful bone metastases : a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52 : 101-109, 1999.
PubMed
4) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain : randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52 : 111-121, 1999.
PubMed
5) Van der Linden YM, Dijkstra PD, Kroon HM, et al : Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 86 : 566-573, 2004.
PubMed
6) Rades D, Stalpers LJ, Veninga T, et al : Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 23 : 3366-3375, 2005.
PubMed
7) Chow E, van der Linden YM, Roos D, et al : Single versus multiple fractions of repeat radiation for painful bone metastases : a randomised, controlled, non-inferiority trial. Lancet Oncol 15 : 164-171, 2014.
PubMed
8) Hird A, Chow E, Zhang L, et al : Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases : results from three canadian cancer centers. Int J Radiat Oncol Biol Phys 75 : 193-197, 2009.
PubMed
9) Cascino TL, Leavengood JM, Kemeny N, et al : Brain metastases from colon cancer. J Neurooncol 1 : 203-209, 1983.
PubMed
10) Gaspar L, Scott C, Rotman M, et al : Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 : 745-751, 1997.
PubMed
11) Sperduto PW, Kased N, Roberge D, et al : Summary report on the graded prognostic assessment : an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 : 419-425, 2012.
PubMed
12) Yamamoto M, Serizawa T, Shuto T, et al : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 : 387-395, 2014.
 
13) Gondi V, Pugh SL, Tome WA, et al : Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933) : a phase II multi-institutional trial. J Clin Oncol 32 : 3810-3816, 2014.
 
P.371 掲載の参考文献
1) Shinoto M, Ebner DK, Yamada S : Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 18 : 17, 2016.
PubMed
2) Hu JB, Sun XN, Yang QC, et al : Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. World J Gastroenterol 12 : 2610-2614, 2006.
PubMed
3) Kim MS, Choi C, Yoo S, et al : Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol 38 : 695-700, 2008.
PubMed
4) Lee JH, Kim DY, Kim SY, et al : Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer. Radiat Oncol 6 : 51, 2011.
PubMed
5) Sun DS, Zhang JD, Li L, et al : Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 85 : 259-264, 2012.
PubMed
6) Dagoglu N, Callery M, Moser J, et al : Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer 7 : 283-288, 2016.
PubMed
7) Hiroshima Y, Ishikawa H, Murakami M, et al : Proton Beam Therapy for Local Recurrence of Rectal Cancer. Anticancer Res 41 : 3589-3595, 2021.
PubMed
8) Shinoto M, Yamada S, Okamoto M, et al : Carbon-ion radiotherapy for locally recurrent rectal cancer : Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. Radiother Oncol 132 : 236-240, 2019.
 
9) Takahashi W, Mori S, Nakajima M, et al : Carbon-ion scanning lung treatment planning with respiratory-gated phase-controlled rescanning : simulation study using 4-dimensional CT data. Radiat Oncol 9 : 238, 2014.
PubMed
10) Aibe N, Ogino H, Teramukai S, et al : Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers. Adv Radiat Oncol 6 : 100690, 2021.
PubMed
11) Makishima H, Yasuda S, Isozaki Y, et al : Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis : A dose escalation study. Cancer Sci 110 : 303-309, 2019.
PubMed
12) Shiba S, Shibuya K, Okamoto M, et al : Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung. Anticancer Res 41 : 1997-2005, 2021.
PubMed
13) Fukumitsu N, Okumura T, Takizawa D, et al : Proton beam therapy for metastatic liver tumors. Radiother Oncol 117 : 322-327, 2015.
PubMed
14) Isozaki Y, Yamada S, Kawashiro S, et al : Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. J Surg Oncol 116 : 932-938, 2017.
PubMed
15) Okonogi N, Kaminuma T, Okimoto T, et al : Carbon-ion radiotherapy for lymph node oligorecurrence : a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Int J Clin Oncol 24 : 1143-1150, 2019.
 

VII その他の治療

P.379 掲載の参考文献
1) Pietrantonio F, Nicolantonio FD, Schrock AB, et al : ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst 109, 2017. (DOI : 10.1093/jnci/djx089)
 
2) Cocco E, Benhamida J, Middha S, et al : Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Res 79 : 1047-1053, 2019.
PubMed
3) Doebele RC, Drilon A, Paz-Ares L, et al : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials. Lancet Oncol 21 : 271-282, 2020.
PubMed
4) Demetri GD, Braud FD, Drilon A, et al : Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors : Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 29 (Supple_8) : abstr LBA 17, 2018.
 
5) Hong DS, DuBois SG, Kummar S, et al : Larotrectinib in patients with TRK fusion-positive solid tumours : a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21 : 531-540, 2020.
PubMed
6) Bando H : The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr Probl Cancer 41 : 166-175, 2017.
PubMed
7) Diehl F, Schmidt K, Choti MA, et al : Circulating mutant DNA to assess tumor dynamics. Nat Med 14 : 985-990, 2008.
PubMed
8) Dudley JC, Diehn M : Detection and diagnostic utilization of cellular and cell-free tumor DNA. Annu Rev Pathol 16 : 199-222, 2021.
PubMed
9) Parikh AR, Van Seventer EE, Siravegna G, et al : Minimal Residual Disease Detection using a Plasmaonly Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res 27 : 5586-5594, 2021.
PubMed
10) Tie J, Cohen JD, Lahouel K, et al : Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med 386 : 2261-2272, 2022.
PubMed
11) Kotani D, Oki E, Nakamura Y, et al : Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29 : 127-134, 2023.
PubMed
P.385 掲載の参考文献
1) Lote H, Starling N, Pihlak R, et al : Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treat Rev 111 : 102480, 2022.
PubMed
2) Hazama S, Nakamura Y, Takenouchi H, et al : A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer ; safety, immunological response, and clinical outcome. J Transl Med 12 : 63, 2014.
PubMed
3) Hazama S, Takenouchi H, Tsunedomi R, et al : Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res 34 : 4201-4205, 2014.
PubMed
4) Hazama S, Nakamura Y, Tanaka H, et al : A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med 12 : 108, 2014.
 
5) Keskin DB, Anandappa AJ, Sun J, et al : Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565 : 234-239, 2019.
PubMed
6) Giannakis M, Mu XJ, Shukla SA, et al : Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep 15 : 857-865, 2016.
PubMed
7) Tran E, Robbins PF, Lu YC, et al : T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375 : 2255-2262, 2016.
PubMed
8) Ghazi B, El Ghanmi A, Kandoussi S, et al : CAR T-cells for colorectal cancer immunotherapy : Ready to go? Front Immunol 13 : 978195, 2022.
 
9) Zhang C, Wang Z, Yang Z, et al : Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. Mol Ther 25 : 1248-1258, 2017.
 
10) Cui J, Chen N, Pu C, et al : A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer. J Clin Oncol 40 (16 Suppl) : 3582, 2022.
 
11) Nakajima M, Sakoda Y, Adachi K, et al : Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci 110 : 3079-3088, 2019.
 
12) Adachi K, Kano Y, Nagai T, et al : IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36 : 346-351, 2018.
 
13) Inoue Y, Hazama S, Iwamoto S, et al : FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther 18 : 541-548, 2014.
 
14) Inoue Y, Hazama S, Suzuki N, et al : Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci 108 : 455-460, 2017.
PubMed
15) Kudo M : Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer 8 : 413-426, 2019.
PubMed
16) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 : 1894-1905, 2020.
PubMed
17) Yamada K, Hazama S, Suzuki N, et al : Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. Oncol Lett 21 : 10, 2021.
PubMed

VIII 病態ほか

P.393 掲載の参考文献
1) 武藤徹一郎 : 大腸ポリープ・ポリポーシス-臨床と病理, 医学書院, 1993.
 
2) 武藤徹一郎 : Adenoma-Carcinoma Sequence. 胃と腸 29 : 149-150, 1994.
 
3) 安達実樹, 松田圭二, 武藤徹一郎 : 大腸癌の発生・進展/組織発生Adenoma-carcinoma sequence. 消化器外科 28 : 547-552, 2005.
 
4) 大倉康男 : 発生・発育進展-病理組織学的観点から. 胃と腸 45 : 624-630, 2010.
 
5) 斉藤裕輔, 富永素矢, 小澤賢一郎, ほか : 臨床病理学的観点からみた大腸癌の発生・発育過程とその特徴-大腸癌の発生における腺腫の癌化 (adenoma-carcinoma sequence) とde novo発癌. 胃と腸 43 : 1891-1896, 2008.
 
6) 斉藤裕輔, 杉山隆治, 中嶋駿介, ほか : Adenoma-carcinoma sequenceとde novo発癌の病理と臨床. 大腸癌 Frontier 5 : 302-307, 2012.
Medical*Online
7) 松田圭二, 渡邉英伸, 味岡洋一, ほか : adenoma-carcinoma sequenceとde novo cancer. 綜合臨牀 46 : 247-250, 1997.
Medical*Online
8) 藤原美奈子 : adenoma-carcinoma sequence. 胃と腸 57 : 734, 2022.
 
9) 味岡洋一 : adenoma-carcinoma sequence. 胃と腸 47 : 827, 2012.
 
10) Muto T, Bussey HJ, Morson BC : The evolution of cancer of the colon and rectum. Cancer 36 : 2251-2270, 1975.
PubMed
11) Winawer SJ, Zauber AG, Ho MN, et al : Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329 : 1977-1981, 1993.
PubMed
12) Zauber AG, Winawer SJ, O'Brien MJ, et al : Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696, 2012.
 
13) Vogelstein B, Fearon ER, Hamilton SR, et al : Genetic alterations during colorectal-tumor development. N Engl J Med 319 : 525-532, 1988.
PubMed
14) Cho KR, Vogelstein B : Genetic alterations in the adenoma-carcinoma sequence. Cancer 70 : 1727-1731, 1992.
PubMed
15) Yamagata S, Muto T, Uchida Y, et al : Lower incidence of K-ras codon 12 mutation in flat colorectal adenomas than in polypoid adenomas. Jpn J Cancer Res 85 : 147-151, 1994.
PubMed
P.397 掲載の参考文献
1) Morson B : President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 67 : 451-457, 1974.
PubMed
2) Spjut HJ, Frankel NB, Appel MF : The small carcinoma of the large bowel. Am J Surg Pathol 3 : 39-46, 1979.
PubMed
3) Crawford BE, Stromeyer FW : Small nonpolypoid carcinomas of the large intestine. Cancer 51 : 1760-1763, 1983.
PubMed
4) Jelinek GP, Nava HR, Nime F : Small primary de novo adenocarcinoma of the colon with mesenteric lymphatic metastasis. J Surg Oncol 23 : 185-188, 1983.
PubMed
5) Kuramoto S, Oohara T : Minute cancers arising de novo in the human large intestine. Cancer 61 : 829-834, 1988.
PubMed
6) Herrera L, Hanna S, Castillo N, et al : Primary de novo adenocarcinoma of the colon measuring 8 mm in diameter with lymph node metastases. Report of a case. Dis Colon Rectum 34 : 275-279, 1991.
PubMed
7) Iishi H, Tatsuta M, Tsutsui S, et al : Early depressed adenocarcinomas of the large intestine. Cancer 69 : 2406-2410, 1992.
PubMed
8) Minamoto T, Mai M, Ogino T, et al : Early invasive colorectal carcinomas metastatic to the lymph node with attention to their nonpolypoid development. Am J Gastroenterol 88 : 1035-1039, 1993.
 
9) 中村恭一 : 大腸癌の構造, 医学書院, 1989.
 
10) Shimoda T, Ikegami M, Fujisaki J, et al : Early colorectal carcinoma with special reference to its development de novo. Cancer 64 : 1138-1146, 1989.
PubMed
11) Kudo S, Tamura S, Hirota S, et al : The problem of de novo colorectal carcinoma. Eur J Cancer 31A : 1118-1120, 1995.
PubMed
12) Kashida H, Kudo SE, Takeuchi T, et al : The importance of depressed lesions in the development of colorectal cancer. In : Early Cancer of the Gastrointestinal Tract : Endoscopy, Pathology, and Treatment (Ed. by Fujita R, Jass JR, Kaminishi M, et al), p243-247, Springer-Verlag, Tokyo, Berlin, Heidelberg, New York, 2005.
 
13) Kashida H, Kudo SE : Early colorectal cancer : concept, diagnosis, and management. Int J Clin Oncol 11 : 1-8, 2006.
PubMed
14) Stolte M, Bethke B : Colorectal mini-de novo carcinoma : a reality in Germany too. Endoscopy 27 : 286-290, 1995.
PubMed
15) Kashida H : Non-polypoid colorectal neoplasms are no longer unique to Japan, but do not mix up flat and depressed lesions. Dig Endosc 27 : 300-302, 2015.
 
16) Maskens AP, Dujardin-Loits RM : Experimental adenomas and carcinomas of the large intestine behave as distinct entities : most carcinomas arise de novo in flat mucosa. Cancer 47 : 81-89, 1981.
PubMed
17) Chang WW : Histogenesis of colon cancer in experimental animals. Scand J Gastroenterol Suppl 104 : 27-43, 1984.
PubMed
18) Vogelstein B, Fearon ER, Hamilton SR, et al : Genetic alterations during colorectal-tumor development. N Engl J Med 319 : 525-532, 1988.
PubMed
19) Fujimori T, Satonaka K, Yamamura-Idei Y, et al : Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int J Cancer 57 : 51-55, 1994.
PubMed
20) Kudo SE, Kouyama Y, Ogawa Y, et al : Depressed colorectal cancer : a new paradigm in early colorectal cancer. Clin Transl Gastroenterol 11 : e00269, 2020.
PubMed
21) Mochizuki K, Kudo SE, Kato K, et al : Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer. PLoS One 17 : e0273566, 1-13, 2022.
 
P.404 掲載の参考文献
1) Shah SC, Itzkowitz SH : Colorectal Cancer in Inflammatory Bowel Disease : Mechanisms and Management. Gastroenterology 162 : 715-730.e3, 2022.
 
2) Rutter M, Saunders B, Wilkinson K, et al : Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 : 451-459, 2004.
 
3) Yaeger R, Shah MA, Miller VA, et al : Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology 151 : 278-287.e6, 2016.
 
4) Rajamaki K, Taira A, Katainen R, et al : Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology 161 : 592-607, 2021.
PubMed
5) Robles AI, Traverso G, Zhang M, et al : Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology 150 : 931-943, 2016.
PubMed
6) Fujita M, Matsubara N, Matsuda I, et al : Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling. Oncotarget 9 : 969-981, 2018.
PubMed
7) Matsumoto K, Urabe Y, Oka S, et al : Genomic Landscape of Early-stage Colorectal Neoplasia Developing From the Ulcerative Colitis Mucosa in the Japanese Population. Inflamm Bowel Dis 27 : 686-696, 2021.
PubMed
8) 松田圭, 渡辺英伸, 味岡洋一, ほか : 早期大腸がんとp53遺伝子異常. 最新医学 51 : 1408-1421, 1996.
Medical*Online
9) Guinney J, Dienstmann R, Wang X, et al : The consensus molecular subtypes of colorectal cancer. Nat Med 21 : 1350-1356, 2015.
PubMed
10) Noguchi T, Ishihara S, Uchino M, et al : Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn's disease. J Gastroenterol, 58 : 14-24, 2023.
PubMed
11) Gordon H, Biancone L, Fiorino G, et al : ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis, 2022 (DOI : 10.1093/ecco-jcc/jjac187).
 
12) Hata K, Anzai H, Ikeuchi H, et al : Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol 114 : 483-489, 2019.
PubMed
13) 岩谷舞, 太田浩良, Robert Riddell : 潰瘍性大腸炎関連腫瘍-診断・治療の現状と課題IBD前癌病変 (dysplasia) 分類における日本と欧米の比較と新WHO 分類について. 胃と腸 55 : 212-216, 2020.
 
14) Watanabe T, Ajioka Y, Mitsuyama K, et al : Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 151 : 1122-1130, 2016.
PubMed
15) Tsai JH, Rabinovitch PS, Huang D, et al : Association of Aneuploidy and Flat Dysplasia With Development of High-Grade Dysplasia or Colorectal Cancer in Patients With Inflammatory Bowel Disease. Gastroenterology 153 : 1492-1495.e4, 2017.
PubMed
P.411 掲載の参考文献
1) Kumar V et al : Injury caused by ionizing radiation. In : Robbins & Kumar Basic Pathology, 11th ed (ed by Kumar V, Abbas AK, Aster JC, et al), p254-257, Elsevier, Philadelphia, 2023.
 
2) 千野晶子, 菅沼孝紀, 浦上尚之, ほか : 放射線性腸炎. Gastroenterological Endoscopy 52 : 1381-1392, 2010.
 
3) Sherman LF : A reevaluation of the factitial proctitis problem. Am J Surg 88 : 773-779, 1954.
PubMed
4) Castro EB, Rosen PP, Quan SH : Carcinoma of large intestine in patients irradiated for carcinoma of cervix and uterus. Cancer 31 : 45-52, 1973.
PubMed
5) Arlen M, Higinbotham NL, Huvos AG, et al : Radiation-induced sarcoma of bone. Cancer 28 : 1087-1099, 1971.
PubMed
6) 酒井邦夫, 日向浩, 北村達夫, ほか : 放射線治療後の発がんに関する全国調査成績. 日本医学放射線学会雑誌 41 : 24-32, 1981.
 
7) 酒井邦夫, 北村達夫, 日向浩, ほか : 悪性腫瘍の放射線治療後における二次発がん-第二次全国アンケート調査から-. 日本医学放射線学会雑誌 46 : 811-818, 1986.
 
8) Sandler RS, Sandler DP : Radiation-induced cancers of the colon and rectum : assessing the risk. Gastroenterology 84 : 51-57, 1983.
PubMed
9) Baxter NN, Tepper JE, Durham SB, et al : Increased risk of rectal cancer after prostate radiation : a population-based study. Gastroenterology 128 : 819-824, 2005.
PubMed
10) Rombouts AJM, Hugen N, van Beek JJP, et al : Does pelvic radiation increase rectal cancer incidence? -A systematic review and meta-analysis. Cancer Treat Rev 68 : 136-144, 2018.
PubMed
11) 金光幸秀, 志田大, 塚本俊輔 : 放射線腸炎による発癌の診断と治療. 大腸癌 FRONTIER 6 : 143-149, 2013.
Medical*Online
12) 森山智彦, 松本主之, 佐藤智雄, ほか : 進行大腸癌と多発dysplasiaを合併した放射線大腸炎の1例. 胃と腸 37 : 1089-1095, 2002.
 
13) Sasaki K, Ishihara S, Hata K, et al : Radiation-associated colon cancer : A case report. Mol Clin Oncol 6 : 817-820, 2017.
PubMed
14) 五十嵐誠治, 齋藤智明, 小林美穂, ほか : 放射線性腸炎と放射線誘発大腸癌の病理. 大腸癌 FRONTIER 6 : 136-142, 2013.
Medical*Online
15) Minami K, Matsuzaki S, Hayashi N, et al : Immunohistochemical study of p53 overexpression in radiation-induced colon cancers. J Radiat Res 39 : 1-10, 1998.
PubMed
16) Gonin-Laurent N, Gibaud A, Huygue M, et al : Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27 : 1266-1272, 2006.
PubMed
17) Tsuji T, Sawai T, Nakagoe T, et al : Genetic analysis of radiation-associated rectal cancer. J Gastroenterol 38 : 1185-1188, 2003.
PubMed
18) Margel D, Baniel J, Wasserberg N, et al : Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg 254 : 947-950, 2011.
PubMed
P.419 掲載の参考文献
1) Sung H, Ferlay J, Siegel RL, et al : Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71 : 209-249, 2021.
PubMed
2) 国立研究開発法人国立がん研究センター : がんの統計 2022. [https://ganjoho.jp/public/qa_links/report/statistics/2022_jp.html]
 
3) 遺伝性大腸癌診療ガイドライン 2020年版 (大腸癌研究会編), 金原出版, 2020.
 
4) Yurgelun MB, Kulke MH, Fuchs CS, et al : Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol 35 : 1086-1095, 2017.
PubMed
5) Cripps WH : Two cases of disseminated polypus of the rectum. Transact Path Soc London 33 : 165-168, 1882.
 
6) Lockhart-Mummery P : Cancer and heredity. Lancet 205 ; 427-429, 1925.
 
7) Warthin AS : Hereditary with reference to carcinoma. Arch Intern Med 12 : 546-555, 1913.
 
8) Nishisho I, Nakamura Y, Miyoshi Y, et al : Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253 : 665-669, 1991.
PubMed
9) Leach FS, Nicolaides NC, Papadopoulos N, et al : Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75 : 1215-1225, 1993.
PubMed
10) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment : Colorectal Version 1. 2022. [http://www.nccn.org]
 
11) Heald B, Hampel H, Church J, et al : Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer 19 : 223-239, 2020.
 
12) 厚生労働科学研究費倫理的法的社会的課題研究事業「国民が安心してゲノム医療を受けるための社会実現に向けた倫理社会的課題抽出と社会環境整備」研究班 (研究代表者小杉眞司) : がん遺伝子パネル検査二次的所見患者開示推奨度別リスト (Ver3.1_20210815), 2021. [http://sph.med.kyoto-u.ac.jp/gccrc/pdf/k101_kentousiryo_v1.pdf]
 
13) Ishikawa H, Yamada M, Sato Y, et al : Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III) : A multicenter prospective interventional study. Endoscopy, 2022. (DOI : 10.1055/a-1945-9120)
 
14) Ishikawa H, Mutoh M, Sato Y, et al : Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV) : a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 6 : 474-481, 2021.
PubMed
15) Burn J, Gerdes AM, Macrae F, et al : Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer : an analysis from the CAPP2 randomised controlled trial. Lancet 378 : 2081-2087, 2011.
PubMed
P.424 掲載の参考文献
1) 遺伝性大腸癌診療ガイドライン [2020年版] (大腸癌研究会編), 金原出版, 2020.
 
2) Vasen HF, van Duijvendijk P, Buskens E, et al : Decision analysis in the surgical treatment of patients with familial adenomatous polyposis : a Dutch-Scandinavian collaborative study including 659 patients. Gut 49 : 231-235, 2001.
PubMed
3) Ishikawa H, Mutoh M, Iwama T, et al : Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. Endoscopy 48 : 51-55, 2016.
PubMed
4) Ishikawa H, Yamada M, Sato Y, et al : Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III) : a multicenter prospective interventional study. Endoscopy 55 : 344-352, 2023.
 
5) Lynch PM, Morris JS, Wen S, et al : A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 84 : 115-125.e4, 2016.
 
6) 石川秀樹 : 家族性大腸腺腫症における大腸癌の予防. 日本消化器病学会雑誌 113 : 1191-1195, 2016.
Medical*Online
7) Burn J, Bishop DT, Chapman PD, et al : A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4 : 655-665, 2011.
PubMed
8) Ishikawa H, Mutoh M, Sato Y, et al : Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV) : a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol 6 : 474-481, 2021.
PubMed
9) Yoshida N, Ishikawa H, Eguchi H, et al : Promotion Effects of Smoking in Polyp Development in Monozygotic Twins with Atypical Colorectal Polyposis. Case Rep Gastroenterol 16 : 375-381, 2022.
PubMed
10) Nakamura T, Ishikawa H, Sakai T, et al : Effect of physical fitness on colorectal tumor development in patients with familial adenomatous polyposis. Medicine (Baltimore) 98 : e17076, 2019.
PubMed
11) Abrahami D, McDonald EG, Schnitzer ME, et al : Proton pump inhibitors and risk of colorectal cancer. Gut 71 : 111-118, 2022.
PubMed
P.430 掲載の参考文献
1) 遺伝性大腸癌診療ガイドライン [2020年版] (大腸癌研究会編), 金原出版, 2020.
 
2) Win AK, Jenkins MA, Dowty JG, et al : Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 26 : 404-412, 2017.
PubMed
3) Chika N, Eguchi H, Kumamoto K, et al : Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 47 : 108-117, 2017.
 
4) Julie C, Tresallet C, Brouquet A, et al : Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) : revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 103 : 2825-2836, 2008.
PubMed
5) Kahn RM, Gordhandas S, Maddy BP, et al : Universal endometrial cancer tumor typing : How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Cancer 125 : 3172-3183, 2019.
PubMed
6) Moller P, Seppala T, Bernstein I, et al : Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer : a report from the prospective Lynch syndrome database. Gut 66 : 1657-1664, 2017.
 
7) Sunami K, Ichikawa H, Kubo T, et al : Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting : A hospital-based study. Cancer Sci 110 : 1480-1490, 2019.
 
8) Yamaguchi T : Screening for Lynch Syndrome. In : Lynch Syndrome (ed by Tomita N), p85-92, Springer, Singapore, 2020.
 
9) Chikatani K, Chika N, Suzuki O, et al : A Model for Predicting DNA Mismatch Repair-deficient Colorectal Cancer. Anticancer Res 40 : 4379-4385, 2020.
 
10) Chung J, Negm L, Bianchi V, et al : Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. J Clin Oncol 41, 766-777, 2023.
PubMed
11) Seppala TT, Latchford A, Negoi I, et al : European guidelines from the EHTG and ESCP for Lynch syndrome : an updated third edition of the Mallorca guidelines based on gene and gender 108 : 484-498, 2021.
PubMed
12) Sinicrope FA, Foster NR, Thibodeau SN, et al : DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103 : 863-875, 2011.
PubMed
13) Chikatani K, Chika N, Suzuki O, et al : Clinically applicable cases of anti-programmed cell death protein 1 immunotherapy for colorectal cancer patients. Surg Today 50 : 1694-1698, 2020.
PubMed
14) Therkildsen C, Jensen LH, Rasmussen M, et al : An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clin Exp Gastroenterol 14 : 181-197, 2021.
PubMed
15) Cercek A, Lumish M, Sinopoli J, et al : PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 386 : 2363-2376, 2022.
PubMed
16) Haanstra JF, Kleibeuker JH, Koornstra JJ : Role of new endoscopic techniques in Lynch syndrome. Fam Cancer 12 : 267-272, 2013.
PubMed
17) Hatamori H, Chino A, Arai M, et al : Malignant potential of colorectal neoplasms in Lynch syndrome : an analysis of 325 lesions endoscopically treated at a single institute. Jpn J Clin Oncol 51 : 737-743, 2021.
 
P.435 掲載の参考文献
1) 松本主之, 飯田三雄 : 消化管ポリポーシスの診断基準・病型分類・重症度. 内科 95 : 1097-1101, 2005.
 
2) Valle L : Recent Discoveries in the Genetics of Familial Colorectal Cancer and Polyposis. Clin Gastroenterol Hepatol 15 : 809-819, 2017.
PubMed
3) Jenne DE, Reimann H, Nezu J, et al : Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18 : 38-43, 1998.
 
4) 山本博徳, 阿部孝, 石黒信吾, ほか : 小児・成人のためのPeutz-Jeghers症候群診療ガイドライン (2020年版). 遺伝性腫瘍 20 : 59-78, 2020.
Medical*Online
5) 山口直之, 磯本一, 宿輪三郎, ほか : 過誤腫性ポリポーシスの拡大観察. 胃と腸 45 : 2093-2100, 2010.
 
6) van Lier MG, Wagner A, Mathus-Vliegen EM, et al : High cancer risk in Peutz-Jeghers syndrome : a systematic review and surveillance recommendations. Am J Gastroenterol 105 : 1258-1265, 2010.
PubMed
7) Syngal S, Brand RE, Church JM, et al : ACG clinical guideline : Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110 : 223-263, 2015.
PubMed
8) Sayed MG, Ahmed AF, Ringold JR, et al : Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 9 : 901-906, 2002.
PubMed
9) 松本主之, 新井正美, 岩間達, ほか : 小児・成人のための若年性ポリポーシス症候群診療ガイドライン (2020年版). 遺伝性腫瘍 20 : 79-92, 2020.
Medical*Online
10) Shikata K, Kukita Y, Matsumoto T, et al : Gastric juvenile polyposis associated with germline SMAD4 mutation. Am J Med Genet A 134 : 326-329, 2005.
PubMed
11) Gallione CJ, Repetto GM, Legius E, et al : A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363 : 852-859, 2004.
PubMed
12) Brosens LA, van Hattem A, Hylind LM, et al : Risk of colorectal cancer in juvenile polyposis. Gut 56 : 965-967, 2007.
PubMed
13) Eng C : Will the real Cowden syndrome please stand up : revised diagnostic criteria. J Med Genet 37 : 828-830, 2000.
PubMed
14) 高山哲治, 五十嵐正広, 大住省三, ほか : 小児・成人のためのCowden症候群/PTEN過誤腫症候群診療ガイドライン (2020年版). 遺伝性腫瘍 20 : 93-114, 2020.
Medical*Online
15) Gammon A, Jasperson K, Champine M : Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. Appl Clin Genet 9 : 83-92, 2016.
PubMed
16) Whitelaw SC, Murday VA, Tomlinson IP, et al : Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 112 : 327-334, 1997.
PubMed
17) Jaeger E, Leedham S, Lewis A, et al : Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 44 : 699-703, 2012.
PubMed
18) Plesec T, Brown K, Allen C, et al : Clinicopathological features of a kindred with SCG5-GREM1-associated hereditary mixed polyposis syndrome. Hum Pathol 60 : 75-81, 2017.
PubMed
19) Lieberman S, Walsh T, Schechter M, et al : Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance. Gastroenterology 152 : 1876-1880.e1, 2017.
 
20) Watanabe C, Komoto S, Tomita K, et al : Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite-Canada syndrome : a Japanese nationwide survey. J Gastroenterol 51 : 327-336, 2016.
PubMed
21) Kopacova M, Urban O, Cyrany J, et al : Cronkhite-Canada syndrome : review of the literature. Gastroenterol Res Pract 2013 : 856873, 2013.
PubMed
22) Sweetser S, Ahlquist DA, Osborn NK, et al : Clinicopathologic features and treatment outcomes in Cronkhite-Canada syndrome : support for autoimmunity. Dig Dis Sci 57 : 496-502, 2012.
PubMed
23) Yashiro M, Kobayashi H, Kubo N, et al : Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion 69 : 57-62, 2004.
PubMed
24) Ohmiya N, Nakamura M, Yamamura T, et al : Steroid-resistant Cronkhite-Canada syndrome successfully treated by cyclosporine and azathioprine. J Clin Gastroenterol 48 : 463-464, 2014.
PubMed
P.441 掲載の参考文献
1) Crockett SD, Nagtegaal ID : Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia. Gastroenterology 157 : 949-966.e4, 2019.
 
2) Williams GT, Arthur JF, Bussey HJ, et al : Metaplastic polyps and polyposis of the colorectum. Histopathology 4 : 155-170, 1980.
PubMed
3) Moreira L, Pellise M, Carballal S, et al : High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. Gut 62 : 476-477, 2013.
PubMed
4) Rivero-Sanchez L, Lopez-Ceron M, Carballal S, et al : Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. Endoscopy 49 : 44-53, 2017.
 
5) Carballal S, Rodriguez-Alcalde D, Moreira L, et al : Colorectal cancer risk factors in patients with serrated polyposis syndrome : a large multicentre study. Gut 65 : 1829-1837, 2016.
PubMed
6) Figueiredo JC, Crockett SD, Snover DC, et al : Smoking-associated risks of conventional adenomas and serrated polyps in the colorectum. Cancer Causes Control 26 : 377-386, 2015.
PubMed
7) Buchanan DD, Sweet K, Drini M, et al : Risk factors for colorectal cancer in patients with multiple serrated polyps : a cross-sectional case series from genetics clinics. PLoS One 5 : e11636, 2010.
PubMed
8) Boparai KS, Dekker E, Van Eeden S, et al : Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 135 : 2014-2018, 2008.
PubMed
9) Gala MK, Mizukami Y, Le LP, et al : Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology 146 : 520-529, 2014.
PubMed
10) Murphy A, Solomons J, Risby P, et al : Germline variant testing in serrated polyposis syndrome. J Gastroenterol Hepatol 37 : 861-869, 2022.
PubMed
11) Biller LH, Ukaegbu C, Dhingra TG, et al : A multi-institutional cohort of therapy-associated polyposis in childhood and young adulthood cancer survivors. Cancer Prev Res (Phila) 13 : 291-298, 2020.
 
12) Shimohara Y, Urabe Y, Oka S, et al : Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS) : results of a multicenter study by the SPS Study Group in Japan. J Gastroenterol 57 : 300-308, 2022.
 
13) Carballal S, Balaguer F, IJspeert JEG : Serrated polyposis syndrome ; epidemiology and management. Best Pract Res Clin Gastroenterol 58-59 : 101791, 2022.
PubMed
14) van Leerdam ME, Roos VH, van Hooft JE, et al : Endoscopic management of polyposis syndromes : European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 51 : 877-895, 2019.
PubMed
15) Boparai KS, Mathus-Vliegen EM, Koornstra JJ, et al : Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome : a multicentre cohort study. Gut 59 : 1094-1100, 2010.
PubMed
P.447 掲載の参考文献
1) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
2) 藤井隆広 : 大腸LSTの歴史的背景. 胃と腸 49 : 1661-1664, 2014.
 
3) 工藤進英 : Lateral Spreading Tumor (LST) -Creeping Tumor. 早期大腸癌-平坦・陥凹型へのアプローチ, p42-44, 医学書院, 1993.
 
4) Kudo Se, Lambert R, Allen JI, et al : Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc 68 : S3-S47, 2008.
PubMed
5) 岡志郎, 田中信治, 河村徹, ほか : LSTの診断と治療腫瘍特性と治療手技からみたLSTの取扱い. 早期大腸癌 10 : 395-403, 2006.
 
6) 岡志郎, 田中信治, 大庭さやか, ほか : 早期大腸癌の肉眼分類側方発育型腫瘍 (LST) とは. 胃と腸 45 : 619-623, 2010.
 
7) 林奈那, 田中信治, 鴫田賢次郎, ほか : LST の定義・細分類とその臨床的意義. 胃と腸 49 : 1665-1672, 2014.
 
8) Oka S, Tanaka S, Kanao H, et al : Therapeutic strategy for colorectal laterally spreading tumor. Dig Endosc 21 (Suppl 1) : S43-S46, 2009.
 
9) 保田和毅, 田中信治, 林奈那, ほか : 大腸側方発育型腫瘍 (LST) の概念および診断と治療. 消化器内視鏡 29 (特集-内視鏡データリファレンスブック 2017) : 1479-1485, 2017.
 
10) Uraoka T, Saito Y, Matsuda T, et al : Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 55 : 1592-1597, 2006.
PubMed
11) Shigita K, Oka S, Tanaka S, et al : Clinical significance and validity of the subclassification for colorectal laterally spreading tumor granular type. J Gastroenterol Hepatol 31 : 973-979, 2016.
PubMed
12) Tanaka S, Kashida H, Saito Y, et al : JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc 27 : 417-434, 2015.
PubMed
13) Tanaka S, Oka S, Chayama K : Colorectal endoscopic submucosal dissection : present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol 43 : 641-651, 2008.
PubMed
14) Terasaki M, Tanaka S, Oka S, et al : Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol 27 : 734-740, 2012.
 
15) Hayashi Y, Sunada K, Takahashi H, et al : Pocket-creation method of endoscopic submucosal dissection to achieve en bloc resection of giant colorectal subpedunculated neoplastic lesions. Endoscopy 46 (Suppl 1) : E421-422, 2014.
 
P.453 掲載の参考文献
1) 狩谷淳, 水野幸一, 間山素行, ほか : IIc型早期大腸癌が認められた家族性大腸ポリポージスの1例. 胃と腸 12 : 1359-1364, 1977.
 
2) 丸山雅一 : I型 (隆起型) からII型 (表面型) へ早期大腸癌肉眼所見の "流行". 胃と腸 22 : 879-882, 1987.
 
3) 工藤進英, 日下尚志, 木俣博之, ほか : 大腸sm癌の診断と治療内視鏡診断の立場から. 胃と腸 26 : 764-775, 1991.
 
4) 工藤進英, 石川恵子, 山野泰穂, ほか : 陥凹型および陥凹型由来大腸早期癌. Gastroenterol Endoscopy 42 : 3-7, 2000.
 
5) Morson BC : Some peculiarities in the histology of intestinal polyps. Dis Colon Rectum 5 : 337-344, 1962.
 
6) Muto T, Bussey HJ, Morson BC : The evolution of cancer of the colon and rectum. Cancer 36 : 2251-2270, 1975.
PubMed
7) Vogelstein B, Fearon ER, Hamilton SR, et al : Genetic alterations during colorectal-tumor development. N Engl J Med 319 : 525-532, 1988.
PubMed
8) 工藤進英, 武藤輝一, 山本睦生, ほか : 大腸の腺腫と早期癌の形態推移. 胃と腸 20 : 903-910, 1985.
 
9) Kudo SE, Kouyama Y, Ogawa Y, et al : Depressed Colorectal Cancer : A New Paradigm in Early Colorectal Cancer. Clin Transl Gastroenterol 11 : e00269, 2020.
PubMed
10) Mochizuki K, Kudo SE, Kato K, et al : Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer. PLoS One 10 : e0273566, 2022.
PubMed
11) Yang K, Cao Y, Gurjao C, et al : Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts. Gastroenterology 163 : 1522-1530.e5, 2022.
 
12) 原栄志, 工藤進英, 樫田博史, ほか : 精査患者を対象とした大腸陥凹型腫瘍の頻度. 早期大腸癌 8 : 15-20, 2004.
 
13) 斎藤博 : 大腸癌の頻度. 早期大腸癌 8 : 9-13, 2004.
 
14) 工藤進英, 三浦宏二, 高野征雄, ほか : 微小大腸癌の診断実体顕微鏡所見を含めて. 胃と腸 25 : 801-812, 1990.
 
15) Tamura S, Furuya Y, Tadokoro T, et al : Pit pattern and three-dimensional configuration of isolated crypts from the patients with colorectal neoplasm. J Gastroenterol 37 : 798-806, 2002.
 
P.459 掲載の参考文献
1) Glasgow SC, Gaertner W, Stewart D, et al : The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. Dis Colon Rectum 62 : 1425-1438, 2019.
PubMed
2) Chicago Consensus Working Group : The Chicago Consensus on Peritoneal Surface Malignancies : Management of Appendiceal Neoplasms. Ann Surg Oncol 27 : 1753-1760, 2020.
 
3) Matsui S, Murata K, Fukunaga Y, et al : Analysis of Clinicopathological Characteristics of Appendiceal Tumors in Japan : A Multicenter Collaborative Retrospective Clinical Study-A Japanese Nationwide Survey. Dis Colon Rectum 63 : 1403-1410, 2020.
PubMed
4) Yamaguchi T, Murata K, Shiota T, et al : Clinicopathological Characteristics of Low-Grade Appendiceal Mucinous Neoplasm. Dig Surg 38 : 222-229, 2021.
PubMed
5) Inoue A, Murata K, Komori T, et al : Open versus laparoscopic surgery for primary appendiceal tumors : a large multicenter retrospective propensity score-matched cohort study in Japan. Surg Endosc 35 : 5515-5523, 2021.
PubMed
6) Takeyama H, Murata K, Takeda T, et al : Clinical Significance of Lymph Node Dissection and Lymph Node Metastasis in Primary Appendiceal Tumor Patients After Curative Resection : a Retrospective Multicenter Cohort Study. J Gastrointest Surg 26 : 128-140, 2022.
PubMed
7) 村田幸平, 賀川義規, 内藤敦, ほか : 虫垂癌, 虫垂腫瘍. 臨床外科 74 : 59-64, 2019.
 
8) 村田幸平, 武田和, 賀川義規, ほか : 虫垂がん. 日本臨牀 79 (増刊 : 希少がん) : 323-327, 2021.
 
9) 武田和, 賀川義規, 藤井誠, ほか : 虫垂腫瘍. 臨床外科 77 : 163-167, 2022.
 
10) Shiota T, Murata K, Kishimoto M, et al : Clinicopathological features of appendiceal goblet cell adenocarcinoma in Japan : a multicenter retrospective study. Surg Today 53 : 174-181, 2023.
PubMed
11) McGory ML, Maggard MA, Kang H, et al : Malignancies of the appendix : beyond case series reports. Dis Colon Rectum 48 : 2264-2271, 2005.
PubMed
12) 虫垂. TNM悪性腫瘍の分類 第8版 日本語版 (UICC日本委員会TNM委員会訳), p70-72, 金原出版, 2017.
 
13) 虫垂. 大腸癌取り扱い規約 [第9版] (大腸癌研究会編), p7, 金原出版, 2018.
 
14) Overman MJ, Asare AE, Compton CC, et al : Appendix-Carcinoma. In : AJCC Cancer Staging Manual 8th ed (ed by Amin MB, Edges SB, Greene FL, et al), p238-250, Springer, Switzerland, 2017.
 
15) Nagtegaal ID, Klimstra DS, Washington MK : Tumours of the appendix. In : WHO Classification of Tumours 5th ed, Digestive System Tumours, p136-155, IARC, Lyon, 2019.
 
P.464 掲載の参考文献
1) 田中信治, 樫田博史, 斎藤豊, ほか : 大腸ESD/EMRガイドライン (第2版). Gastroenterol Endosc 61 : 1321-1344, 2019.
 
2) Yoshida N, Inoue K, Dohi O, et al : Efficacy of precutting endoscopic mucosal resection with full or partial circumferential incision using a snare tip for difficult colorectal lesions. Endoscopy 51 : 871-876, 2019.
PubMed
3) Sakamoto T, Matsuda T, Nakajima T, et al : Efficacy of endoscopic mucosal resection with circumferential incision for patients with large colorectal tumors. Clin Gastroenterol Hepatol 10 : 22-26, 2012.
PubMed
4) Ohata K, Muramoto T, Minato Y, et al : Usefulness of a multifunctional snare designed for colorectal hybrid endoscopic submucosal dissection (with video). Endosc Int Open 6 : E249-E253, 2018.
PubMed
5) Yoshii S, Kubo M, Matsumoto M, et al : Efficacy and Safety of Complete Endoscopic Resection of Colorectal Neoplasia Using a Stepwise Endoscopic Protocol with SOUTEN, a Novel Multifunctional Snare. Clin Endosc 53 : 206-212, 2020.
PubMed
6) Jung Y, Kim JW, Byeon JS, et al : Factors Predictive of Complete Excision of Large Colorectal Neoplasia Using Hybrid Endoscopic Submucosal Dissection : A KASID Multicenter Study. Dig Dis Sci 63 : 2773-2779, 2018.
 
7) Bae JH, Yang DH, Lee S, et al : Optimized hybrid endoscopic submucosal dissection for colorectal tumors : a randomized controlled trial. Gastrointest Endosc 83 : 584-592, 2016.
PubMed
8) Byeon JS, Yang DH, Kim KJ, et al : Endoscopic submucosal dissection with or without snaring for colorectal neoplasms. Gastrointest Endosc 74 : 1075-1083, 2011.
 
9) Kim YJ, Kim ES, Cho KB, et al : Comparison of clinical outcomes among different endoscopic resection methods for treating colorectal neoplasia. Dig Dis Sci 58 : 1727-1736, 2013.
PubMed
10) Takeuchi Y, Iishi H, Tanaka S, et al : Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection : retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis 29 : 1275-1284, 2014.
PubMed
11) Okamoto Y, Oka S, Tanaka S, et al : Indications and outcomes of colorectal hybrid endoscopic submucosal dissection : a large multicenter 10-year study. Surg Endosc 36 : 1894-1902, 2022.
PubMed
12) Okamoto K, Muguruma N, Kagemoto K, et al : Efficacy of hybrid endoscopic submucosal dissection (ESD) as a rescue treatment in difficult colorectal ESD cases. Dig Endosc 29 (Suppl 2) : : 45-52, 2017.
 
13) Seo M, Yang DH, Kim J, et al : Clinical outcomes of colorectal endoscopic submucosal dissection and risk factors associated with piecemeal resection. Turk J Gastroenterol 29 : 473-480, 2018.
PubMed
P.470 掲載の参考文献
1) Rabeneck L, Paszat LF : Circumstances in which colonoscopy misses cancer. Frontline Gastroenterol 1 : 52-58, 2010.
PubMed
2) Rutter MD, Beintaris I, Valori R, et al : World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. Gastroenterology 155 : 909-925.e3, 2018.
 
3) Robertson DJ, Lieberman DA, Winawer SJ, et al : Colorectal cancers soon after colonoscopy : a pooled multicohort analysis. Gut 63 : 949-956, 2014.
PubMed
4) Bressler B, Paszat LF, Chen Z, et al : Rates of new or missed colorectal cancers after colonoscopy and their risk factors : a population-based analysis. Gastroenterology 132 : 96-102, 2007.
PubMed
5) le Clercq CM, Bouwens MW, Rondagh EJ, et al : Postcolonoscopy colorectal cancers are preventable : a population-based study. Gut 63 : 957-963, 2014.
PubMed
6) Iwatate M, Kitagawa T, Katayama Y, et al : Post-colonoscopy colorectal cancer rate in the era of high-definition colonoscopy. World J Gastroenterol 23 : 7609-7617, 2017.
PubMed
7) Macken E, Van Dongen S, De Brabander I, et al : Post-colonoscopy colorectal cancer in Belgium : characteristics and influencing factors. Endosc Int Open 7 : E717-E727, 2019.
PubMed
8) Chen WY, Cheng HC, Cheng WC, et al : Lead Time Bias May Contribute to the Shorter Life Expectancy in Post-colonoscopy Colorectal Cancer. Dig Dis Sci 64 : 2622-2630, 2019.
 
9) Forsberg A, Widman L, Bottai M, et al : Postcolonoscopy Colorectal Cancer in Sweden From 2003 to 2012 : Survival, Tumor Characteristics, and Risk Factors. Clin Gastroenterol Hepatol 18 : 2724-2733.e3, 2020.
 
10) Adler J, Robertson DJ : Interval Colorectal Cancer After Colonoscopy : Exploring Explanations and Solutions. Am J Gastroenterol 110 : 1657-1665, 2015.
PubMed
11) Arain MA, Sawhney M, Sheikh S, et al : CIMP status of interval colon cancers : another piece to the puzzle. Am J Gastroenterol 105 : 1189-1195, 2010.
 
12) Shaukat A, Arain M, Thaygarajan B, et al : Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci 55 : 2352-2356, 2010.
PubMed
13) Bogie RMM, le Clercq CMC, Voorham QJM, et al : Molecular pathways in post-colonoscopy versus detected colorectal cancers : results from a nested case-control study. Br J Cancer 126 : 865-873, 2022.
PubMed
14) Matsuda T, Fujii T, Sano Y, et al : Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy : the Japan Polyp Study Workgroup. Gut 70 : 1469-1478, 2020.
 
15) 斎藤豊, 岡志郎, 河村卓二, ほか : 大腸内視鏡スクリーニングとサーベイランスガイドライン. Gastroenterological Endoscopy 62 : 1519-1560, 2020.
 
16) Sano Y, Fujii T, Matsuda T, et al : Study design and patient recruitment for the Japan Polyp Study. Open Access J of Clin Trials 6 : 37-44, 2014.
 
P.473 掲載の参考文献
1) Ferlay J, Ervik M, Lam F, et al : Global Cancer Observatory : Cancer Today. International Agency for Research on Cancer, Lyon, 2020. [https://gco.iarc.fr/today]
 
2) 国立がん研究センターがん情報サービス : がん統計予測. [https://ganjoho.jp/reg_stat/statistics/stat/short_pred.html] (2023年2月閲覧)
 
3) World Cancer Research Fund Intgernational (WCRF International) : Global Cancer Update Programme. [https://www.wcrf.org/diet-activity-and-cancer/global-cancer-update-programme/]
 
4) World Cancer Research Fund Intgernational (WCRF International). Diet,Nutrition, physical activity and colorectal cancer. [https://www.wcrf.org/diet-activity-and-cancer/cancer-types/colorectal-cancer/]
 
5) 厚生労働省 : 喫煙と健康喫煙の健康影響に関する検討会報告書. [https://www.mhlw.go.jp/stf/shingi2/0000135586.html] (2023年2月閲覧)
 
6) Liang PS, Chen TY, Giovannucci E : Cigarette smoking and colorectal cancer incidence and mortality : systematic review and meta-analysis. Int J Cancer 124 : 2406-2415, 2009.
PubMed
7) Rothwell PM, Wilson M, Elwin CE, et al : Long-term effect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of five randomised trials. Lancet 376 : 1741-1750, 2010.
PubMed
8) Johnson JR, Lacey JV Jr, Lazovich D, et al : Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18 : 196-203, 2009.
PubMed
P.479 掲載の参考文献
1) Who Classification of Tumours, 5th ed, Digestive System Tumours (ed by WHO Classification of Tumours Editorial Board), IARC, Lyon 2019.
 
2) TNM Classification of Malignant Tumours, 8th ed (ed by Brireley JD, Gospodarowics MK, Wittekind C) Wiley-Blackwell, 2016.
 
3) AJCC Cancer Staging Manual, 8th ed (ed by Amin MD, Edge SB, Greene FL, et al), Springer, 2017.
 
4) 領域横断的がん取扱い規約 (日本癌治療学会/日本病理学会編), 金原出版, 2019.
 
5) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2018.
 
P.487 掲載の参考文献
1) 大腸癌取扱い規約 [第9版] (大腸癌研究会編), 金原出版, 2019.
 
2) Brierley JD, Gospodarowicz MK, Wittekind C, et al, ed : Union for International Cancer Control (UICC) TNM Classification of Malignant tumours, Eight edition. Wiley Blackwell, Oxford, 2017.
 
3) TNM悪性腫瘍の分類 [第8版] 日本語版 (UICC日本委員会TNM委員会訳), 金原出版, 2017.
 
4) 瀧井康公, 丸山聡, 野上仁 : 虫垂癌-虫垂癌の特殊性と, 規約第8版と規約第9版 (TNM分類 第8版) の相違. 臨床外科 74 : 930-933, 2019.
 
5) 山田一隆, 佐伯泰愼, 高野正太, ほか : 肛門肝癌-腺癌と扁平上皮癌の治療戦略の違いと, 規約第8版と規約第9版 (TNM分類 第8版) の相違. 臨床外科 74 : 934-938, 2019.
 
P.495 掲載の参考文献
1) NCCN Clinical Practice Guidelines Version 3. 2022 Colon Cancer [https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf]
 
2) NCCN Clinical Practice Guidelines Version 4. 2022 Rectal Cancer [https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf]
 
3) 大腸癌治療ガイドライン 医師用 2022年版 (大腸癌研究会編), 金原出版, 2022.
 
4) Fujita S, Mizusawa J, Kanemitsu Y, et al : Colorectal Cancer Study Group of Japan Clinical Oncology Group : Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212) : a multicenter, randomized controlled, noninferiority trial. Ann Surg 266 : 201-207, 2017.
PubMed
5) Bahadoer RR, Dijkstra EA, van Etten B, et al : Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO) : a randomised, open-label, phase 3 trial. Lancet Oncol 22 : 29-42, 2021.
PubMed
6) Conroy T, Bosset JF, Etienne PL, et al : Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22 : 702-715, 2021.
PubMed
7) Nordlinger B, Sorbye H, Glimelius B, et al : Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983) : a randomised controlled trial. Lancet 371 : 1007-1016, 2008.
PubMed
8) Nordlinger B, Sorbye H, Glimelius B, et al : Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14 : 1208-1215, 2013.
PubMed
9) Portier G, Elias D, Bouche O, et al : Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases : FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24 : 4976-4982, 2006.
 
10) Hasegawa K, Saiura A, Takayama T, et al : Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases : a randomized controlled trial. PLoS One 11 : e0162400, 2016.
PubMed
11) Kanemitsu Y, Shimizu Y, Mizusawa J, et al : Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603) : A Phase II or III Randomized Controlled Trial. J Clin Oncol 39 : 3789-3799, 2021.
PubMed
12) Cremolini C, Antoniotti C, Rossini D, et al : Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2) : a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21 : 497-507, 2020.
PubMed
13) Kopetz S, Grothey A, Yaeger R, et al : Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 381 : 1632-1643, 2019.
PubMed

書評

最近チェックした商品履歴

Loading...